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Background and Purpose: With the introduction of potent antiretroviral therapy (ART) 
leading to longevity, cardio-metabolic diseases are emerging health concerns in people 
living with HIV. This thesis aims to 1) quantify the burden of metabolic syndrome (MS), 
which is a constellation of cardio-metabolic risk factors, in people living with HIV infection 
(PLWHIV) from a global perspective; and in ≥18-year-old PLWHIV receiving HIV-care in the 
Western Cape, South Africa to 2) determine the MS prevalence and the agreement between 
the popular MS diagnostic criteria, 3) assess the distribution of cardio-metabolic risk factor 
clustering by adiposity levels, 4) determine the optimal waist circumference (WC) 
thresholds, and 5) HbA1c to define abdominal obesity and dysglycaemia, respectively, for 
the purpose of MS screening in South African PLWHIV.  
Methods: A systematic review with meta-analysis was conducted to determine the MS 
prevalence globally. The main study comprised a representative cross-sectional study of 
PLWHIV receiving HIV-care at 17 public healthcare clinics across the Western Cape, South 
Africa.  
Results: The global prevalence of MS was 16.7%-31.3% by different diagnostic criteria with 
substantial heterogeneity not explained by major study characteristics. The prevalence was 
higher in women than in men (International Diabetes Federation [IDF]-2005, 23.2% vs. 
13.4%, p=0.030), in antiretroviral therapy (ART) versus non-ART users (Adult Treatment 
Panel III [ATPIII]-2001, 18.4% vs. 11.8%, p=0.001), and varied significantly by participant’s 
age, duration of HIV diagnosis, CD4 count level, ART regimens. In the study conducted in the 
Western Cape (N=748, median age 38 years), MS prevalence among PLWHIV was 28.2% (JIS-
2009), 26.5% (IDF-2005), and 24.1% (ATPIII-2005), which was higher in women, participants 
with longer duration of diagnosed HIV infection, ART users not receiving 1st line regimen (all 
p≤0.039). There was a good agreement between sets of the criteria that was not affected by 
HIV-related factors (all kappa ≥0.81). Cardio-metabolic risk factors clustered across all 
categories of adiposity levels: 11.7% of normal-weight, and 15.1% of obese PLWHIV had two 
or more factors, and this distribution was not affected by HIV-specific features. The optimal 
WC thresholds for abdominal obesity were 92 cm (sensitivity 64%, specificity 64%) in 
vi 
women and 87 cm (sensitivity 48%, specificity 85%) in men, which differed from the 
internationally recommended 80 cm (women) and 94 cm (men). The optimal HbA1c 
thresholds to define oral glucose tolerance test diagnosed dysglycaemia was 5.75% 
(39.3 mmol/mol) (sensitivity 52%, specificity 85%), similar to the threshold of 5.7% 
(39 mmol/mol) recommended by the American Diabetes Association. The MS prevalence by 
the JIS was 28.2% and 29.7% using glucose-defined and HbA1c-defined dysglycaemia, with a 
good agreement between the original and modified criteria (kappa=0.81). 
Conclusions: The high prevalence of cardio-metabolic risk factor clustering in PLWHIV 
highlights the need for effective management strategies. Optimal performance of MS 
criteria in South African PLWHIV requires the use of the African-population-specific WC 
thresholds, while using HbA1c to diagnose dysglycaemia could be both effective and more 
practical than blood glucose defined dysglycaemia. However, these findings need to be 
confirmed and the effects of their introduction in routine care on healthcare behaviour and 
patient outcomes assessed through impact and implementation studies. 
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Cardiovascular diseases (CVD) account for 60% of all chronic non-communicable disease 
(NCD) deaths, killing 38 million people annually, including adults infected with HIV [1]. The 
rise of CVD in the HIV-infected population has occurred following the introduction of 
antiretroviral treatment (ART) which has improved the survival and longevity in this 
population [2, 3]. Worldwide, there were approximately 37 million people living with HIV 
(PLWHIV) in 2015 [4], compared with less than 10 million in 1990 [5]. Advances in ART and 
improved access to this treatment have successfully modified the natural progression of HIV 
infection from a fatal disease from acquired immunodeficiency syndrome (AIDS) and related 
infections, to a manageable chronic condition, with non-AIDS-defining conditions becoming 
the major cause of morbidity and mortality in PLWHIV [4, 6]. CVD and metabolic diseases 
are among the most frequent non-infectious co-morbidities, and likely results from 
combined effects of HIV infection, extended exposure to ART related metabolic effects, and 
traditional risk factors for CVD that increase with ageing [7, 8].  
The growing importance of cardio-metabolic diseases and non-infectious co-morbidities in 
PLWHIV has fuelled recommendations for a more integrated approach to their healthcare 
by routinely co-addressing common infectious and non-infectious comorbidities in this 
population. However, the lack of robust evidence-based recommendations applicable to 
PLWHIV will likely compromise the successful integration of major non-infectious co-
morbidities and HIV care, particularly in the low-resources settings of Africa where over 60% 
of PLWHIV reside [9]. Regarding cardio-metabolic diseases, adequate risk screening is the 
foundation of prevention and control strategies. Approaches to cardio-metabolic disease 
risk screening in the general population can be distinguished into single risk factor and 
multiple risk factors approaches. Single risk factor approach uses level of individual CVD risk 
factors to classify people as high or low risk (for instance hypertension vs. no hypertension, 
diabetes vs. no diabetes, dyslipidaemia vs. no dyslipidaemia) and target risk reducing 
interventions to those ranked at high risk. While single risk factor approach has been the 
basis of strategies that have achieved some of the decline in CVD in recent decades, it has 
important limitations and has been gradually abandoned [10]. CVD by nature are 
multifactorial and the likelihood of a CVD event depends on the combined effect of many 
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risk factors instead of a single one. The multiple risk factors approach to CVD risk screening 
aims to integrate this multifactorial nature of CVDs, by defining high risk status and need for 
treatment based on combined knowledge from several CVD risk factors.  
Multiple risk factor approaches to CVD risk stratification include risk factors counting and 
multivariable risk model approach. Multivariable risk model approach use mathematical 
function to combine information for several CVD risk factors and derive the probability 
(absolute risk of CVD). The most popular CVD risk models are those developed from the 
Framingham heart study [11], but such models have also been developed recently for 
people with HIV infection [12]. While absolute risk models have been positioned as the most 
accurate approach to CVD risk stratification, models tend to be population specific; and as 
such models developed from other populations cannot be uncritically applied to African 
populations where similar models are lacking. Furthermore, risk factors (predictors) 
included in CVD risk models specific to HIV population, are less likely to be routinely 
collected at primary health care level across Africa where most people with HIV are seen. 
Therefore, absolute risk models are currently a less attractive solution for CVD risk 
stratification in the largest proportion of people with HIV infection. Risk factors counting just 
like single risk factor approach use dichotomies to categorise individuals based on risk 
factors of interest, then defines high risk based on the presence of abnormal levels of more 
than one risk factor. Metabolic syndrome (MS) is of the commonest risk factor counting 
approach to CVD risk screening. It combines information on the presence or absence of high 
blood pressure, dysglycaemia/dysregulation of glucose homeostasis, dyslipidaemia and 
central obesity to define high risk. Because MS is based on parameters that are potentially 
measurable in routine care across Africa, it is more appealing for application in Africa than 
absolute risk model-based approaches to cardio-metabolic risk screening. However, there 
are important challenges to address prior to promoting MS as an approach for CVD risk 
evaluation in HIV infected African populations. 
Study motivation 
Several MS definitions with different criteria, components and thresholds have been 
developed for use in the general population. Whether these criteria diagnose the same 
individuals with MS in HIV-infected populations is unknown. This information is needed to 
4 
inform the recommendation of a particular set of criteria in this population [13]. Existing 
studies of MS prevalence have variably applied various criteria in PLWHIV. In the absence of 
efforts of pool those studies, the true prevalence of MS and factors influencing this 
prevalence in people with HIV are still unknown. It will be important to know how different 
MS criteria compare and agree with each other in PLWHIV, and to what extent the MS 
prevalence is affected by HIV specific characteristics both from a global and from an Africa 
perspective.  
Obesity, a component of MS [14], has been found to be linked with dyslipidaemia, insulin 
resistance, and chronic inflammation [15], but not every obese person has cardio-metabolic 
abnormalities, and conversely, metabolic disturbances are present in some non-obese 
individuals [16-19]. This has led to the use of concepts such as “metabolically healthy” and 
“metabolically abnormal” to characterise the burden of cardio-metabolic abnormalities that 
define MS among others, in relation with background level of adiposity (obesity 
phenotypes). Metabolically healthy obese individuals seem resistant to developing cardio-
metabolic complications associated with obesity; however, whether this status is 
maintained over the long-term remains inconclusive [20]. Despite the important 
implications of these phenotypes for disease risk prevention and reduction, evidence on its 
utility for obesity risk stratification and its overall impact on health is very limited. Further, 
obesity is increasingly common in PLWHIV, especially those on ART [21], the distribution and 
correlates of obesity phenotypes have not yet been investigated in this population.  
Regardless of the MS criteria used, their application in the African context is often 
compromised by the lack of African-population-specific thresholds for some components of 
the MS. This is the case for abdominal obesity, a central component of MS, currently 
diagnosed in the African population using waist circumference (WC) thresholds derived from 
Caucasians, despite fundamental differences in the body fat distribution between the two 
populations [22]. Current evidence from cross-sectional studies conducted in the general 
population across Africa is not in support of the application of WC cut-offs derived from 
Caucasians to African populations [23-25]. However, the performance of internationally 
recommended WC thresholds for MS diagnosis has not been examined in HIV-infected 
Africans in whom body fat distribution and metabolic rearrangements are often modified by 
the disease and related treatments.  
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Another MS component less optimally diagnosed in Africans is possibly dysglycaemia using 
fasting plasma glucose (FPG). Data from African population suggest that a significant 
proportion of people with dysglycaemia rather express derangements of post-load glucose 
and will be missed in the absence of the oral glucose tolerance test (OGTT) [26], which can 
lead to misdiagnosis of MS. However, OGTT is very cumbersome, while both FPG and OGTT 
require fasting, which can be challenging to obtain in the often poly-medicated patients 
with HIV infection. Haemoglobin A1c (HbA1c) has been increasingly recommended as an 
alternative test to diagnose dysglycaemia in recent years [27, 28]. The use of HbA1c has the 
potential to overcome the disadvantages of FPG and OGTT and improve the detection of 
dysglycaemia and MS screening in African populations with HIV. However, factors 
interfering with HbA1c measurement such as haemoglobinopathies have been suggested to 
be more frequent in the general population in Africa [29], while others e.g. anaemia and 
haemolysis are specifically common in people with HIV/AIDS [30, 31]. Therefore, whether 
HbA1c is an effective replacement for the OGTT for dysglycaemia and MS screening in 
African PLWHIV is unknown. This information is important since HIV-infected patients 
require ongoing screening for dysglycaemia as well as other cardio-metabolic abnormalities 
using simple and accurate tests as part of their routine care. 
The issues identified above have not been investigated across Africa, and in South Africa in 
particular, which is home to approximately seven million HIV-infected people and has the 
largest ART programme in the world [4]. Therefore, it is important to investigate the MS and 
its related issues in the South African HIV-infected population to enable optimal 
management of CVD in HIV-infected people receiving care in the country.  
Thesis layout  
This thesis will address the topics described above via a series of five manuscripts; three 
have been published in peer-reviewed journals, while the other two are currently under 
peer-review. The Background to this study comprises a literature review on the 
epidemiology of HIV/AIDS, the evolution of the MS criteria, and a published meta-analysis 
on the global prevalence of MS in PLWHIV. Thereafter, the main cross-sectional study titled 
“Utilizing HIV/AIDS infrastructure as a gateway to chronic care for hypertension in Africa” 
conducted among HIV-infected patients receiving care at 17 public healthcare facilities in 
6 
 
the Western Cape Province, South Africa is described in detail. This is followed by the 
findings of this present study in two published and two unpublished manuscripts. These 
include the MS prevalence in this study sample using various criteria (published), the 
distribution of cardio-metabolic abnormalities by obesity phenotype (published), and the 
optimal WC and HbA1c cut-off points to identify abdominal obesity and dysglycaemia 
(unpublished). The thesis concludes with the summary of novel insights from this study and 
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Aims and objectives 
Aims 
To determine the prevalence of the metabolic syndrome and the distribution of cardio-
metabolic abnormalities across categories of adiposity, and to identify the optimal waist 
circumference and haemoglobin A1c (HbA1c) levels for diagnosing metabolic syndrome in a 
South African HIV-infected population receiving antiretroviral therapy (ART).   
Objectives:  
I. To review the literature on the prevalence of the metabolic syndrome in HIV-
infected men and women globally. 
II. To determine the following in HIV-infected men and women in South Africa:  
1. The prevalence of the metabolic syndrome according to National Cholesterol 
Education Program, Adults Treatment Panel III (ATPIII-2005), International 
Diabetes Federation (IDF 2005) and Joint Interim Statement (JIS-2009) criteria 
and the agreement between these criteria.  
2. The distribution of cardio-metabolic abnormalities across BMI categories. 
3. The optimal waist circumference cut-off points that identify ≥2 non-adipose 
components of metabolic syndrome.  
4. The optimal HbA1c cut-off point, in those without treated diabetes, that 
correlates with: 
4.1. dysglycaemia defined by fasting glucose ≥5.6 mmol/L fasting alone, and 
glucose ≥5.6 mmol/L and/or 2-hour post oral glucose tolerance test (OGTT) 
glucose ≥7.8 mmol/L; 
4.2. fasting glucose ≥7.0 mmol/L and/or 2-hour post (OGTT) glucose ≥11.1 
mmol/L; and 
4.3. the effect of replacing fasting glucose defined hyperglycaemia with HbA1c 












Chapter 2         
Human Immunodeficiency Virus 
and Acquired Immune Deficiency 
Syndrome: Epidemiology, 




The human immunodeficiency virus (HIV) infection was first mentioned about 100 years ago 
when it was assumed to have resulted from multiple cross-species transmissions of simian 
immunodeficiency viruses from African primates to humans [1]. Acquired immunodeficiency 
disease syndrome (AIDS), however, was first recognised as a new disease entity in 1981 only 
when increasing numbers of young homosexual men presented with opportunistic 
infections and rare malignancies [2]. Subsequently, HIV type 1 (HIV-1) lentivirus group M 
was discovered as the causal agent of AIDS [3]. Soon thereafter, HIV/AIDS became one of 
the most disastrous infectious diseases in recent history [4].  
Burden of HIV/AIDS 
HIV is a major contributor to the global burden of disease. The HIV pandemic has touched at 
least 70 million people and caused more than 36 million deaths worldwide since AIDS was 
first diagnosed [5]. Developing countries have had the greatest HIV/AIDS morbidity and 
mortality rates, with the highest rates found in young adults in sub-Saharan Africa as shown 
in Figure 2.1 [5, 6]. 
Figure 2.1. Age-standardised HIV prevalence in 2013, both sexes [6]. 
ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. Isl=Islands. FSM=Federated 




The global epidemiology of HIV infection, however, has undergone a remarkable 
transformation with the introduction and improved access to antiretroviral therapy (ART), 
under the Millennium Development Goal (MDG) 6 of the United Nations [7]. Currently, 
nearly 10 million people living with HIV in low- and middle-income countries (LMIC) are 
receiving ART, 70% of whom live in sub-Saharan Africa [5].  
In Figure 2.2 below, the global trends of HIV epidemiology are shown. According to the 
Global Burden of Disease study, the global population of HIV in 2015 was 37 million 
individuals (with 26 million from sub-Saharan Africa), against less than 10 million in 1990 
[6, 8]. The mortality rates have fallen from 1.7 million in 2005 to 1.2 million in 2015 [8]. 
In addition, the number of new HIV infections also decreased from a peak of 2.8 million 
in 1997 to 1.8 million in 2013 [6]. Apart from a reduction in new HIV incidences, the 
progressive increase in HIV-infected survivors is attributed to an increased access to ART 





Figure 2.2. Global HIV incidence (A), prevalence (B), and mortality (C), 1990-2013, 
for all ages and both sexes combined [6]. Shaded areas are 95% uncertainty 
intervals. 
 
Antiretroviral therapy and emerging challenges in the ART era 
The ART era began in 1985 with the discovery of the first generation of antiretroviral (ARV) 
drugs, nucleoside reverse transcriptase inhibitors (NRTIs), then the development of drugs 
from different classes including protease inhibitors (PIs) in 1995, non-nucleoside reverse 




approved and are available for use [9]. Combination ART has led to the development of 
single tablets, fixed doses, and once-daily administration [10, 11], higher rates of treatment 
success, mainly because of improved adherence [9, 11]. Consequently, ART has successfully 
reduced hospitalisation, morbidities and mortalities in HIV-infected patients [12]. Patients 
who achieve a suppressed viral load and a normal CD4 count on combined ART may have a 
normal life expectancy [11].  
However, the combination of ART has brought along new challenges. With the increase of 
patients’ life expectancy, the number of HIV-infected elderly is now growing [8]. The 
proportion of HIV-infected adults who are 50 years and older is now above 10% in LMIC, 
particularly sub-Saharan Africa, although the HIV population remains relatively young [13]. 
The proportion of older people with HIV is much higher in high-income countries (HIC); 50% 
in the USA [14] and 30% in Europe [15]. Concomitant with ageing, non-AIDS-defining 
comorbidities such as hepatic disorders, chronic kidney disease, non-AIDS-defining cancers, 
neurocognitive deficits, bone disease, diabetes and CVD are increasing commonly in people 
living with HIV (PLWHIV) [12]. For instance, there was a three-fold increase in the 
percentage of deaths among Brazilian PLWHIV between 2000 and 2007 that was not 
HIV/AIDS-related [16]. The Antiretroviral Therapy Cohort Collaboration group reported that 
in HIC 50% of all deaths in people on ART were not caused by AIDS [17]. Others found that 
non-AIDS-defining causes of deaths accounted for a quarter of all deaths in HIV/AIDS 
patients, with CVD being a leading cause of death in this category [18]. These new threats 
are possibly associated with ARV toxicities, and also with chronic inflammation caused by 
HIV infection and perhaps incomplete restoration of the immune system following ART as 
well as with accelerated ageing of PLWHIV [19]. 
HIV/AIDS in South Africa  
South Africa has the largest number of HIV-infected people in the world, with 6.8 million 
people living with the virus in 2014 according to the Joint United Nations Programme on 
HIV/AIDS (UNAIDS) report [5]. Most of those affected were younger than 49-years-old [5]. 
The 2012 HIV-infected prevalence among the 15-49-year-old persons was 16.6% overall, 
lowest in the Western Cape (7.8%) and highest in KwaZulu-Natal (39.5%) [20].  
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In 2004, the South African government initiated a highly active antiretroviral therapy 
(HAART) programme for all HIV-infected people who qualified under certain HIV-related 
criteria, which have been expanded since then [21]. Today, South Africa has the largest ART 
programme in the world, with approximately half of the individuals who are in need of ART 
receiving such treatment [22]. Notably, South Africa has recently embraced the “screening 
and treat strategy”, i.e. all HIV-positive patients are eligible for ART irrespective of their CD4 
level [23].  
Greater access to ART in the past decade has led to a notable decline in HIV-associated 
morbidity and mortality in the country [24]. Since 2006, the mortality profile provided by 
Statistics South Africa shows a decrease in the proportion of overall deaths related to AIDS 
[24]. The increase in life expectancy from a low 53.8 years in 2004 to 62.4 years in 2016 [20] 
explains the epidemiological shift in the main causes of death and disease from 
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Chapter 3         






Early history of metabolic syndrome 
Although the first international definition of the metabolic syndrome (MS) was released less 
than two decades ago [1], research in this field started nearly a century ago when several 
European physicians discussed the interrelation of metabolic disorders, hypertension and 
type 2 diabetes mellitus (diabetes) [2] (Table 3.1). In the early history of research on MS, 
scientists, who worked independently in different countries, used diverse terms for the 
clustering of metabolic disorders when reporting their observations as indicated in Table 
3.1. 
Table 3.1. Diverse terms used for referring to the clustering of metabolic disorders 
Terminology Author and Year 
Hypertension-hyperglycaemia-hyperuricaemia syndrome Kylin, 1923 [3] 
Metabolic trisyndrome Camus, 1966 [4] 
Plurimetabolic syndrome Avogaro and Crepaldi, 1967 [5] 
Syndrome of affluence Mehnert and Kuhlmann, 1968 [6] 
Metabolic syndrome Hanefeld and Leonhardt, 1981 [7] 
Syndrome X Reaven, 1988 [8] 
Deadly quartet Kaplan, 1989 [9] 
Insulin resistance syndrome DeFronzo and Ferrannini, 1991 
[10]; Haffner, 1992 [11] 
 
The exciting moment in history of the MS research was probably marked with the Reaven 
Banting lecture in 1988 [8]. In his lecture, Reaven reported the presence of resistance to 
insulin-mediated glucose uptake in most patients with diabetes or impaired glucose 
tolerance (IGT), and in about 25% of non-obese individuals with normal glucose tolerance 
[8]. This was after he had been working on insulin resistance and diabetes for a few years. 
He proposed a theory indicating that resistance to insulin-stimulated glucose uptake is the 
backbone in the aetiology and clinical course of a group of disorders. These include IGT, 
hyper-insulinaemia, high levels of very low-density lipoprotein cholesterol (VLDL-C) 
triglycerides, low levels of high-density lipoprotein cholesterol (HDL-C) and hypertension. He 
21 
pointed out that this set of related variables clustered in the same individual and may be 
associated with increased risk for coronary artery disease and diabetes and called it 
“Syndrome X”. Another important matter that Reaven highlighted, was the effect that 
genetic and environmental factors such as obesity and physical inactivity had on the severity 
of insulin resistance. These helped outlining the importance of MS in public health, and as 
such triggered epidemiological studies of the syndrome. The most remarkable of Reaven’s 
work is perhaps that it opened a new era of research in the MS field [1]. This has since 
focused on the development of uniform definitions, the pathophysiology and treatment of 
the MS.  
International definitions of the metabolic syndrome 
There are various definitions of the MS which have been proposed by different 
organisations, institutions and expert groups (Table 3.2). Variations in opinions have been as 
to which disorders should be included in the definition of the MS and their relative 
importance for defining CVD risk. These different perspectives led to numerous MS criteria 
(Table 3.2).  
The first international definition of the MS was formulated in 1998 by the World Health 
Organisation (WHO) with effort to take into account the high prevalence of the clustering, 
its association with increased CVD risk and the possible causal role of insulin resistance in 
the development of concomitant disorders [1]. The WHO definition consists of insulin 
resistance or its surrogates (IGT or diabetes) as essential components and at least another 
two from hypertension, elevated triglycerides, low HDL-C, obesity (increased BMI or waist-
to-hip ratio (WHR)), and microalbuminuria (Table 3.2) [1].  
A year later, in 1999, the European Group for the Study of Insulin Resistance (EGIR) 
produced another definition of the MS which was originally modified from the proposal of 
the WHO definition [12]. This definition excluded diabetes and microalbuminuria, had 
hyper-insulinaemia as compulsory component, used waist circumference (WC) instead of 
body mass index or waist-to-hip ratio (WHR) as adiposity surrogate with different cut-off 




The National Cholesterol Education Programme/Adult Treatment Panel III (NCEP/ATPIII) in 
USA suggested another MS definition in 2001 [13]. The primary purpose of this definition 
was to identify individuals at high risk for CVD beyond the traditional cardiac risk factors. 
This definition differed from the previous two in that the ATPIII 2001 removed insulin 
resistance as a component and required at least three out of five variables. These included 
central obesity (estimated by WC), increased blood pressure (BP) and triglycerides, low HDL-
C, and impair fasting glucose (IFG) to be present in diagnosing the MS. The ATPIII 2001 panel 
definition assumed that most of the individuals meeting three or more components would 
also be insulin resistant and, therefore, would not require routine insulin resistance 
measurements (Table 3.2). This definition was modified in 2004 and 2005 to reduce the cut-
off point for FPG and added previously diagnosed or treated lipid abnormalities, 
hypertension or diabetes into its components [14, 15]. 
Another set of criteria for defining MS was put forward by the American Association of 
Clinical Endocrinologists (AACE) in 2003, with emphasis on the interrelationship between 
cardiovascular and metabolic diseases [16]. Thus, the AACE definition placed its focus on 
insulin resistance and excluded individuals with diabetes. A major limitation of this 
definition is that the risk factors proposed for diagnosing MS are not specified, and 
therefore require clinical judgement [16].  
In 2005, the International Diabetes Federation (IDF) released a new definition of the MS that 
was formulated at a consensus workshop by a group of scientists from over the world [17]. 
The reasons for developing this new set of criteria was that the IDF working group 
recognised the challenges in applying MS criteria across ethnic populations and in 
comparing the data from studies using different definitions. The main difference between 
the IDF and the NCEP/ATPIII definitions was that the IDF definition included central obesity 
as its essential component, and recommended new cut-off points for WC based on ethnic 
specificities. In addition to central obesity, the IDF required any two of another four factors 
(similar to the ATPIII 2005 definition) to meet the diagnosis of the MS [17]. However, the IDF 
definition did not receive worldwide acceptance as expected, because according to its 
recommendations, it seems that MS is the result of a single unifying pathological process of 




releasing the IDF definition just opened a new round of discussions on the consensus 
definition for MS [19]. 
The latest effort in unifying the MS definition was in 2009, when several major organisations 
came together to propose the Joint Interim Statement (JIS) criteria for MS definition [19]. 
This harmonised definition differed from the IDF in that central obesity was not a 
prerequisite but one of five components. A single set of cut-off points would be used for all 
components except WC for which population- and country-specific thresholds were 
recommended [19]. These will be discussed in more details subsequently.  
Overall, the adoption of various MS definitions reflects the unknown aspects of the 
syndrome. The efforts to define the MS should be considered as working definitions 
providing a platform for evaluating the dimensions of the syndrome in different 
populations. The possibility that the progress of our understanding of the syndrome 
together with formulating more specific surrogates for factors such as insulin resistance, 
glucose concentration and central obesity, will result in new definitions of the MS in future. 
The next chapter provides an overview of studies on the prevalence of MS in people with 
































 plus any 2 




percentile plus any 2 
of following features: 
None, but any 3 of 
the following:  
IGT or IFG plus any of 
the following based 
on clinical 
assessment: 
None, but any 3 of 5 
the following: 
None None, but any 3 of 
the following: 
None, but any 3 of 
the following:  
2. Body 
composition 
WHR >0.90 in men, 
>0.85 in women 




WC ≥94 cm in men, 
≥80 cm in women 
WC ≥102 cm in men, 
≥88 cm in women 
BMI ≥25 kg/m
2
 WC ≥102 cm in men, 
≥88 cm in women 
Increased WC >94 cm 
in men, ≥80 cm in 
women plus any 2 of 
the following: 
WC ≥102 cm in men, 





3. Lipids TG ≥ 1.7 mmol/L 
and/or  
HDL-C <0.9 mmol/L in 
men, <1 mmol/L in 
women 
TG ≥2.0 mmol/L 
and/or  
HDL-C <1.01 mmol/L 
or treated for 
dyslipidaemia 
TG ≥1.69 mmol/L, 
HDL-C <1.03 mmol/L 
in men, <1.3 mmol/L 
in women 
TG ≥1.7 mmol/L and 
HDL-C <1 mmol/L 
TG ≥1.69 mmol/L; 
HDL-C <1.03 mmol/L 
in men, <1.3 mmol/L 
in women 
TG ≥1.7 mmol/L or 
TG Rx; HDL-C 
<1.03 mmol/L in 
men, <1.3 mmol/L in 
women or HDL-C Rx 
TG ≥1.7 mmol/L or on 
TG Rx; 
HDL-C <1 mmol/L in 
men, <1.3 mmol/L in 
women or HDL-C Rx 
TG ≥ 1.7 mmol/L or 
on TG Rx; HDL-C < 
1.03 mmol/L in men, 
<1.3 mmol/L in 




≥160/90 mmHg  
SBP/DBP 
≥140/90 mmHg  
SBP/DBP 






≥130/85 mmHg or 
hypertension Rx 
SBP/DBP 
 ≥130/85 mmHg or 
hypertension Rx 
SBP/DBP  














≥ 5.6 mmol/L or on 
hyperglycaemic Rx 
≥ 5.6 mmol/L or on 
hyperglycaemic Rx 




    
         
BMI, body mass index; DBP, diastolic blood pressure; HDL-C, high density lipoprotein cholesterol; IGT indicates impaired glucose tolerance; IFG, impaired fasting glucose; Ins-R, 
Insulin resistance; mALB, micro albumin; Rx, prescription; SBP, systolic blood pressure; TG, triglycerides; T2DM indicates type 2 diabetes mellitus; WC, waist circumference; WHR, 
waist-to-hip ratio 
a 
Insulin sensitivity measured under hyperinsulinaemic, euglycaemic conditions; glucose uptake below lowest quartile for background population under investigation. 
b 
Includes family history of T2DM, sedentary lifestyle, advancing age, and ethnic groups susceptible to T2DM 
c 
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Cardio-metabolic risk factors are of increasing concern in HIV-infected individuals, 
particularly with the advent of antiretroviral therapy (ART) and the subsequent rise in 
longevity. However, the prevalence of cardio-metabolic abnormalities in this population and 
the differential contribution, if any, of HIV specific factors to their distribution, are poorly 
understood. Therefore, we conducted a systematic review and meta-analysis to estimate 
the global prevalence of metabolic syndrome (MS) in HIV-infected populations, its variation 
by the different diagnostic criteria, severity of HIV infection, ART used and other major 
predictive characteristics. 
Methods 
We performed a comprehensive search on major databases for original research articles 
published between 1998 and 2015. The pooled overall prevalence as well as by specific 
groups and subgroups were computed using random effects models. 
Results 
A total of 65 studies across five continents comprising 55094 HIV-infected participants aged 
17–73 years (median age 41 years) were included in the final meta-analysis. The overall 
prevalence of MS according to the following criteria were: ATPIII-2001:16.7% (95%CI: 14.6–
18.8), IDF-2005: 18% (95%CI: 14.0–22.4), ATPIII-2004-2005: 24.6% (95%CI: 20.6–28.8), 
Modified ATPIII-2005: 27.9% (95%CI: 6.7–56.5), JIS-2009: 29.6% (95%CI: 22.9–36.8), and 
EGIR: 31.3% (95%CI: 26.8–36.0). By some MS criteria, the prevalence was significantly higher 
in women than in men (IDF-2005: 23.2% vs. 13.4, p=0.030), in ART compared to non-ART 
users (ATPIII-2001: 18.4% vs. 11.8%, p=0.001), and varied significantly by participant age, 
duration of HIV diagnosis, severity of infection, non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) use and date of study publication. Across criteria, there were significant 
differences in MS prevalence by sub-groups such as in men, the Americas, older 
publications, regional studies, younger adults, smokers, ART-naïve participants, NNRTIs 
users, participants with shorter duration of diagnosed infection and across the spectrum of 
HIV severity. Substantial heterogeneities across and within criteria were not fully explained 
by major study characteristics, while evidence of publication bias was marginal. 
Conclusions 
The similar range of MS prevalence in the HIV-infected and general populations highlights 
the common drivers of this condition. Thus, cardio-metabolic assessments need to be 
routinely included in the holistic management of the HIV-infected individual. Management 
strategies recommended for MS in the general population will likely provide similar benefits 
in the HIV-infected. 
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Introduction 
The Global Burden of Disease Expert Group estimated that approximately 30 million people 
were infected with HIV worldwide in 2013, most of who reside in sub-Saharan Africa [1]. Life 
expectancy and quality of life in those infected with HIV have improved dramatically with 
the introduction of effective antiretroviral therapy (ART). Between 1990 and 2013, ART 
saved an estimated 19.1 million life-years in HIV-infected adults [1].  
With increased longevity in HIV-infected individuals, other diseases, similar to the general 
population, are likely to develop. These include obesity, type 2 diabetes mellitus (T2DM) and 
other cardio-metabolic diseases.  Although exposure to risky behaviours of unhealthy diets 
and reduced physical activity levels contribute to these conditions [2], additional influences 
unique to HIV-infected populations further increase their susceptibility to cardio-metabolic 
abnormalities. For example, the use of ART is associated with body fat redistribution and 
cardio-metabolic abnormalities such as hypertension, dyslipidaemia, insulin resistance, and 
dysglycaemia [3]. Moreover, HIV infection itself through chronic inflammation and immune 
dysfunction mechanisms is assumed to be an important determinant of dyslipidaemia, 
atherosclerosis and T2DM [4].  
Cardio-metabolic abnormalities frequently cluster and manifest as the metabolic syndrome 
(MS), a constellation of interrelated metabolic disorders comprising abdominal obesity, 
raised blood pressure, dyslipidaemia and hyperglycaemia. The importance of the MS is that 
it is a powerful predictor of future cardiovascular disease and T2DM [5]. Therefore, 
determining the magnitude of MS in a given population highlights the need for preventive 
and management strategies, and enables healthcare services planning.  
This is particularly relevant in HIV-infected populations who have the potential to develop 
cardio-metabolic abnormalities and MS through multiple pathways. Notably, the prevalence 
of MS in HIV-infected populations and the differential contributions, if any, of HIV specific 
influences on the estimates have yet to be fully examined. Accordingly, we conducted a 
systematic review and meta-analysis to assess the MS prevalence and its relationship with 






Identification of relevant studies 
We undertook a comprehensive electronic search across major databases including 
Medline, CINAHL, Academic Search Premier, Africa-Wide Information and Scopus to identify 
relevant studies. The search terms comprised combinations of MESH terms, CINAHL 
headings, and free words relating to prevalence, metabolic syndrome, and HIV/AIDS (S4.1 
Table). Additionally, we traced the citations of identified articles via the ISI Web of 
Knowledge, and scanned the reference lists of review papers and conference proceedings. 
We also examined publications on the websites of key organisations such as UNAIDS, WHO, 
and International AIDS Society. We limited the search to studies reported from January 1998 
to April 2015 because highly active antiretroviral therapy (HAART) was introduced only in 
1996 [6] and the first MS criteria were defined in 1998 [7].  
Selection of included studies 
Two investigators (KAN and NP) independently reviewed the studies by title, abstract and 
full text where relevant for inclusion. Disagreements were resolved by consensus or by 
consulting a third investigator (APK). Included studies had to: 1) be population- or hospital-
based cross-sectional studies, 2) comprise adults diagnosed with HIV-infection, treated or 
not; 3) report the prevalence of MS overall and by different subgroups of interest, according 
to any of the internationally accepted diagnostic criteria for MS (see Chapter 3, Table 3.2); 
or provide enough data to estimate this prevalence; and 4) be published in English or 
French. We made no restriction by sample size, sampling methods or study setting. For 
studies reported more than once, the article with the largest number of participants was 
used. If an article reported multiple surveys conducted in different countries, each survey 





































Records identified through database 
searches (N=1278)
Additional records identified through hand 
searches (N=2)
Records identified after duplicates removed 
(N=898)
Articles screened: full-text (N=78)
Records screened: title and abstract (N=888)
Records excluded due to 
no abstract (N=10)
Articles included in qualitative synthesis 
(N=59)
Records excluded due to 
irrelevant (N=810)
Articles excluded (N=19): 
 Duplicates (8)
 Languages other than English or 
French (5): Spanish (3), Portuguese 
(1), Rumanian (1)
 Other reasons (6): no MS prevalence 
(2); 1 MS incidence (1); 1 no MS 
definition provided (1); commentary 
paper (1); supplementary (1)




Assessment of the methodological quality of included studies 
We evaluated the methodological quality of the included studies using a checklist adapted 
from Hoy et al. [8]. It consists of nine questions that assesses the representativeness of the 
sample, the sampling technique, the response rate, the data collection method, the 
measurement tools, the case definitions, and the statistical reporting. Each checked 
question was scored either as “1” or “0” corresponding respectively to “low risk of bias” and 
“high risk of bias”. The total score ranged from 0 to 9 with the overall score categorised as 
follows: 7 to 9: “low risk of bias”, 4 to 6: “moderate risk”, and 0 to 3: “high risk” (S4.2 Table). 
For each included study, we also estimated the precision (C) or margin of error, considering 
the sample size (SS) and the observed prevalence (p) of MS from the formula SS=Z2*p*(1-
p)/C2 where Z was the z-value fixed at 1.96 across studies (corresponding to 95% confidence 
interval). The desirable margin of error was 5% (0.05) or lower. 
Data extraction 
Relevant data were extracted using a data extraction form which was designed for the 
purposes of this review and piloted before using. The information extracted included 1) 
Author details [names and year of publication]; 2) Study characteristics [country, study 
design, setting, data source, sampling method, sample size, data collection period, response 
rate]; 3) Participants’ characteristics [age, gender, lifestyle habits (smoking, alcohol misuse), 
HIV-related factors [time since diagnosis, severity of the disease, ART regimens and duration 
of treatment]; and 4) MS characteristics [diagnostic criteria used, prevalence, number of 
participants tested and diagnosed with MS overall and by subgroups of interest].  
Data synthesis and analysis 
For each included study, the unadjusted prevalence of MS was estimated (number with 
MS/total number of participants tested) overall and across major subgroups of interest. We 
used DerSimonian-Laird random effects models to combine estimates from different studies 
to generate the overall prevalence of MS according to each diagnostic criteria. The random 
effects model was chosen over the fixed effects in anticipation of substantial variations in 
MS prevalence estimates across the included studies. To minimise the effect of extreme 
33 
prevalence on the overall estimates, we first stabilised the variance of the raw prevalence 
with a single arcsine transformation before pooling the data [9].   
To account for the small number of studies that applied some definition criteria, and to 
account for similarities between some criteria, a decision was made to group together 
studies that applied the Adult Treatment Panel III (ATPIII)-2004 and ATPIII-2005 criteria into 
the ATPIII-2004-2005 group. Furthermore, studies that applied variants of the same criteria 
(e.g. through the substitution of variables) were assessed together with studies that applied 
the original criteria.  
We assessed the heterogeneity between studies using the Cochran’s Q, I2 and H statistics 
[10]. Noteworthy is that statistical approaches to assess heterogeneity can yield spurious 
results within uncontrolled studies [11]. We explored the sources of heterogeneity by 
comparing the prevalence of MS between subgroups defined by naturally occurring 
categories (e.g. gender and geographic regions), or by using median values of the summary 
estimates of the continuous characteristics (e.g. age, ART duration) across all eligible 
studies. Subgroups comparisons then used the Q-test based on the Analysis of the Variance 
(ANOVA). Publication bias was assessed using the funnel plots supplemented by formal 
statistical assessments using the Egger test of bias [12]. All analyses were performed using 
the R programme (version 3.0.3 [2014-03-06]) and “meta” package. 
The following sections report the findings of the systematic review and meta-analyses. The 
data are presented by the overall MS prevalence as well as by subgroups of age, gender, 
HIV-related factors, study location, publication year, sample size, and smoking status. Within 
each subgroup, MS prevalence is presented by the definition criteria used.   
Results 
The review process 
The process for selecting the relevant studies is summarised in Figure 4.1. In total, 1280 
records were identified via database searches. After removing all duplicates, we scanned 
the titles and abstracts of 888 articles, of which 78 articles were further reviewed via full-





article reported surveys conducted in seven South American countries, leading to a total of 
65 studies in the main analyses. 
Methodological quality of included studies 
In all, 18 studies were categorised as having a low risk of bias while the remainder had a 
moderate risk of bias. However, 37 studies did not indicate how participants were selected; 
seven studies reported some form of random selection whereas 21 studies indicated a non-
random sampling technique. A total of 25 studies reported the response rates which ranged 
from 31.2% to 100% (median 88%).  
Characteristics of included studies 
The characteristics of the included studies are summarised in Table 4.1. Studies from all 
continents were represented as follows: Europe: 23, the Americas: 26, Africa: nine and Asia: 
four, while three studies were intercontinental. Of the 65 included studies, 33 were 
localised studies, mainly conducted in urban settings, while the rest had national coverage. 
With regards to the actual study sites, the majority (58) were solely hospital- or clinic-based, 
four were community-based and three studies involved both locales. While about half of the 
studies (34) collected data before or during 2007, only one-fifth (12 studies) were published 
































Intercontinental              














Unspecified 788 NR - 
Age ≥ 17 years; not 
diagnosed with AIDS 
Low 0.03 








Urban Hospital  C/S 1999-2002 Random 881 94 38.7  Adults not receiving ART Low 0.02 
















Adults on ART and regular 
follow-up 
Low 0.01 
Americas              
Baum, et al [16] 2006 USA National Community  C/S 2002-2003 Unspecified 118 NR 41.7  Adult chronic drug users  Moderate 0.06 
Jacobson, et al 
[17] 
2006 USA Urban Community  C/S 2000-2003 Unspecified 477 NR - Self-selected Moderate 0.04 
Johnsen, et al 
[18]  
2006 USA National Hospital  C/C 2002-2003 Unspecified 97 NR 41  
Women with BMI≥20 







Mondy, et al 
[19] 
2007 USA Urban Hospital  C/S 2005 
Not 
random 
471 78 - 
All clinic attendees during 
the study period 
Moderate 0.04 
Adeyemi,  et al 
[20] 
2008 USA Urban Hospital  C/S 2005-2006 Unspecified 121 NR 
54  
 
Age ≥ 50 years; outpatient Moderate  0.09 
Sobieszczyk, et 
al [21] 
2008 USA Urban 
Hospital + 
community  
C/S 2000-2004 Unspecified 1725 NR 40  Women Low 0.02 
Sterling, et al 
[22] 
2008 USA Urban Hospital  C/S 1998-2006 Unspecified 222 82 45.4 
Adults co-infected with 
HCV 
Moderate 0.04 
Ances, et al [23] 2009 USA National Hospital  C/C 
Not 
provided 
Unspecified 66 NR 41 
Cryptogenic stroke (case 
subgroup) 
Moderate 0.09 
Pullinger, et al 
[24] 
2010 USA Urban Community  C/S 2005-2007 Unspecified 296 84.6 45.3  
Age ≥ 18 years; diagnosed 
duration >3 months 
Moderate 0.05 
Krishnan, et al 
[25] 
2012 USA National Hospital  C/S 2001-2007 random 2247 88 - Age ≥13 years Low 0.02 
Hadigan, et al 
[26] 






182 72 45 
Absence of chronic NCDs 
or co-infection 
Moderate 0.05 
Tiozzo, et al [27] 2015 USA Urban Hospital  C/S 2013 
Not 
random  
89 90 48 Age ≥18 years on ART Moderate 0.1 
Da Silva, et al 
[28] 






319 NR 39.5 
ART use ≥ 2 months, and 
no anti- lipid agents 
Moderate 0.04 








C/S 2006-2007 Unspecified 4010 NR 41.9  ART use ≥1 month Moderate 0.01 
Leite, et al [30] 2010 Brazil Urban Hospital  C/S 2008 Unspecified 100 NR - - Moderate 0.1 
Ramirez-
Marrero, et al 
[31] 
2010 Puerto Rico Urban 
Hospital + 
community 
C/S 2003-2007 Random 897 31.2 44.7  - Low 0.03 
Lauda, et al [32] 2011 Brazil Urban Hospital  C/S 2007-2008 Unspecified 249 NR - Age ≥18 years Moderate 0.05 
Alencastro, et al 2012 Brazil Urban Hospital  C/S Not Not 1240 96 38.6  Age 18-79 years  Low  0.02 
37 
[33] provided random 
Gasparotto, et al 
[34] 







Unspecified 614 NR 42.6  
Age ≥18 years; ART use ≥1 
year; viral load ≤50 
copies/ml 
Moderate 0.04 
Signorini, et al 
[35] 
2012 Brazil National Hospital  C/S 2005 Unspecified 819 NR 41 Age ≥18 years  Low 0.03 
Europe NR 
Gazzaruso, et al 
[36] 
2003 Italy National Hospital  C/S 
Not 
provided 
Unspecified 287 NR 41 ART use Moderate 0.05 
Jerico, et al [37] 2005 Spain Urban Hospital  C/S 2003 Unspecified 710 88 41.9  
Age ≥20 years; no 
evidence of AIDS or ART 
disruption 
Low 0.03 
Bergersen, et al 
[38]  
2006 Norway Urban Hospital  C/S 2000-2001 
Not 
random 
263 78 43.3  - Moderate 0.04 
Estrada, et al 
[39] 





146 NR 40.6  




Bonfanti, et al 
[40] 







1243 98.4 43.2  -  Moderate 0.02 
Palacios, et al 
[41] 
2007 Spain National Hospital  C/S 2002-2003 Unspecified 60 81 40.9  ART use >48 weeks Moderate 0.09 





- Low  0.04 
Martin, et al 
(SHIVA study) 
[43] 
2008 France Urban Hospital  C/S 2003 Unspecified 140 86.9 - - Moderate 0.04 
Schillaci, et al 
[44] 
2008 Italy Urban Hospital  C/C 
Not 
provided 
Unspecified 39 NR 37 Outpatients; no ART Moderate 0.12 






Young, et al [46] 2009 Switzerland National Hospital  C/S 2000-2006 Unspecified 1644 70 - ART use Low 0.02 
Bonfanti, et al 
[47] 







292 NR 37  Age ≥18 years; ART naive Moderate 0.04 
Calza, et al [48] 2011 Italy Urban Hospital  C/S 2009 
Not 
random  
755 NR 37 Outpatients Moderate 0.02 
Cubero, et al 
[49] 





159 NR 39 
1st line ART regimen, no 
kidney or liver disease, no 
lipid modifying treatment 
or hormone use 
Moderate 0.07 






C/S 2005-2006 Random  678 66.4 39.5  - Low 0.03 
Freitas, et al [51] 2011 Portugal National Hospital  C/S 
Not 
provided 
Unspecified 345 NR 43.8 ART use lipodystrophy Moderate 0.05 
Guaraldi, et al 
[52] 
2011 Italy National 
Hospital (2 
centers) 
C/S 2007-2008 Unspecified 103 NR 46.9  Age ≥18 years on ART Moderate 0.06 
Janiszewski et al 
[53] 
2011 Italy National Hospital  C/S 2005-2009 Unspecified 2322 NR - ART use ≥ 18 months Moderate 0.02 






269 85.7 43 
Aged ≥18 years, ART use 
for 1-4 years without 
disruption 
Low  0.05 
Guaraldi, et al 
[55] 
2012 Italy National  
Hospital (2 
centers) 
C/S 2009-2010 Unspecified 133 NR - 
Men, sexually active in 
the 4 last weeks 
Moderate 0.07 





Hospital  C/S 
Not 
provided 
Unspecified 108 NR - 
Free of known CVD risk 
factors 
Moderate 0.07 
De Socio, et al 
(HIV-Hy study) 
[57] 
2014 Italy National Hospital  C/S 2010-2011 
Not 
random 










Urban Hospital  C/S 2011 Random 400 NR 41.4 
Age ≥18 years; ART use ≥ 
6 months 
Moderate 0.03 
Africa              
Zannou, et al 
[59] 
2009 Benin Urban Hospital  C/S 2004-2005 Unspecified 79 90 38 
Age > 16 years; ART use; 
not obese 
Moderate 0.07 





Urban Hospital  C/S 2009-2010 
Not 
random 
196 NR 36.8  
No lipid modifying 
medications 
Moderate 0.07 





Community  C/S 2005 Random  300 NR 44 
Aged ≥35 years; no 
chronic medications or 
self-reported disease 
Moderate 0.05 
Ayodele, et al 
[62] 





291 94 39.5  
No liver or thyroid disease 
or concurrent infections 
Moderate 0.05 
Berhane, et al 
[63] 
2012 Ethiopia Urban Hospital  C/S 2010 
 Not 
random 
313 100 - 





2013 Nigeria Urban Hospital  C/S 2009 
Not 
random 
200 NR 32.5 
Age ≥18 years; not 
diagnosed with 




Ngatchou, et al 
[65] 
2013 Cameroon Urban Hospital  C/S 2009-2010 
Not 
random 
108 NR 39 





Mbunkah, et al 
[66] 
2014 Cameroon National Hospital  C/S 2010-2011 Unspecified 173 100 38.7 - Low 0.05 
Tesfaye, et al 
[67] 
2014 Ethiopia Urban Hospital  C/S 2013 Random 374 97.2 32.6 Age ≥18 years  Low 0.04 
Asia              
Gupta, et al [68] 2011 India Urban  Hospital  C/S 2007-2009 
Not 
random  
68 NR 35.9  




Wu, et al [69] 2012 Taiwan National Hospital  C/S 2008-2009 Unspecified 803 60.2 - Age ≥18 years Low 0.03 
Bajaj, et al [70]  2013 India Urban Hospital C/S 2010-2011 
Not 
random   
70 NR - 





2014 Thailand National 
Hospital (6 
centres) 
C/S 2009-2011 Unspecified 580 99 37 Adults Low  0.03 
BMI, body mass index; C/C, case-control; C/S, cross-sectional; HCV, hepatitis C virus; NCDs, non-communicable diseases; NR, not reported. *Quality 
grades: Low risk (score range, 7-9), Moderate risk (score range, 4-6), and High risk (score range, 0-3). 
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The studies consisted of 39 to 23853 participants with men comprising 19-95% (median 
70.7%) of the samples.[60, 69] The median age of participants was 41 years (range 17-73 
years). Smoking prevalence, reported in 47 studies, was 0-84% (median 39.8%) [16, 65]. In 
the 37 studies with data on CD4 cell count, levels ranged from 105 cells/μL (Benin) [59]  to 
535 cells/μL (USA) [22]  (median 394 cells/μL). The timespan of diagnosed HIV infection, 
reported in 20 studies, was 19.3 to 224.4 months [22, 65]  (median 67.6 months) while the 
duration of ART, described in 21 studies, was 14.6-78 months [37, 59], (median 27 months). 
In the 28 studies that reported on ART usage, 45-94% of the HIV-infected participants, were 
on ART [31, 57] (median 76.2%). Of those on ART, 17.3-61.5% (median 37.4%) were on 
protease inhibitors (PIs),[29, 58] 19.4% (median 43.4%) on non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) [24, 58], and 1.5-85.5% (median 77.0%) on nucleoside 
reverse transcriptase inhibitors (NRTIs) [13, 57]. Very few studies provided information on 
the stage of the disease (S4.3 Table). 
The included studies applied various international criteria to diagnose MS (S4.4 Table). Fifty-
one studies applied a single set of criteria; the most frequently used was the ATPIII-2001 in 
30 studies followed by the ATPIII-2004-2005 (14 studies). The International Diabetes 
Federation (IDF)-2005, Joint Interim Statement (JIS)-2009 and modified ATPIII-2005 criteria 
were used in 2 studies each while the European Group for the Study of Insulin Resistance 
(EGIR)-2003 in one only. Of the 14 studies that compared the MS prevalence using two or 
more criteria, the following combinations were reported: two criteria: IDF-2005 + ATPIII-
2001 (7 studies), and IDF-2005 + ATPIII-2005 (4 studies), and three criteria (1 study each): 
IDF-2005 + ATPIII-2005 + JIS-2009; IDF-2005 + ATPIII-2001 + EGIR-2003; IDF-2005 + ATPIII-
2001 + EGIR-2003.  
Overall prevalence of metabolic syndrome 
The most commonly used criteria to determine MS prevalence, alone or in combination with 
other criteria, were the ATPIII-2001 (Figure 4.2: 38 studies, n=16984), IDF-2005 (Figure 4.3a: 
16 studies, n=8250) and ATPIII-2004-2005 definitions (Figure 4.3b: 20 studies, n=11255). The 
overall MS prevalence rates by these criteria were 16.7% (95%CI, 14.6-18.8; I2=92.1%, p-
heterogeneity <0.001), 18.0% (95%CI: 14.0–22.4; I2=95.8%, p <0.001) and 24.6% (95%CI: 





[18] (ATPIII 2001), 7.8% [14] to 43.2% [51] (IDF 2005) and 12.3% [58] to 52% [30] (ATPIII 
2004-2005).
 
Figure 4.2. Overall metabolic syndrome prevalence in the HIV-infected populations 
according to the Adult Treatment Panel III (ATPIII) 2001 criteria 
For each study the black box represents the study estimate (prevalence of the metabolic syndrome 
[MS]) and the horizontal bar the 95% confidence intervals (95%CI). The size of the boxes is 
proportional to the inverse variance. The diamond at the lower tail of the figure is for the pooled 
effect estimates from random effects models. The proportional contribution of each study (weight) to 
the pooled estimates is also shown, together with the prevalence estimates and measures of 
heterogeneity. The dotted vertical line is centred on the pooled estimates. 
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Figure 4.3a. Overall metabolic syndrome prevalence in the HIV-infected populations 
according to the International Diabetes Federation 2005 criteria  
(Conventions are per Figure 4.2) 
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Figure 4.3b. Pooled metabolic syndrome prevalence in the HIV-infected, overall and 
presented by continent 
Adult Treatment Panel III 2005 criteria: Conventions are per Figure 4.2. In addition, pooled effect 
estimates are provided separately for each continent. The horizontal arrow head indicates that the 





The highest overall MS prevalence was by the EGIR criteria (31.3%, 95%CI: 26.8–36.0; 
I2=9.8%, p=0.300) used in two studies (n=446) (S4.1 Figure). A similarly high prevalence by 
the JIS criteria (29.6%, 95%CI: 22.9-36.8; I2=91%, p <0.001) was based on four studies 
(n=2404) (S4.2 Figure). MS prevalence by the modified ATPIII 2005 criteria, obtained from 
two studies (n = 23919), was also high at 27.9% (95%CI: 6.7–56.5; I2=95.8%, p <0.001) (S4.3 
Figure). However, there were relatively few studies that determined the MS by these three 
criteria. The margin of error (precision) across studies ranged from 1% to 12%, with only 18 
studies (28%) having a margin of error >5% (Table 4.1). 
With a wide range of 16.7% to 31.3%, the pooled prevalence of MS differed significantly by 
the various diagnostic criteria (p <0.001). Unsurprisingly, however, MS prevalence by 
modified criteria was similar to that of studies that used the related original definition (S4.4 
Table). There was insufficient evidence of publication bias (all p ≥0.060 for the Egger test) 
except for studies that used the ATPIII 2001 criteria (p-Egger test=0.040) (Figure 4.4) 
Prevalence of metabolic syndrome within and across subgroups 
Some of the findings are presented in the accompanying tables and figures while other data 
such as the prevalence of MS by age, intra-country location, duration of HIV infection, ART 
status, treatment period and year of publication are reported in the supplementary tables 
and figures. 
Age  
Older (>median age 41 years) compared with younger participants (≤41 years) had higher 
MS prevalence (S4.5 Table): ATPIII-2001: 19.7% vs. 13.2%, p <0.001, ATIII 2004-2005: 26.6% 
vs. 21.5%, p=0.479 and IDF-2005: 22.3% vs. 16.4%, p=0.361. Substantial heterogeneity was 




Figure 4.4. Funnel plots for included studies across different diagnostic criteria for the 
metabolic syndrome  
For the diagnostic criteria, the arcsine transformed proportion of participants with metabolic syndrome 
(relative to the total sample) for each relevant study (horizontal axis) is plotted against its standard 
error (vertical axis) and represented by the dots. When the dots distribute symmetrically in a funnel 
shape, this implies an absence of bias. A p-value <0.05 (Egger test) indicates significant publication bias. 












































































Thirty-two of the 65 studies presented the MS data by gender; of these a single study was 
conducted in men only (Italy) [55] and two in women only (USA) [18, 21]. The criteria most 
commonly used was the ATPIII 2001 in 16 studies for men (n=8269) and 17 studies for 
women (n=3971). This was followed by the ATPIII 2004-2005 (13 studies, men: n=5742, 
women: n=4470) and IDF 2005 definitions (11 studies, men: n=3556, women: n=2293). The 
MS prevalence in men and women was as follows: ATPIII 2001: 14.6% (95%CI: 11.5-18.1) 
and 17.5% (95%CI: 14.0-21.2); ATPIII 2004-2005: 23.7% (95%CI: 19.0-28.7) and 26.7% 
(95%CI: 20.8-33.0); and IDF 2005: 13.4% (95%CI: 8.7-18.9) and 23.2% (95%CI: 15.9-31.4); 
Figure 4.5 and S4.5 Table. MS prevalence by the various criteria was significantly different in 
men (p=0.001) but not in women (p=0.118). Heterogeneity presented within gender-groups 
across criteria (all p-heterogeneity <0.001) 
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Figure 4.5. Pooled metabolic syndrome prevalence in the HIV-infected presented by gender 
according to the International Diabetes Federation 2005 criteria 
(Conventions are per Figures 4.2 and 4.3b) 
HIV-related factors 
Duration of diagnosed HIV infection 
The prevalence of MS, categorised by the duration of diagnosed HIV infection (median cut-
off point 68 months), differed across MS criteria (S4.5 Table). By the ATPIII-2001 definition, 
MS prevalence was significantly higher (p=0.044) in participants with longer (20.6%, 95%CI: 
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13.8-28.4) compared to shorter duration of diagnosed HIV-infection (13.2%, 95%CI: 11.2-
15.4). However, by the ATPIII-2004-2005, MS prevalence was not significantly different: 
longer: 32.0% vs. shorter: 19.1%, p=0.251. There was substantial heterogeneity across and 
within criteria for MS prevalence by the duration of diagnosed HIV infection; all p-
heterogeneity <0.030 for within criteria except for studies below the median duration which 
used the ATPIII-2001 criteria (p-heterogeneity=0.581) 
CD4 counts 
Using a median cut-off point of 394 cells/μL, MS prevalence in participants with high CD4 
counts was significantly lower than in those with low CD4 counts by the IDF 2005 criteria: 
10.4% (8.2–12.9) vs. 17.5% (14.4–20.8), p <0.001 (S4.5 Table). However, there was little 
difference in MS prevalence by CD4 count levels using the ATPIII-2001 (17.4% vs. 15.6%, 
p=0.514) and ATPIII-2004-2005 definitions (24.6% vs. 26.5%, p=0.747). The prevalence 
across MS diagnostic criteria was significantly different by CD4 count levels (all p <0.020). 
Substantial heterogeneity was noted in MS prevalence by CD4 count levels within studies 
that applied the ATPIII-2001 and ATPIII-2004-2005 criteria (all p-heterogeneity ≤0.035) but 
not within studies that used the IDF-2005 definition (p-heterogeneity≥0.272) 
Exposure to antiretroviral therapy 
In studies that included treatment status (S4.5 Table), the most commonly used MS criteria 
was the ATPIII 2001 (ART-exposed: 20 studies, n=12148, ART-naïve: 17 studies, n=2659). MS 
prevalence, at 18.4% (95% CI: 15.9–21.1) in the ART-exposed, was significantly higher 
(p=0.001) than in the ART-naïve (11.8%, 95%CI: 9.3–14.7) (Figure 4.6). MS prevalence by the 
IDF 2005 criteria was also higher in the ART-exposed (19.6%, 95%CI: 14.2-25.6) compared to 
the ART-naïve (14.9%, 95%CI: 8.6-22.6) but this difference was not significant; prevalence 
was similar by the ATPIII 2004-2005 definition (21.6%, 95%CI: 13.5-31.0 vs. 19.9%, 95%CI: 
18.3–21.5). Interestingly, MS prevalence by the various criteria was similar in the ART-
exposed (p=0.730) but significantly different in the ART-naïve (p <0.001). Excluding the non-
ART studies based on the ATPIII-2004-2005 where homogeneity was found (p-
heterogeneity=0.398), there was significant heterogeneity within ART-exposed and ART-






Figure 4.6. Pooled metabolic syndrome prevalence in the HIV-infected presented by 
antiretroviral therapy (ART) use according to the Adult Treatment Panel 2001 criteria 
(Conventions are per Figures 4.2 and 4.3b) 
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Proportions of ART users and duration of ART treatment 
MS prevalence by a high or low proportion of ART users (median cut-off point 76.2%) was 
not significantly different within criteria: ATPIII 2001: 15.8% vs. 19.1%, p=0.172; ATPIII 2004-
2005: 38.3% vs. 23.8%, p=0.256; IDF 2005: 14.4% vs. 19.4%, p=0.176. Using a cut-off point of 
27 months for the median length of ART use, MS prevalence was not significantly different 
for a longer or shorter treatment duration within MS criteria: ATPIII 2001: 17.1% vs. 15.6%, 
p=0.649; ATPIII 2004-2005: 25.6% vs. 14.2%, p=0.192; IDF 2005: 14.6% vs. 13.4%, p=0.811. 
The prevalence within the two sub-groups was similar across MS criteria (all p ≥0.111). 
Substantial heterogeneity was noted within all the above subgroups (all p-
heterogeneity <0.001).  
ART regimen 
The median proportion of participants using PIs across the included studies was 37.4% (S4.5 
Table). Using this cut-off point, the pooled MS prevalence in studies with more compared to 
fewer PI users by the IDF 2005 criteria was 18.5% (95%CI: 12.3–25.6) from six studies 
(n=4927) versus 10.0% (95%CI: 7.2–13.4) (p=0.016) in a single study (n=400). However, the 
MS prevalence by proportion of PI users was not significantly different by the ATPIII 2001 
(17.7% vs. 19.3%, p=0.593) and ATPIII 2004-2005 definitions (25.8% vs. 30.4%, p=0.517). MS 
prevalence, determined by the various criteria, differed across studies of PI users (p=0.022) 
and in those with fewer median participants on PIs (p=0.001).  
The median proportion of participants using NNRTIs was 43.4%, the cut-off value used to 
determine a high and low proportion of users. The pooled MS prevalence in studies with 
more compared to fewer NNRTI users was 17.2% (95%CI: 9.5-26.6) versus 33.8% (95%CI: 
23.4- 45.1) (p=0.020) by the ATPIII 2004-2005 criteria. MS prevalence according to NNRTI 
regimen status was not significantly different by the ATPIII 2001 (19.5% vs. 15.1%, p=0.221) 
and IDF 2005 criteria (10.5% vs. 19.8%, p=0.058). However, MS prevalence within the two 
NNRTI subcategories was significantly different by the various MS criteria (all p <0.007). 
(S4.5 Table) 
In studies with a high proportion of participants on NRTI (median >77.0%), the pooled 
prevalence by the ATPIII 2001 criteria was 17.9% (95%CI: 9.4-28.7) compared to 22.8% 
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(95%CI: 14.3-32.7) in studies with fewer participants on NRTIs (p=0.474) (S4.5 Table). There 
was insufficient data by the IDF 2005 and ATPIII 2004-2005 criteria for analysis.  
Study location 
Intercontinental 
The ATPIII 2004-2005 MS criteria was the only one commonly used by studies across 
continents. The pooled MS prevalence by these criteria was the highest in the Americas (9 
studies, n=7450) at 27.3% (95%CI: 21.7-33.4; I2=96.6%, p <0.001).  This was followed by 
Europe (5 studies, n=1571) and Asia (4 studies, n=1521) where the prevalence was similar. 
At 24.1% (95%CI: 11.2–40.1; I2=97.7%, p<0.001) in Europe and 24.1% (95%CI: 21.6–26.8; 
I2=16.8%, p=0.307) in Asia, MS prevalence on these continents were almost as high as in the 
Americas. MS prevalence in Africa (2 studies, n=713), however, was much lower at 16.4% 
(95%CI: 8.7–25.9; I2=90%, p=0.002), (Figure 4.3b and S4.5 Table). The differences in 
prevalence across continents was not statistically significant (p=0.284).  
Intra-country 
MS prevalence was similar across regional studies compared with the corresponding 
national data (ATPIII 2001: 16.0% vs. 17.1%, p=0.607; ATPIII 2004-2005: 24.3% vs. 25.4%, 
p=0.861; IDF 2005: 17.4% vs. 18.7%, p=0.785) (S4.5 Table). According to the criteria used, 
the prevalence of MS within a country differed in regional studies (p=0.024) but was not 
significantly different in national studies (p=0.109).  
Year of publication 
The prevalence of MS in studies reported before, compared to after, 2010 was significantly 
higher by the ATPIII 2004-2005 criteria (30.6% vs. 21.5%, p=0.012) but not by the other 
definitions (all p >0.100). However, MS prevalence in the earlier publications differed 
significantly by criteria (16.4% vs. 30.6% vs. 14.5% for ATPIII-2001, ATPIII-2004-2005, IDF-





Sample size and smoking status 
The median number of participants per study was 292 with this sample size used to classify 
studies as either large or small. MS prevalence was similar in large and small studies within 
criteria: ATPIII 2001:18.3% vs. 15.1%, p=0.115; ATPIII 2004-2005: 24.7% vs. 25.6%, p=0.989; 
IDF 2005: 19.0% vs. 16.1%, p=0.388. There was no significant difference in prevalence by 
sample size category across MS criteria (all p ≥0.059).  
Smoking status 
The absence of a significant difference in the prevalence of MS in studies with a high or low 
proportion of smokers (median 39.8%) within criteria is demonstrated in S4.5 Table. The 
prevalence was as follows: ATPIII 2001: 14.8% vs. 17.6%, p=0.234; ATPIII 2004-2005: 28.8% 
vs. 22.2%, p=0.193; IDF 2005: 18.4% vs. 14.6%, p=0.565. However, MS prevalence varied 
significantly across criteria in studies with a higher proportion of smokers (p=0.010). There 
was substantial heterogeneity within all the above subgroups (all p-heterogeneity <0.001).  
Discussion 
Overview of MS prevalence 
To our knowledge, this is the first comprehensive review and meta-analysis of the MS 
prevalence in the global HIV-infected population. Among the key findings was the high 
burden of MS in the HIV-infected population; 16.7-31.3% of HIV-infected adults had MS by 
the various definitions. The wide prevalence range is indicative of substantial 
heterogeneities across and within the diagnostic criteria. Two different criteria, the ATPIII-
2001 and the EGIR-2003, reported the overall lowest and highest prevalence, respectively. 
Notably, the differences in prevalence were not fully explained by the major study 
characteristics. For example, variations in MS prevalence were also apparent within 
subgroups such as in younger participants, men, the Americas, regional studies, older 
publications and smokers.  
Notably, the MS prevalence in the HIV-infected is within the range of the 17-46% reported 
in the general population. This suggests that the drivers of MS in HIV-infected individuals are 





traditional cardio-metabolic risk factors in the former; these are likely to exert an equal 
influence on HIV-infected individuals as they do in the general population. The wide range in 
MS prevalence in the general population mimics that found in this review and is possibly 
due to similar reasons discussed above [72-74]. 
The similar exposure to cardio-metabolic risk factors in the HIV-infected compared to the 
general population is likely attributable to the introduction of ART which has dramatically 
reduced HIV-related morbidity and mortality. ART has prolonged lifespans and subsequently 
enabled the HIV-infected to be exposed to the same risk factors and diseases as the general 
population. Reinforcing the likelihood of similar pathways in the development of MS in the 
HIV-infected and general populations was the higher MS prevalence in older compared to 
younger HIV-infected individuals, which is mirrored in general populations [72].  
The higher MS prevalence in women compared to men in this analysis has also been shown 
in general populations but reports diverge in the latter [72-74]. Further research may be 
required to understand the differences in MS prevalence by gender which is usually driven 
by higher rates of obesity [75]. There may also be HIV specific factors that contribute to 
greater cardio-metabolic abnormalities in women compared to men that require further 
investigation.  
MS prevalence by diagnostic criteria 
Across the three major criteria (ATPIII 2001, ATPIII 2004-2005, and IDF 2005) used by most 
studies in this review, the estimated MS prevalence was highest by the ATPIII 2004-2005 
definition (24.6%). This was not unexpected because the threshold for hyperglycaemia in 
the ATPIII 2004-2005 is lower than that for the ATPIII 2001criteria; this leads to more 
individuals diagnosed with MS by the former classification. Furthermore, the inclusion of 
lipid-lowering and/or antihypertensive medications in the ATPIII 2004-2005 definition also 
contributes to a higher MS diagnosis compared with the ATPIII 2001. In contrast, the 
compulsory incorporation of waist circumference in the IDF 2005 criteria excludes many 
HIV-infected participants with abnormal biochemical parameters but normal waist 
circumference from the diagnosis. This is of particular relevance and frequently reported in 
HIV studies [13, 17, 25, 50, 68, 76].  
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Not surprisingly, few studies that used more than one definition to diagnose MS applied the 
same combination of criteria [13, 49]. In this review, direct comparison of MS prevalence by 
the various criteria is not meaningful because there was substantial overlap of the 
confidence intervals around the prevalence estimates. Also, only few studies used multiple 
diagnostic criteria which would limit the value of such an analysis.  
HIV-related influences on MS prevalence 
Although HIV specific characteristics were associated with the prevalence of MS in the 
current analyses, these need to be interpreted with care because of the inability to control 
for the many confounding influences. Nonetheless, the association of MS prevalence with a 
greater duration of diagnosed HIV infection accords with the influence of HIV infection on 
the development of cardio-metabolic abnormalities. Then again, a longer interval since HIV 
diagnosis likely correlates with older age, which is a risk factor for MS in both the HIV-
infected and general populations. It may also possibly reflect the specific effects of 
prolonged ART.  
The relation between CD4 count and MS was unclear with some studies reporting a direct 
link [19, 35] while others demonstrate the inverse [67] or no association [54, 66]. However, 
these findings were based on only seven studies and did not report the viral loads [42, 49, 
58-60, 62, 68]. Without such information, it is difficult to draw conclusions on this
relationship o. A high viral load has been associated with the development of MS, possibly 
contributing to the high incidence of low high density lipoprotein cholesterol (HDL-C) levels 
and high triglycerides in some studies [16, 47].  
The higher MS prevalence in ART-exposed compared to ART-naïve participants by the ATPIII-
2001 criteria was consistent with findings from prospective studies. One of these studies 
demonstrated an increase in MS prevalence from 16.6% to 25% with an incidence of 14/100 
patients-year among participants initiated and maintained on the same HAART regimen for 
48 weeks [41]. In another study, a large international, multicentre, randomised trial 
conducted for three years after the initiation of ART, the incidence of MS was 12/100 





respectively [14]. Also, the D:A:D study which followed HIV patients on ART over a long 
period, demonstrated a substantial increase in MS prevalence [15]. 
ART regimen was significantly associated with MS with notable differential findings by the 
class of drug used. The higher MS prevalence in studies with a greater compared to smaller 
proportion of PI users accords with four trials where PI-based regimens were found to 
accelerate progression to MS [17, 25]. The initiation of ART leads to chronic inflammation 
and an incompletely restored immune system. This may perhaps be the link between PI use 
and the development of MS [56, 77]. Patients on this regimen thus need to be closely 
monitored for the development of cardio-metabolic abnormalities. Moreover, once such 
abnormalities arise, it is important to review ART management and change to metabolically 
neutral regimens.  
An alternative ART regimen to PIs in patients with MS may be NNRTIs because a lower MS 
prevalence, by some criteria, was detected in studies with a high compared to low 
proportion of participants on these drugs. Although our analyses were based on only seven 
studies [17, 19, 31, 50, 51, 58, 69] this suggests that, unlike PIs, NNRTIs do not adversely 
influence cardio-metabolic function and may possibly even have a beneficial impact. Indeed, 
a randomised controlled study reported improvements in cardio-metabolic profiles with 
increases in HDL-C levels in patients on nevirapine and nelfinavir [78]. On the other hand, 
several prospective trials have found no association between the use of NNRTIs and MS [17, 
25]. Further research is required to clearly describe the relationship between NNRTIs and 
cardio-metabolic functioning, particularly since there is a dearth of data on the influence of 
this class of ART on MS.  
Other influences on MS prevalence  
Although there was no difference in MS prevalence between studies with a high and low 
proportion of smokers, conclusions on the absence of an association should be cautioned 
against. The studies analysed included only current smokers with no consideration given to 
recent smoking cessation or ex-smokers. Reports describe the duration of smoking cessation 
to be inversely related to future cardiovascular disease risk to a moderate degree. 





quantity smoked have been strongly correlated with the development of MS and 
atherosclerosis progression [79-81]. 
The lower MS prevalence by the ATPIII 2004-2005 criteria in recent compared to older 
publications was surprising. We expected the trend to mimic that of the general population 
with a rise in MS prevalence in the HIV-infected over time. Moreover, with the introduction 
and widespread uptake of ART leading to longevity, we anticipated the subsequent 
development of MS with age, which would be reported in recent publications. Nevertheless, 
our findings are elucidated by the differences in participant characteristics between the two 
publication periods. Participants in publications prior to 2010 were older and included more 
women who were shown to have a higher MS prevalence than men in this review.  
Despite an unbalanced representation of studies worldwide, the prevalence of MS was 
essentially similar within and across the major regions including by continent and intra-
country site, regardless of the definition criteria used. The absence of studies conducted 
specifically in rural settings with a likely lower MS prevalence than in urban centres, 
particularly in developing regions, may account for this finding. Alternatively, it may perhaps 
reflect the ubiquitous worldwide influence of globalisation and highlight the likelihood of 
similar influences on the development of MS in the HIV-infected population globally. Thus, 
broad-based general strategies may perhaps be devised to address the MS burden in all HIV-
infected populations.   
Strengths and limitations 
We searched multiple databases extensively, applying reproducible criteria to capture the 
most number of studies on MS prevalence worldwide. This allowed us to provide a 
comprehensive global perspective on the emerging burden of adverse cardio-metabolic 
profiles in the HIV-infected population. Furthermore, we used robust approaches to pool 
studies while minimising the effects of extreme studies. We also used a detailed approach 
to investigate the potential sources of heterogeneity. Our post-hoc power estimation 
revealed that over two-thirds of the included studies were adequately powered to provide 
precise estimates of the MS prevalence in the overall sample. This has likely translated into 





Our findings may not be generalizable to all HIV-infected individuals because most of the 
studies were conducted in non-randomly selected populations. The wide range in MS 
prevalence, because of the different criteria used across studies, although expected, made 
estimations of the actual burden difficult. Nevertheless, apart from differences in the 
criteria themselves that contributed to this wide range, other factors were also likely 
responsible. For example, MS prevalence would be expected to differ across time, 
particularly in the HIV-infected as access to care expanded, the uptake of ART increased and 
the effectiveness of therapy improved with the introduction of HAART.  
The infrequent reporting of the HIV specific markers of CD4 count and viral load precluded 
in-depth analyses of their effects on MS. Similarly, data were missing on key study 
characteristics which could be used in advanced analyses via meta-regressions. 
Furthermore, the inconsistent number of studies across subgroups precluded meta-
regression analyses to investigate the possible contribution of each factor to MS prevalence. 
However, such comparisons would possibly have been biased by differences in study design 
and objectives, data collection techniques, laboratory facilities and participant 
characteristics, and could not have been fully accounted for in our meta-analyses. Especially 
difficult to control for would be HIV related characteristics such as differences in disease 
stage, fat distribution including lipodystrophy, obesity and co-existent infections such as 
hepatitis C and hepatitis B [82]. 
Conclusions  
The MS prevalence in HIV-infected individuals worldwide appears to be similar to that found 
in the general population, suggesting similarities in the drivers of the syndrome, 
independent of HIV status. Indeed, despite suggestions of significant signals, the 
inconsistent association of HIV specific features including treatments with MS prevalence 
suggest that their contribution, if any, is of a lesser magnitude. Comparable with general 
populations, traditional risk factors are likely the major contributors to the burden of cardio-
metabolic abnormalities and MS in HIV-infected individuals. Therefore, management 
strategies implemented in the general population for these conditions, will likely reap 





strengthening approaches to maximise cardio-metabolic care while simultaneously ensuring 








S4.1 Table. Details of the search strategies  
PubMed 
Search (((((((("Metabolic Syndrome X"[Mesh]) OR Metabolic Syndrome) OR Reaven Syndrome) OR 
Cardiometabolic syndrome) OR cardiometabolic disease) OR syndrome X)) AND (((((HIV[MeSH Terms]) OR HIV) 
OR human immunodeficiency virus)) OR (((acquired immunodeficiency syndrome[MeSH Terms]) OR acquired 
immunodeficiency syndrome) OR AIDS))) AND ((((prevalence[MeSH Terms]) OR prevalence) OR 
epidemiology[MeSH Terms]) OR epidemiology) Filters: Publication date from 1998/01/01 to 2015/04/30 
Scopus 
(TITLE-ABS-KEY (prevalence OR epidemiology)) AND ((TITLE-ABS-KEY(hiv OR aids)) AND ((TITLE-ABS-
KEY(metabolic syndrome x)) OR (TITLE-ABS-KEY(metabolic syndrome)))) AND (LIMIT-TO(PUBYEAR, 2015) 
(LIMIT-TO(PUBYEAR, 2014) OR LIMIT-TO(PUBYEAR, 2013) OR LIMIT-TO(PUBYEAR, 2012) OR LIMIT-
TO(PUBYEAR, 2011) OR LIMIT-TO(PUBYEAR, 2010) OR LIMIT-TO(PUBYEAR, 2009) OR LIMIT-TO(PUBYEAR, 2008) 
OR LIMIT-TO(PUBYEAR, 2007) OR LIMIT-TO(PUBYEAR, 2006) OR LIMIT-TO(PUBYEAR, 2005) OR LIMIT-
TO(PUBYEAR, 2014) OR LIMIT-TO(PUBYEAR, 2013) OR LIMIT-TO(PUBYEAR, 2012) OR LIMIT-TO(PUBYEAR, 2011) 
OR LIMIT-TO(PUBYEAR, 2010) OR LIMIT-TO(PUBYEAR, 2009) OR LIMIT-TO(PUBYEAR, 2008) OR LIMIT-
TO(PUBYEAR, 2007) OR LIMIT-TO(PUBYEAR, 2006) OR LIMIT-TO(PUBYEAR, 2005) OR LIMIT-TO(PUBYEAR, 2004) 
OR LIMIT-TO(PUBYEAR, 2003) OR LIMIT-TO(PUBYEAR, 2002) OR LIMIT-TO(PUBYEAR, 2001) OR LIMIT-
TO(PUBYEAR, 2000) OR LIMIT-TO(PUBYEAR, 1999) OR LIMIT-TO(PUBYEAR, 1998) OR LIMIT-TO(PUBYEAR, 2014) 
OR LIMIT-TO(PUBYEAR, 2013) OR LIMIT-TO(PUBYEAR, 2012) OR LIMIT-TO(PUBYEAR, 2011) OR LIMIT-
TO(PUBYEAR, 2010) OR LIMIT-TO(PUBYEAR, 2009) OR LIMIT-TO(PUBYEAR, 2008) OR LIMIT-TO(PUBYEAR, 2007) 
OR LIMIT-TO(PUBYEAR, 2006) OR LIMIT-TO(PUBYEAR, 2005) OR LIMIT-TO(PUBYEAR, 2004) OR LIMIT-
TO(PUBYEAR, 2003) OR LIMIT-TO(PUBYEAR, 2002) OR LIMIT-TO(PUBYEAR, 2001) OR LIMIT-TO(PUBYEAR, 2000) 
OR LIMIT-TO(PUBYEAR, 1999) OR LIMIT-TO(PUBYEAR, 1998)) 
EbscoHost 
S9 S3 AND S8 (prevalence OR epidemiology) AND (((HIV OR human immunodeficiency virus) OR (AIDS OR 
acquired immunodeficiency syndrome)) AND (Metabolic syndrome X OR metabolic Syndrome)) 
S8 S6 AND S7 (((HIV OR human immunodeficiency virus) OR (AIDS OR acquired immunodeficiency 
syndrome)) AND (Metabolic syndrome X OR metabolic Syndrome)) 
S7 S2 OR metabolic syndrome (Metabolic syndrome X OR metabolic Syndrome)  
S6 S4 OR S5 ((HIV OR human immunodeficiency virus) OR (AIDS OR acquired immunodeficiency 
syndrome)) 
S5 AIDS OR acquired immunodeficiency syndrome   
S4 HIV OR human immunodeficiency virus   
S3 prevalence OR epidemiology   
S2 (MM "Metabolic Syndrome X+")   
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S4.2 Table. Quality assessment checklist for prevalence studies (adapted from Hoy et al. [8])
Name of author(s):  
Year of publication: 
Study title:  
Risk of bias items Risk of bias levels Points 
scored 
1. Was the study’s target population a close 
representation of the national population 
in relation to relevant variables, e.g. age,
sex, occupation? 
Yes (LOW RISK): The study’s target population was a close representation of the 
national population.  
0 
No (HIGH RISK): The study’s target population was clearly NOT representative of 
the national population.   
1 
2.  Was the sampling frame a true or close 
representation of the target population? 
Yes (LOW RISK): The sampling frame was a true or close representation of the 
target population.   
0 
No (HIGH RISK): The sampling frame was NOT a true or close representation of 
the target population.   
1 
3. Was some form of random selection 
used to select the sample, OR, was a 
census undertaken? 
Yes (LOW RISK): A census was undertaken, OR, some form of random selection 
was used to select the sample (e.g. simple random sampling, stratified random 
sampling, cluster sampling, systematic sampling).   
0 
No (HIGH RISK): A census was NOT undertaken, AND some form of random 
selection was NOT used to select the sample.   
1 
4.  Was the likelihood of non-response bias 
minimal? 
Yes (LOW RISK): The response rate for the study was ≥75%, OR, an analysis was 
performed that showed no significant difference in relevant demographic 
characteristics between responders and non- responders   
0 
No (HIGH RISK): The response rate was <75%, and if any analysis comparing 
responders and non-responders was done, it showed a significant difference in 
relevant demographic characteristics between responders and non-responders 
1 
5.  Were data collected directly from the 
subjects (as opposed to a proxy)? 
Yes (LOW RISK): All data were collected directly from the subjects. 0 
No (HIGH RISK): In some instances, data were collected from a proxy. 1 
6. Was an acceptable case definition used 
in the study? 
Yes (LOW RISK): An acceptable case definition was used. 0 
No (HIGH RISK): An acceptable case definition was NOT used 1 
7.  Was the study instrument that 
measured the parameter of interest (e.g. 
prevalence of low back pain) shown to 
have reliability and validity (if 
necessary)? 
Yes (LOW RISK): The study instrument had been shown to have reliability and 
validity (if this was necessary), e.g. test-re- test, piloting, validation in a previous 
study, etc.   
0 
No (HIGH RISK): The study instrument had NOT been shown to have reliability or 
validity (if this was necessary).  
1 
8.  Was the same mode of data collection 
used for all subjects? 
Yes (LOW RISK):  The same mode of data collection was used for all subjects.  0 
No (HIGH RISK):  The same mode of data collection was NOT used for all 
subjects.  
1 
9. Were the numerator(s) and denominato 
r(s) for the parameter of interest 
appropriate
Yes (LOW RISK): The paper presented appropriate numerator(s) AND 
denominator(s) for the parameter of interest (e.g. the prevalence of low back 
pain).  
0 
No (HIGH RISK): The paper did present numerator(s) AND denominator(s) for 
the parameter of interest but one or more of these were inappropriate.  
1 
10. Summary on the overall risk of study bias LOW RISK 0-3 
MODERATE RISK 4-6 




























































































































HIV disease stage 
Stage 1+2  Stage 3+4  Stage A Stage B Stage C 
   % mean % % % mean 
mean 
(Log10) 
mean mean % % % % % % % % % 
Adeyemi,  et al, 2008 [20] Overall 121 79 54 65 NR NR 382 NR 144 NR NR NR NR NR NR NR NR NR NR 
 Men 95 NA 54 66 NR NR 383 NR 140 NR NR NR NR NR NR NR NR NR NR 
 Women 26 NA 54 61 NR NR 376 NR 153.6 NR NR NR NR NR NR NR NR NR NR 
Alencastro, et al, 2012 [33] Overall 1240 51 38.6 NR NR NR NR NR 58.8 NR 65.7 37.7 NR NR NR NR NR NR NR 
 Men 628 NA 39.5 NR NR NR NR NR 62.4 NR 66.9 33.8 NR NR NR NR NR NR NR 
 Women 612 NA 37.7 NR NR NR NR NR 55.2 NR 64.5 42.0 NR NR NR NR NR NR NR 
Ances, et al, 2009 [23] Overall 66 82 41 NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR 
Awotedu, et al, 2010 [60] Overall 196 19 36.8 NR NR NR 366 NR NR NR NR NR NR NR NR NR NR NR NR 
 ART 86 13 37.7 NR NR NR 350 NR NR NR NR NR NR NR NR NR NR NR NR 
 No-ART 110 24 36 NR NR NR 379 NR NR 0 0 NR NR NR NR NR NR NR NR 
Ayodele, et al, 2012 [62] Overall 291 33 39.5 1.4 NR NR 326 NR NR 17.2 81 NR NR NR NR NR NR NR NR 
 Men 95 NA 42.5 4.3 NR NR 250 NR NR 15.6 81 NR NR NR NR NR NR NR NR 
 Women 196 NA 38 0.5 NR NR 362 NR NR 18 81 NR NR NR NR NR NR NR NR 
Badiou, et al, 2008 [42] Overall 232 75 41 70 37 NR 465 2.9 NR 37 80 46 31 NR NR NR NR NR NR 
Bajaj, et al, 2013 [70] Overall 70 71.4 NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR 
Baum, et al, 2006 [16] Overall 118 74 41.7 84 NR NR 333 9.3 NR NR 71 36.5 NR NR NR NR NR NR NR 
 Men 87 100 NR NR NR NR 316 9.2 NR NR NR NR NR NR NR NR NR NR NR 
 Women 31 0 NR NR NR NR 382 9.6 NR NR NR NR NR NR NR NR NR NR NR 
Bergersen,et al, 2006 [38] Overall 263 81 43.3 54.7 NR NR 380 2.6 61.4 26 78.7 NR NR NR NR NR NR NR NR 
 ART 207 81.6 43.4 55.1 NR NR 380 2.1 85.5 33 100 77 39 NR NR NR NR 27.5 NR 
 No-ART 56 76.8 42.8 53.6 NR NR 380 4.6 37.3 0 0 NA NA NR NR NR NR 1.8 NR 
Berhane, et al, 2012 [63] Overall 313 34.8 NR NR 12.1 NR NR NR NR NR NR NR NR NR 43.5 56.5 NA NA NA 





 ART 269 66.9 43 48.3 14.5 NR 438 2.4 56.4 29.8 100 NR NR NR NA NA 51.3 24.2 24.5 
Bonfanti, et al, 2010 [47] Overall 292 75 37 50.7 NR NR NR NR NR NA NA NA NA NA NA NA 80 10.6 9.4 
Bonfanti, et al, 2007 [40] Overall 1243 71.8 43.2 60.2 NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR 
Cahn, et al, 2010 [29] Argentina 1015 70.4 41.6 34.1 NR NR 447 2.1 NR 23 100 36.2 61.9 NR NR NR NR NR NR 
 Brazil 1001 65.4 44 22.1 NR NR 474 2.3 NR 40 100 51.4 51.8 NR NR NR NR NR NR 
 Colombia 474 86.7 40.8 18.9 NR NR 390 2.2 NR 23 100 38 58.9 NR NR NR NR NR NR 
 Chile 44 90.9 40.6 50.0 NR NR 362 2.2 NR 24.5 100 20 81.8 NR NR NR NR NR NR 
 Ecuador 252 77.8 39 10.3 NR NR 363 2.7 NR 19 100 30.6 70.6 NR NR NR NR NR NR 
 Peru 417 70.7 39.1 15.6 NR NR 255 2.8 NR 18 100 31.9 71.7 NR NR NR NR NR NR 
 Venezuela 807 80.9 42.6 18.2 NR NR 452 2.4 NR 27 100 61.5 38.2 NR NR NR NR NR NR 
Calza, et al, 2011 [48] Overall 755 66.2 37 35 40.5 NR 453 4.1 85.3 66 87 41.2 43.4 NR NA NA 68 28 4.0 
Cubero, et al, 2011 [49] Overall 159 75.5 39 64.2 44.6 NR 388 3.7 63 NR 100 NR NR NR NR NR NR NR NR 
 ART 159 75.5 39 64.2 44.6 NR 388 3.7 63 NR 100 NR NR NR NR NR NR NR NR 
Da Silva, et al, 2009 [83] Overall 319 60.9 39.5 27 NR NR 502.9 NR 61 NR 76.2 NR NR NR NR NR NR NR NR 
 ART 243 59.7 41 25.5 NR NR 476.5 NR 69.6 NR 100 NR NR NR NR NR NR NR NR 
 No-ART 76 65.8 34.8 30.3 NR NR 587.2 NR 33.6 0 0 NR NR NR NR NR NR NR NR 
De Socio, et al, 2014 [57] Overall 765 74 45.6 49.9 30.8 NR NR NR NR NR 94 53.4 38.8 1.5 NR NR NR NR NR 
Elgalib, et al, 2011 [50] Overall 678 74 39.5 38.3 NR NR NR NR NR 26 74 37 38 NR NR NR NR NR NR 
Estrada, et al, 2006 [39] Overall 146 65.8 40.6 67.1 67.3 NR 527 2.13 NR NR 100 NR NR NR NR NR NR NR NR 
 ART 146 65.8 40.6 67.1 67.3 NR 527 2.13 NR NR 100 NR NR NR NR NR NR NR NR 
Fourie, et al, 2010 [61] Overall 300 38.7 44 42.3 NR NR NR NR NR NA NA NA NA NA NR NR NR NR NR 
Freitas, et al, 2011 [51] Overall 345 69.3 43.8 43.2 58.7 NR NR NR NR NR NR NR NR NR NR NR NR NR NR 
Gasparotto, et al, 2012 [34] Overall 614 55.5 42.6 NR NR NR NR NA NR NR 100 NR NR NR NR NR NR NR NR 
 ART 614 55.5 42.6 NR NR NR NR NA NR NR 100 NR NR NR NR NR NR NR NR 
 Men 341 100 43.6 NR 48.5 NR NR NR NR 59 100 47.5 NR NR NR NR NR NR NR 
 Women 237 0 41.3 NR 54.8 NR NR NR NR 59.5 100 51.6 NR NR NR NR NR NR NR 
Gazzaruso, et al, 2003 [36] Overall 287 70.7 41 NR 41.1 NR 477 3.97 NR NR 100 NR NR NR NR NR NR NR NR 
 ART 287 70.7 41 NR 41.1 NR 477 3.97 NR NR 100 NR NR NR NR NR NR NR NR 
Guaraldi, et al, 2012 [55] Overall 133 100 NR 39.8 85 NR NR NR NR NR NR NR NR NR NR NR NR NR NR 





 ART 143 66.4 NR NR NR 28 NR NR NR NR 100 NR NR NR NR NR NR NR NR 
 HIV alone 103 68 46.9 NR NR NA NR 2.13 NR NR 100 NR NR NR NR NR NR NR NR 
 HIV/HCV 40 63 46.2 NR NR NA NR 1.69 NR NR 100 NR NR NR NR NR NR NR NR 
Gupta, et al, 2011 [68] Overall 68 84 35.9 NR NR NR 109 NR NR NR 100 NR NR NR NR NR NR NR NR 
 ART 68 84 35.9 NR NR NR 109 NR NR NR 100 NR NR NR NR NR NR NR NR 
Hadigan, et al, 2013 [26] Overall 182 64.3 45 28.6 NR 7.7 513 2.1 168 NR NR NR NR NR NR NR NR NR NR 
Hansen, et al, 2009 [45] Overall 566 81.4 44.1 NR NR NR 494 NR 114 62.4 83 31.4 53.5 55.4 NR NR NR NR 20.3 
Jacobson, et al, 2006 [17] Overall 477 72.5 NR NR NR NR NR NR NR NR 72 NR NR NR NR NR NR NR 40 
 ART 342 72.8 42 NR NR NR NR NR NR NR 100 52 27 7 NR NR NR NR 41 
 No-ART 135 71.9 44 NR NR NR NR NR NR 0 0 0 0 0 NR N NR NR 38 
Janiszewski, et al, 2011 [53] Overall 2322 63.8 NR 30.6 34.9 NR NR NR NR NR 100 NR NR NR NR NR NR NR NR 
 ART 2322 63.8 NR 30.6 34.9 NR NR NR NR NR 100 NR NR NR NR NR NR NR NR 
 Men 1481 100 NR 32.2 31.5 NR NR NR NR NR 100 NR NR NR NR NR NR NR NR 
 Women 841 0 NR 27.7 41 NR NR NR NR NR 100 NR NR NR NR NR NR NR NR 
Jantarapakde, et al, 2014 [71] Overall 580 46.2 37 16.4 45.2 NR 394 NR 60 NR 70.7 NR NR NR NA NA 50 19 30.5 
 ART 410 51 39 16.3 56.1 NR 394 1.6 60 NR 100 14.9 79 NR NA NA 37.1 22.4 40.2 
 No-ART 170 34.7 34 16.5 18.8 NR 392 4.1 36 0 0 0 0 0 NA NA 81.2 10.6 7.1 
Jerico, et al, 2005 [37] Overall 710 72 41.9 67.5 36.6 NR 479 NR 113 78 88.2 28.6 NR NR NA NA 47.7 19.6 32.7 
Johnsen, et al, 2006 [18] Overall 97 0 41 47 NR NR 390 2.7 96 NR 81 45 51 81 NR NR NR NR NR 
Krishnan, et al, 2012 [25] Overall 2247 82 NR 59 NR NR NR NR NR 0 0 0 0 0 NR NR NR NR NR 
Lauda, et al, 2011 [32] Overall 249 52.2 NR NR NR NR NR NR NR NR 87 NR NR NR NR NR NR NR NR 
Leite, et al, 2010 [30] Overall 100 63 NR 23 NR NR 525 NR 72 50.2 77 30 NR NR NR NR NR NR NR 
Maloberti, et al, 2013 [56] Overall 108 82.4 NR 55.6 NR NR NR NR NR NA 66.7 NR NR NR NR NR NR NR NR 
 ART 72 83 46.5 58.3 NR NR 450 5.15 NR 77 100 65.2 31.9 97.2 NR NR NR NR NR 
 No-ART 36 81 40.7 50 NR NR 478 4.8 NR 0 0 0 0 0 NR NR NR NR NR 
Martin, et al, 2008 [43] Overall 140 72 NA NA 39.3 NR NA NA NA NA NA NA NA NA NR NR NR NR NR 
Mbunkah, et al, 2014 [66] Overall 173 29 38.7 2.9 NR NR 358 NR 34.1 23.7 65 NR NR NR 100 NA NA NA NA 
Mondy, et al, 2007 [19] Overall 471 64.5 40.2 42.5 NR NR NR NR NR NR 73 35 41 NR NR NR NR NR NR 
Muhammad, et al, 2013 [64] Overall 200 47 32.5 9 NR NR 318 NR NR NR 50 NR NR NR NR NR NR NR NR 
 ART 100 46 32.8 10 NR NR 376 NR NR NR 100 NR NR NR NR NR NR NR NR 
65 
No-ART 100 48 32.4 8 NR NR 261 NR NR NR 0 NR NR NR NR NR NR NR NR 
Palacios, et al, 2007 [41] Overall 60 83.3 40.9 78.3 NR 26.7 186 5.64 38.4 0 0 0 0 NR NR NR NR NR 43.3 
Ngatchou, et al, 2013 [65] Overall 108 26 39 0 NR NR 353 NR 19.3 0 0 0 0 0 NR NR NR NR NR 
Pullinger, et al, 2010 [24] Overall 296 73.3 45.3 NR NR 33.8 455 NR 145 NR 70.9 42.2 19.3 5.1 NR NR NR NR 53.7 
Ramirez-Marrero, et al, 2010 [31] Overall 897 64 44.7 50 NR 21 473 NR NR NR 45 3 34 NR NR NR NR NR NR 
Men 574 100 44.4 53 NR 23 467 NR NR NR 46 3 32 NR NR NR NR NR NR 
Women 323 0 45.2 44 NR 17 486 NR NR NR 42 2 38 NR NR NR NR NR NR 
Samaras, et al, 2007 [13] Overall 788 84 NR 30 57.2 NR NR NR NR NR 92.9 50.3 37.9 85.5 NR NR 50.4 23.4 26.4 
Sawadogo, et al, 2014 [58] Overall 400 29 41.4 4.8 NR NR 503 NR NR 50.7 100 17.3 95.0 NR 51 49 NA NA NA 
ART 400 29 41.4 4.8 NR NR 503 NR NR 50.7 100 17.3 95.0 NR 51 49 NA NA NA 
Men 116 100 41.6 15.5 NR NR 485 NR NR 53.5 100 17.2 96.6 NR 50 50 NA NA NA 
Women 284 0 39.6 0.4 NR NR 457 NR NR 49.6 100 17.3 94.4 NR 51.4 48.6 NA NA NA 
Schillaci, et al, 2008 [44] Overall 39 67 37 49 NR NR NR 4.71 60 0 0 0 0 0 NR NR NR NR NR 
No-ART 39 67 37 49 NR NR NR 4.71 60 0 0 0 0 0 NR NR NR NR NR 
Signorini, et al, 2012 [35] Overall 819 54.6 41 26 38.5 NR 394 NR NR 54 76.1 27.6 48.5 NR NR NR NR NR NR 
Sobieszczyk, et al, 2008 [21] Overall 1725 0 40 47 NR NR 474 3.1 NR NR 48 24 NR NR NR NR NR NR NR 
Women 1725 100 40 47 NR NR 474 3.1 NR NR 48 24 NR NR NR NR NR NR NR 
Sterling, et al, 2008 [22] Overall 222 74 45.4 NR NR 100 535 NR 224.4 NR 83 47 30 82 NR NR NR NR NR 
Tesfaye, et al, 2014 [67] Overall 374 33.7 32.6 2.7 NR NR NR NR NR 42.6 50.3 NR NR NR NR NR NR NR NR 
ART 188 36.2 32.7 2.7 NR NR 441.6 NR NR 42.6 100 NR NR NR NR NR NR NR NR 
No-ART 186 31.2 32.6 2.7 NR NR 493 NR NR 0 0 NR NR NR NR NR NR NR NR 
Tiozzo, et al, 2015 [27] Overall 89 47 48 NR NR NR NR NR 204 NR NR NR NR NR NR NR NR NR NR 
Wand, et al, 2007 [14] Overall 881 79 38.7 40.2 NR NR NR NR NR NR 100 NR NR NR NA NA 62.4 20 20.8 
ART 881 79 38.7 40.2 NR NR NR NR NR NR 100 NR NR NR NA NA 62.4 20 20.8 
Worm, et al, 2010 [15] Overall 33347 74 38 33.9 NR NR NR NR NR NR NR 58 32.2 72.9 NA NA NA NA 24.6 
Wu, et al, 2012 [69] Overall 803 95 NR 33.5 NR NR NR NR NR NR 80.7 57.8 51.1 81.7 NR NR NR NR NR 
Young, et al, 2009 [46] Overall 1644 NR NR NR NR NR NR NR NR NR NR 43 38 NR NR NR NR NR NR 
Zannou, et al, 2009 [59] Overall 79 40.5 38 8.9 NR NR 105.3 NR NR 14.6 100 NR NR NR 51.9 48.1 NA NA NA 





ART, antiretroviral; HCV, hepatitis C virus; NA not applicable; NNRTI, non-nucleoside reserve transcriptase inhibitor; NR, not reported; NRTI, nucleoside reverse transcriptase inhibitors; 
PI, protease inhibitor  
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S4.4 Table. The prevalence of metabolic syndrome estimated by the included studies according to criteria 
Reference Country  Area Study  
site 
Study type Study  
period 












ATPIII 2005  
* Modifications noted
Intercontinental 









Case-control  NR 788 18 14 






Urban Hospital  Cross-sectional 1999-2002 881 8.5 7.8 
Worm, et al, 
2010 [15] 





Cross-sectional 2006-2007 23853 41.6* 
Adapted ATPIII 2005, using 
BMI ≥30 for central obesity 
component 
America 
Adeyemi,  et al, 
2008 [20] 
USA Urban Hospital Cross-sectional 2005-2006 121 34 
Ances, et al, 
2009 [23] 
USA National Hospital  Case-control NR 66 15.2* 
Adapted ATPIII 2005, using 
BMI for central obesity 
Baum, et al, 
2006 [16] 
USA National Community  Cross-sectional 2002-2003 118 15.1 
Hadigan, et al, 
2013 [26] 
USA Urban 
Hospital  (2 
clinics) 
Cross-sectional 2007-2011 182 13.7 
Jacobson, et al, 
2006 [17] 
USA Urban Community  Cross-sectional 2000-2003 477 24 
Johnsen, et al, 
2006 [18] 
USA National Hospital  Case-control 2002-2003 97 31 
Krishnan, et al, 
2012 [25] 
USA National Hospital  Cross-sectional 2001-2007 2247 20 
Mondy, et al, 
2007 [19] 
USA Urban Hospital  Cross-sectional 2005 471 25.5 
Pullinger, et al, 
2010 [24] 
USA Urban Community  
Longitudinal, 
cross-sectional 








2000-2004 1725 33 
Sterling, et al, 
2008 [22] 
USA Urban Hospital  Cross-sectional 1998-2006 222 9 
Tiozzo, et al, 
2015 [27] 
USA Urban Hospital  Cross-sectional 2013 89 33* 
Adapted ATPIII 2001, including 
taking treatments for 






Cahn, et al, 
2010 [29] 
Argentina National Hospital  Cross-sectional 2006-2007 1015  22.3      
 Brazil National Hospital   Cross-sectional 2006-2007 1001  25.4      
 Colombia National Hospital  Cross-sectional 2006-2007 474  8.4      
 Chile National Hospital  Cross-sectional 2006-2007 44  13.6      
 Ecuador National Hospital  Cross-sectional 2006-2007 252  19.1      
 Peru National Hospital Cross-sectional 2006-2007 417  13.7      
 Venezuela National Hospital  Cross-sectional 2006-2007 807  22.4      
Alencastro, et 
al, 2012 [33] 
Brazil Urban Hospital  Cross-sectional NR 1240   17.2 22.1 24.7   
Da Silva, et al, 
2009 [83] 
Brazil Urban 
Hospital  (7 
centers) 
Cross-sectional 2004-2006 319  12.3      
Gasparotto, et 





Cross-sectional NR 614  19.4  31.9    
Lauda, et al, 
2011 [32] 
Brazil Urban Hospital  Cross-sectional 2007-2008 249  20.9      
Leite, et al, 
2010 [30] 
Brazil Urban Hospital  Cross-sectional 2008 100   52     
Signorini, et al, 
2012 [35] 
Brazil National Hospital  Cross-sectional 2005 819  20.6      
Ramirez-
Marrero, et al, 
2010 [31] 
Puerto Rico Urban 
Hospital 
community 
Cross-sectional 2003-2007 897   35.4     
 Europe             
Hansen, et al, 
2009 [45] 
Denmark National Hospital  Cross-sectional 2004-2006 566  27      
Badiou, et al, 
2008 [42] 
France National Hospital  Cross-sectional 1999 232  7.3  11.2    
Biron, et al, 
2012 [54] 
France National  
Hospital  (5 
centers) 
Cross-sectional 2000-2007 269   18.2     
Martin, et al, 
2008 (SHIVA 
study) [43] 
France Urban Hospital  Cross-sectional 2003 140  7.1      
Sawadogo, et al, 
2014 [58] 
Burkina Faso Urban Hospital  Cross-sectional  2011 400   12.3 10    
Bonfanti, et al, 
2010 [47] 
Italy Urban 
Hospital  (14 
centers) 
Cross-sectional 2007 292  12.3*     
Adapted ATPIII 2001, including 
taking medication for HTN or 
DM 
Bonfanti, et al, 
2007[40] 
Italy Urban 
Hospital  (18 
centers) 
Cross-sectional 2005 1243  20.8*     
Adapted ATPIII 2001, including 
taking medication for HTN or 
DM 
Calza, et al, 
2011 [48] 
Italy Urban Hospital  Cross-sectional 2009 755  9.1      







Gazzaruso, et al, 
2003 [36] 
Italy National Hospital  Cross-sectional NR 287 33.1       
Guaraldi, et al, 
2012 [55] 
Italy National  
Hospital (2 
centers) 
Cross-sectional 2009-2010 133   24.8     





Cross-sectional 2007-2008 143  14.7      
Janiszewsk,i et 
al, 2011 [53] 
Italy National Hospital  Cross-sectional 2005-2009 2322  25.6      





Hospital  Cross-sectional NR 108  17.6*     
Adapted ATPIII 2001, using 
BMI levels corresponding with 
WC in Italian adults 
Schillaci, et al, 
2008 [44] 
Italy Urban Hospital  Case-control  NR 39  18      
Bergersen,et al, 
2006 [38] 
Norway Urban Hospital  Cross-sectional 2000-2001 263  13.3*     
Adapted ATPIII 2001, including 
taking medications for HTN or 
DM 
Freitas, et al, 
2011 [51] 
Portugal National Hospital  Cross-sectional NR 345   52.2 43.2    
Cubero, et al, 
2011 [49] 
Spain National Hospital  Cross-sectional NR 159 28.3 10.1  15.1    
Estrada, et al, 
2006 [39] 
Spain  National Hospital  Cross-sectional NR 146   15.8     
Jerico, et al, 
2005 [37] 
Spain Urban Hospital  Cross-sectional 2003 710  17*     
Adapted ATPIII 2001, including 
taking medications for HTN or 
DM 
Palacios, et al, 
2007 [41] 
Spain National Hospital  Cross-sectional 2002-2003 60  16.6*     
Adapted ATPIII 2001, using 
BMI≥26.7 (validated) for 
central obesity 
Young, et al, 
2009 [46] 
Switzerland National Hospital  Cross-sectional 2000-2006 1644    15*   
Adapted IDF 2005, using 
random glucose level for 
raised glucoism 





Hospital  (2 
centers) 
Cross-sectional 2005-2006 678   14 10    
 Africa             
Zannou, et al, 
2009 [59] 
Benin Urban Hospital  Cross-sectional 2004-2005 79    13    
Mbunkah, et al, 
2014 [66] 
Cameroon National Hospital  Cross-sectional 2010-2011 173  15.6      
Ngatchou, et al, 
2013 [65] 
Cameroon Urban Hospital  Cross-sectional 2009-2010 108     47   
Berhane, et al, 
2012 [63] 
Ethiopia Urban Hospital  Cross-sectional 2010 313   21.1     






Ayodele, et al, 
2012 [62] 
Nigeria Urban Hospital  Cross-sectional NR 291  12.7  17.2 21   
Muhammad, et 
al, 2013 [64] 
Nigeria Urban Hospital  Cross-sectional 2009 200  15      
Awotedu, et al, 
2010 [60] 
South Africa Urban Hospital  Cross-sectional 2009-2010 196  20.4  22.9    
Fourie, et al, 
2010 [61] 
South Africa Urban; Rural Community  Cross-sectional 2005 300  15.2  21.1    
 Asia             
Gupta, et al, 
2011 [68] 
India Urban  Hospital  Cross-sectional 2007-2009 68   25 19.1    
Bajaj, et al, 
2013 [70] 
India Urban Hospital Cross-sectional 2010-2011 70   20     
Wu, et al, 2012 
[69] 
Taiwan Nationwide Hospital  Cross-sectional 2008-2009 803   26.2     
Jantarapak,de 
et al, 2014 [71] 
Thailand National 
Hospital  (6 
centers) 
Cross-sectional 2009-2011 580   22.2     
              
ATPIII, Adults Treatment Panel III; BMI, body mass index; DM, diabetes mellitus; EGIR, European Group for the Study of Insulin Resistance; HTN, hypertension; IDF, International 






S4.5 Table. Summary statistics from meta-analyses of prevalence studies on metabolic syndrome in people with HIV using random effects model and 
arcsine transformations 














Overall          0.001   
  ATPIII2001 38 16984 3179 16.7 [14.6-18.8] 3.56 [3.18-3.99] 92.1 [90.1-93.7] <0.001   0.040 
  ATPIII2004-2005 20 11255 2768 24.6 [20.6-28.8] 4.90 [4.30-5.60] 95.8 [94.6-96.8] <0.001   0.870 
  IDF2005 16 8250 1471 18.0 [14.0-22.4] 4.90 [4.20-5.60] 95.8 [94.4-96.9] <0.001   0.610 
  JIS2009 4 2404 654 29.6 [22.9-36.8] 3.40 [2.30-5.00] 91.0 [80.6-96.0] <0.001   0.490 
  Modified ATPIII2005 2 23919 9923 27.9 [06.7-56.5] 4.90 [ - ] 95.8 [ - ] <0.001   - 
  EGIR2003 2 446 140 31.3 [26.8-36.0] 1.10 [ - ] 09.8 [ - ] 0.300   - 
Gender Overall         0.001   
  ATPIII2001 33 12240 2299 16.2 [13.8-18.4] 3.26 [2.87-3.71] 90.6 [87.9-92.7] <0.001  0.250 0.140 
  ATPIII2004-2005 26 10212 2523 25.1 [21.3-29.1] 4.36 [3.86-4.92] 94.7 [93.3-95.9] <0.001  0.450 0.710 
  IDF2005 22 5849 1088 17.9 [13.6-22.7] 4.50 [3.96-5.12] 95.1 [93.6-96.2] <0.001  0.030 0.710 
 Men         0.003   
  ATPIII2001 16 8269 1530 14.6 [11.5-18.1] 3.82 [3.22-4.52] 93.1 [90.4-95.1] <0.001   0.060 
  ATPIII2004-2005 13 5742 1262 23.7 [19.0-28.7] 4.15 [3.47-4.96] 94.2 [91.7-95.9] <0.001   0.290 
  IDF2005 11 3556 553 13.4 [08.7-18.9] 4.30 [3.55-5.22] 94.6 [92.1-96.3] <0.001   0.750 
 Women         0.118   
  ATPIII2001 17 3971 769 17.5 [14.0-21.2] 2.87 [2.31-3.42] 86.7 [82.6-90.5] <0.001   0.780 
  ATPIII2004-2005 13 4470 1261 26.7 [20.8-33.0] 4.26 [3.57-5.09] 94.5 [92.2-96.1] <0.001   0.560 
  IDF2005 11 2293 535 23.2 [15.9-31.4] 4.32 [3.57-5.23] 94.6 [92.1-96.3] <0.001   0.810 
Continent Overall         0.002   
  ATPIII2001 38 16984 3179 16.7 [14.6-18.8] 3.56 [3.18-3.99] 92.1 [90.1-93.7] <0.001  0.216 0.040 
  ATPIII2004-2005 20 11255 2768 24.6 [20.6-28.8] 4.90 [4.30-5.60] 95.8 [94.6-96.8] <0.001  0.284 0.870 
  IDF2005 16 8250 1471 18.0 [14.0-22.4] 4.90 [4.20-5.60] 95.8 [94.4-96.9] <0.001  0.100 0.610 
 Intercontinental        0.748   
  ATPIII2001 2 1669 214 12.7 [05.2-22.9] 5.60 [ - ] 96.8 [ - ] <0.001   - 





  IDF2005 2 1669 183 10.9 [05.3-18.2] 4.35 [ - ] 94.7 [ - ] <0.001   - 
 Americas         0.021   
  ATPIII2001 16 6798 1364 20.0 [16.0-22.2] 3.15 [2.60-3.80] 89.9 [85.3-93.1] <0.001   0.598 
  ATPIII2004-2005 9 7450 1902 27.3 [21.7-33.4] 5.39 [4.47-6.49] 96.6 [95.0-97.6] <0.001   0.950 
  IDF2005 2 1854 470 26.8 [17.8-36.9] 4.50 [ - ] 95.1 [ - ] <0.001   - 
 Europe         0.423   
  ATPIII2001 14 7032 1368 15.1 [11.5-19.1] 4.14 [3.49-4.92] 94.2 [91.8-95.9] <0.001   0.040 
  ATPIII2004-2005 5 1571 381 24.1 [11.2-40.1] 6.6 [5.24-8.32] 97.7 [96.4-98.6] <0.001   0.770 
  IDF2005 5 3058 517 18.0 [09.6-28.2] 6.15 [4.83-7.82] 97.4 [95.7-98.4] <0.001   0.670 
 Africa         0.741   
  ATPIII2001 6 1485 233 15.6 [13.8-17.5] 1.00 [1.00-1.950] 00.0 [00.0-73.6] 0.440   0.490 
  ATPIII2004-2005 2 713 115 16.4 [08.7-25.9] 3.17 [ - ] 90.0 [ - ] 0.002   - 
  IDF2005 6 1601 288 17.7 [12.9-23.1] 2.65 [1.86-3.78] 85.8 [71.0-93.0] <0.001   0.910 
 Asia         0.329   
  ATPIII2001 -          
  ATPIII2004-2005 4 1521 370 24.1 [21.6-26.8] 1.10 [1.00-2.80] 16.8 [00.0-87.3] 0.307   0.610 
  IDF2005 1 68 13 19.1 [10.7-29.2] - - -   - 
Region Overall         0.002   
  ATPIII2001 38 16984 3179 16.7 [14.6-18.8] 3.56 [3.18-3.99] 92.1 [90.1-93.7] <0.001  0.607 0.040 
  ATPIII2004-2005 20 11255 2768 24.6 [20.6-28.8] 4.90 [4.30-5.60] 95.8 [94.6-96.8] <0.001  0.861 0.870 
  IDF2005 16 8250 1471 18.0 [14.0-22.4] 4.90 [4.20-5.60] 95.8 [94.4-96.9] <0.001  0.785 0.610 
 Regional         0.024   
  ATPIII2001 16 5610 924 16.0 [13.2-19.1] 2.87 [2.35-3.50] 87.8 [81.8-91.8] <0.001   0.870 
  ATPIII2004-2005 13 6732 1694 24.3 [19.1-30.0] 4.99 [4.25-5.86] 96.0 [94.5-97.1] <0.001   0.730 
  IDF2005 9 3587 648 17.4 [13.4-21.8] 3.11 [2.40-4.03] 89.7 [82.6-93.8] <0.001   0.802 
 National         0.109   
  ATPIII2001 22 11374 2255 17.1 [14.4-20.1] 3.90 [3.39-4.49] 93.4 [91.3-95.0] <0.001   0.060 
  ATPIII2004-2005 7 4523 1074 25.1 [18.3-32.7] 5.08 [4.06-6.35] 96.1 [93.9-97.5] <0.001   0.520 
  IDF2005 7 4663 823 18.7 [11.4-27.3] 6.83 [5.67-8.22] 97.9 [96.9-98.5] <0.001   0.503 




ATPIII2001 38 16984 3179 16.7 [14.6-18.8] 3.56 [3.18-3.99] 92.1 [90.1-93.7] <0.001 0.694 0.040 
ATPIII2004-2005 20 11255 2768 24.6 [20.6-28.8] 4.90 [4.30-5.60] 95.8 [94.6-96.8] <0.001 0.012 0.870 
IDF2005 16 8250 1471 18.0 [14.0-22.4] 4.90 [4.20-5.60] 95.8 [94.4-96.9] <0.001 0.101 0.607 
Above median 0.326 
ATPIII2001 13 6296 1246 17.3 [13.7-21.2] 3.63 [2.98-4.45] 92.4 [88.8-94.8] <0.001 0.131 
ATPIII2004-2005 13 7328 1531 21.5 [17.2-26.1] 4.40 [3.70-5.21] 94.8 [92.6-96.3] <0.001 0.638 
IDF2005 9 4169 908 20.8 [14.4-27.9] 5.24 [4.34-6.34] 94.8 [92.6-96.3] <0.001 0.943 
Below median 0.000 
ATPIII2001 25 10688 1933 16.4 [13.8-19.1] 3.56 [3.10-4.09] 92.1 [89.6-94.0] <0.001 0.214 
ATPIII2004-2005 7 3927 1237 30.6 [25.2-36.2] 3.40 [2.56-4.51] 91.3 [84.7-95.1] <0.001 0.694 




ATPIII2001 38 16984 3179 16.7 [14.6-18.8] 3.56 [3.18-3.99] 92.1 [90.1-93.7] <0.001 0.115 0.040 
ATPIII2004-2005 20 11255 2768 24.6 [20.6-28.8] 4.90 [4.30-5.60] 95.8 [94.6-96.8] <0.001 0.989 0.870 
IDF2005 16 8250 1471 18.0 [14.0-22.4] 4.90 [4.20-5.60] 95.8 [94.4-96.9] <0.001 0.388 0.610 
Above median 0.095 
ATPIII2001 17 13382 2646 18.3 [15.3-21.4] 4.60 [3.98-5.33] 95.3 [93.7-96.5] <0.001 0.012 
ATPIII2004-2005 12 10176 2517 24.7 [19.7-29.9] 5.96 [5.13-6.92] 97.2 [96.2-97.9] <0.001 0.849 
IDF2005 10 7264 1312 19.0 [13.6-25.0] 6.20 [5.28-7.29] 97.4 [96.4-98.1] <0.001 0.354 
Below median 0.059 
ATPIII2001 21 3602 533 15.1 [12.8-17.6] 2.02 [1.64-2.50] 75.5 [62.7-83.9] <0.001 0.137 
ATPIII2004-2005 8 1079 251 25.6 [17.1-32.9] 3.03 [2.29-4.01] 89.1 [80.8-93.8] <0.001 0.217 




ATPIII2001 32 13234 2343 16.6 [14.4-18.9] 3.44 [3.04-3.90] 91.6 [89.2-93.4] <0.001 0.000 0.373 
ATPIII2004-2005 13 7112 1829 23.8 [18.2-30.0] 5.72 [4.94-6.63] 96.9 [95.9-97.7] <0.001 0.479 0.580 
IDF2005 14 5818 1112 18.5 [13.5-24.1] 5.14 [4.42-5.98] 96.2 [94.9-97.2] <0.001 0.361 0.850 
Above median 0.525 
ATPIII2001 16 8392 1757 19.7 [17.1-22.5] 2.98 [2.45-3.62] 88.7 [83.3-92.4] <0.001 0.311 
ATPIII2004-2005 6 2204 659 26.6 [15.0-40.0] 6.51 [5.28-8.02] 97.6 [96.4-98.4] <0.001 0.580 





 Below median         0.021   
  ATPIII2001 16 4842 586 13.2 [11.2-15.2] 1.95 [1.52-2.50] 73.7 [56.8-83.9] <0.001   0.011 
  ATPIII2004-2005 7 4908 1170 21.5 [15.6-28.2] 5.12 [4.10-6.39] 96.2 [94.0-97.5] <0.001   0.485 




Overall         0.005   
 ATPIII2001 37 16887 3149 16.4 [14.4-18.6] 3.58 [3.20-4.01] 92.2 [90.2-93.8] <0.001  0.148 0.021 
  ATPIII2004-2005 18 9397 2163 24.1 [20.0-28.5] 4.69 [4.08-5.40] 95.5 [94.0-96.6] <0.001  0.574 0.442 
  IDF2005 15 6606 1226 18.2 [13.7-23.3] 5.00 [4.31-5.80] 96.0 [94.6-97.0] <0.001  0.002 0.773 
 Above median         0.000   
  ATPIII2001 19 7655 1283 14.9 [12.0-18.0] 3.57 [3.04-4.19] 92.1 [89.2-94.3] <0.001   0.269 
  ATPIII2004-2005 7 4454 939 22.6 [18.5-26.9] 2.83 [2.07-3.88] 87.5 [76.6-93.3] <0.001   0.476 
  IDF2005 6 2806 319 12.2 [09.3-15.3] 2.23 [1.51-3.29] 79.9 [56.3-90.7] <0.001   0.328 
 Below median         0.112   
  ATPIII2001 18 9232 1866 18.0 [15.2-20.9] 3.39 [2.85-4.02] 91.3 [87.7-93.8] <0.001   0.068 
  ATPIII2004-2005 11 4943 1224 24.9 [18.3-32.2] 5.59 [4.75-6.58] 96.8 [95.6-97.7] <0.001   0.773 





Overall         0.003   
 ATPIII2001 30 14607 2694 16.4 [14.1-18.8] 3.69 [3.26-4.18] 92.7 [90.6-94.3] <0.001  0.234 0.059 
  ATPIII2004-2005 15 9087 2344 25.7 [20.8-31.0] 5.41 [4.70-6.24] 96.6 [95.5-97.4] <0.001  0.193 0.922 
  IDF2005 11 4527 707 16.3 [11.3-22.0] 4.87 [4.08-5.82] 95.8 [94.0-97.0] <0.001  0.565 0.314 
 Above median         0.001   
  ATPIII2001 14 4546 695 14.8 [11.7-18.2] 2.81 [2.27-3.50] 87.4 [80.5-91.8] <0.001   0.863 
  ATPIII2004-2005 8 6211 1750 28.8 [21.9-36.2] 5.86 [4.85-7.08] 97.1 [95.8-98.0] <0.001   0.676 
  IDF2005 5 1917 331 18.4 [07.5-32.8] 7.00 [5.66-8.74] 98.0 [96.8-98.7] <0.001   0.456 
 Below median         0.140   
  ATPIII2001 16 10061 1999 17.6 [14.5-20.8] 4.05 [3.40-4.76] 93.9 [91.5-95.6] <0.001   0.057 
  ATPIII2004-2005 7 2876 594 22.2 [15.9-29.3] 4.22 [3.29-5.42] 94.4 [90.8-96.6] <0.001   0.557 
  IDF2005 6 2610 376 14.6 [10.8-18.8] 2.79 [1.97-3.94] 87.1 [74.4-93.6] <0.001   0.723 
Antiretroviral 
(ART) use 





  ATPIII2001 37 14807 2780 15.5 [13.4-17.7] 3.26 [2.89-3.68] 90.6 [88.0-92.6] <0.001  0.001 0.016 
  ATPIII2004-2005 12 4939 1050 21.2 [15.9-27.0] 4.27 [3.55-5.13] 94.5 [92.1-96.2] <0.001  0.710 0.850 
  IDF2005 18 6601 1178 17.8 [13.6-22.4] 4.48 [3.88-5.18] 95.0 [93.4-96.3] <0.001  0.322 0.586 
 Non-ART         0.000   
  ATPIII2001 17 2659 319 11.8 [09.3-14.7] 1.96 [1.54-2.48] 73.9 [57.8-83.8] <0.001   0.710 
  ATPIII2004-2005 4 2508 499 19.9 [18.3-21.5] 1.00 [1.00-2.54] 00.0 [00.0-84.5] 0.398   0.980 
  IDF2005 7 1628 216 14.9 [08.6-22.6] 3.45 [2.60-4.57] 91.6 [85.3-95.2] <0.001   0.351 
 On ART         0.731   
  ATPIII2001 20 12148 2461 18.4 [15.9-21.1] 3.27 [2.77-3.85] 90.6 [87.0-93.3] <0.001   0.240 
  ATPIII2004-2005 8 2431 551 21.6 [13.5-31.0] 5.27 [4.31-6.46] 96.4 [94.6-97.6] <0.001   0.999 





Overall         0.015   
 ATPIII2001 24 9402 1709 16.4 [13.8-19.2] 3.46 [2.99-4.00] 91.6 [88.8-93.7] <0.001  0.514 0.162 
 ATPIII2004-2005 10 4478 1272 25.2 [19.0-32.0] 4.67 [3.86-5.67] 95.4 [93.3-96.9] <0.001  0.747 0.298 
  IDF2005 7 1386 199 14.9 [11.5-18.7] 1.82 [1.23-2.70] 70.0 [34.2-86.3] 0.003  0.001 0.292 
 Above median         0.000   
  ATPIII2001 10 5888 1156 17.4 [13.1-22.1] 4.59 [3.78-5.58] 95.3 [93.0-96.8] <0.001   0.202 
  ATPIII2004-2005 7 3719 1088 24.6 [16.6-33.6] 5.53 [4.47-6.83] 96.7 [95.0-97.9] <0.001   0.269 
  IDF2005 2 632 66 10.4 [08.2-12.9] 1.00 [ - ] 00.0 [ - ] 0.635   - 
 Below median         0.020   
  ATPIII2001 14 3514 553 15.6 [12.9-18.5] 2.22 [1.73-2.84] 79.7 [66.7-87.6] <0.001   0.921 
  ATPIII2004-2005 3 759 184 26.5 [19.3-34.5] 1.83 [1.00-3.39] 70.2 [00.0-91.3] 0.035   0.484 




Overall         0.240   
 ATPIII2001 13 3713 632 17.5 [13.3-22.2] 3.44 [2.81-4.21] 91.6 [87.4-94.3] <0.001  0.044 0.562 
  ATPIII2004-2005 6 2482 506 24.7 [17.8-32.3] 3.80 [2.84-5.08] 93.1 [87.6-96.1] <0.001  0.251 0.170 
  IDF2005 2 1399 298 19.1 [12.7-26.4] 2.15 [ - ] 78.3 [ - ] 0.032  - - 
 Above median         0.338   
  ATPIII2001 7 2735 502 20.6 [13.8-28.4] 4.61 [3.64-5.84] 95.3 [92.4-97.1] <0.001   0.336 
  ATPIII2004-2005 3 393 115 32.0 [11.8-56.7] 4.98 [3.40-7.30] 96.0 [91.3-98.1] <0.001   0.141 





 Below median         0.007   
  ATPIII2001 6 978 130 13.2 [11.2-15.4] 1.00 [1.00-1.73] 00.0 [00.0-66.5] 0.581   0.265 
  ATPIII2004-2005 3 2089 391 19.1 [15.9-22.6] 1.80 [1.00-3.33] 69.1 [00.0-91.0] 0.039   0.707 




Overall         0.352   
 ATPIII2001 16 8193 1503 16.3 [13.3-19.6] 3.82 [3.22-4.52] 93.1 [90.4-95.1] <0.001  0.649 0.102 
  ATPIII2004-2005 4 1447 246 22.1 [12.2-34.0] 4.80 [3.48-6.63] 95.7 [91.7-97.7] <0.001  0.192 0.112 
  IDF2005 6 2054 288 14.0 [09.9-18.8] 2.84 [2.02-4.00] 87.6 [75.4-93.7] <0.001  0.811 0.765 
 Above median         0.544   
  ATPIII2001 7 4457 846 17.1 [12.1-22.9] 4.82 [3.83-6.07] 95.7 [93.2-97.3] <0.001   0.336 
  ATPIII2004-2005 3 769 150 25.6 [09.7-45.8] 5.67 [3.98-8.07] 96.9 [93.7-98.5] <0.001   0.031 
  IDF2005 3 1006 155 14.6 [07.0-24.2] 3.93 [2.54-6.10] 93.5 [84.5-97.3] <0.001   0.854 
 Below median         0.740   
  ATPIII2001 9 3736 657 15.6 [12.0-19.6] 3.10 [2.39-4.02] 89.6 [82.5-93.8] <0.001   0.187 
  ATPIII2004-2005 1 678 96 14.2 [11.6-17.0]  - - -   - 




Overall         0.006   
 ATPIII2001 19 7817 1385 16.9 [14.3-19.7] 3.10 [2.60-3.69] 89.6 [85.2-92.7] <0.001  0.172 0.572 
  ATPIII2004-2005 10 7041 1838 26.2 [20.9-31.9] 5.10 [4.25-6.12] 96.2 [94.5-97.3] <0.001  0.256 0.981 
  IDF2005 7 3760 662 17.1 [13.1-21.6] 3.34 [2.51-4.45] 91.1 [84.1-95.0] <0.001  0.176 0.822 
 Above median         0.111   
  ATPIII2001 12 5700 967 15.8 [12.4-19.6] 3.64 [2.97-4.46] 92.5 [88.7-95.0] <0.001   0.496 
  ATPIII2004-2005 2 903 262 38.3 [15.5-64.3] 5.07 [ - ] 96.1 [ - ] <0.001   - 
  IDF2005 3 1311 190 14.4 [11.6-17.3] 1.38 [1.0-2.56] 47.7 [00.0-84.7] 0.148   0.880 
 Below median         0.385   
  ATPIII2001 7 2117 418 19.1 [16.2-22.3] 1.68 [1.12-2.52] 64.4 [19.8-84.2] 0.009   0.507 
  ATPIII2004-2005 8 6138 1576 23.8 [18.0-30.0] 5.40 [4.42-6.58] 96.6 [94.9-97.7] <0.001   0.504 





Overall         0.142   




ATPIII2004-2005 7 4071 1087 26.2 [17.9-35.5] 6.48 [5.35-7.85] 97.6 [96.5-98.4] <0.001 0.020 0.976 
IDF2005 6 4087 647 16.4 [10.1-23.8] 5.72 [4.56-7.18] 96.9 [95.2-98.1] <0.001 0.058 0.683 
Above median 0.001 
ATPIII2001 10 4745 993 19.5 [15.5-23.9] 3.48 [2.76-4.37] 91.7 [86.9-94.8] <0.001 0.533 
ATPIII2004-2005 3 1881 355 17.2 [09.5-26.6] 4.94 [3.36-7.25] 95.9 [91.2-98.1] <0.001 0.464 
IDF2005 2 1078 113 10.5 [08.7-12.4] 1.00 [ - ] 00.0 [ - ] 0.690 - 
Below median 0.008 
ATPIII2001 7 3208 525 15.1 [10.1-21.0] 4.19 [3.26-5.39] 94.3 [90.6-96.6] <0.001 0.743 
ATPIII2004-2005 4 2190 732 33.8 [23.4-45.1] 5.40 [4.00-7.29] 96.6 [93.7-98.1] <0.001 0.848 






ATPIII2001 5 1781 361 19.7 [13.1-27.2] 3.44 [2.45-4.85] 91.6 [83.3-95.7] <0.001 0.474 0.930 
ATPIII2004-2005 2 1148 390 38.7 [15.6-64.9] 8.40 [ - ] 98.6 [ - ] <0.001 - - 
IDF2005 2 1133 263 27.6 [05.3-58.8] 10.13 [ - ] 99.0 [ - ] <0.001 - - 
Above median 0.268 
ATPIII2001 3 1107 189 17.9 [09.4-28.7] 3.43 [2.14-5.49] 91.5 [78.2-96.7] <0.001 0.900 
ATPIII2004-2005 2 1148 390 38.7 [15.6-64.9] 8.40 [ - ] 98.6 [ - ] <0.001 - 
IDF2005 2 1133 263 27.6 [05.3-58.8] 10.13 [ - ] 99.0 [ - ] <0.001 - 
Below median - 
ATPIII2001 2 674 172 22.8 [14.3-32.7] 2.17 [ - ] 78.8 [ - ] <0.001 - 
ATPIII2004-2005 0 - - - - - - - 





ATPIII2001 19 8752 1668  18.2 [15.1-21.4] 3.76 [3.21-4.39] 92.9 [90.3-94.8] <0.001 0.593 0.647 
ATPIII2004-2005 10 7136 1924 28.0 [21.3-35.3] 6.51 [5.56-7.61] 97.6 [96.8-98.3] <0.001 0.517 0.737 
IDF2005 7 5327 921 17.2 [11.6-23.5] 5.67 [4.61-6.99] 96.9 [95.3-98.0] <0.001 0.016 0.878 
Above median 0.353 
ATPIII2001 11 4869 878 17.7 [12.9-23.0] 4.53 [3.76-5.46] 95.1 [92.9-96.6] <0.001 0.960 
ATPIII2004-2005 5 3543 813 25.8 [16.2-36.7] 6.99 [5.60-8.73] 98.0 [96.8-98.7] <0.001 0.164 





 Below median         0.000   
  ATPIII2001 8 3883 790 19.3 [16.3-22.6] 2.30 [1.66-3.18] 81.0 [63.5-90.1] <0.001   0.411 
  ATPIII2004-2005 5 3593 1111 30.4 [21.6-39.9] 5.56 [4.30-7.19] 96.8 [94.6-98.1] <0.001   0.783 
  IDF2005 1 400 40 10.0 [07.2-13.4] - - -   - 
             
- not computable; ATP, Adults Treatment Panel; ART, antiretroviral; CI, confidence interval; IDF, International Diabetes Federation; HIV, human immunodeficiency virus; 








S4.1 Figure. Overall prevalence of metabolic syndrome based on Joint Interim 
Statement (JIS) 2009 criteria 
For each study the black box represents the study estimate (prevalence of metabolic 
syndrome [MS]) and the horizontal bar about the 95% confidence intervals. (95%CI) The size 
of the boxes is proportional to the inverse variance. The diamond at the lower tail of the 
figure is for the pooled effect estimates from random effects models. The proportional 
contribution of each study (weight) to the pooled estimates is also shown, together with the 
prevalence estimates and measures of heterogeneity. The dotted vertical line is centred on 
the pooled estimates. 
 
S4.2 Figure. Overall prevalence of metabolic syndrome based on European Group for 
the Study of Insulin Resistance (EGIR) criteria 
For each study the black box represents the study estimate (prevalence of metabolic 
syndrome [MS]) and the horizontal bar about the 95% confidence intervals. (95%CI) The size 
of the boxes is proportional to the inverse variance. The diamond at the lower tail of the 
figure is for the pooled effect estimates from random effects models. The proportional 
contribution of each study (weight) to the pooled estimates is also shown, together with the 
prevalence estimates and measures of heterogeneity. The dotted vertical line is centred on 








S4.3 Figure. Overall prevalence of metabolic syndrome based on Modified Adult 
Treatment Panel III (ATPIII) 2005 criteria 
For each study the black box represents the study estimate (prevalence of metabolic 
syndrome [MS]) and the horizontal bar about the 95% confidence intervals. (95%CI) The size 
of the boxes is proportional to the inverse variance. The diamond at the lower tail of the 
figure is for the pooled effect estimates from random effects models. The proportional 
contribution of each study (weight) to the pooled estimates is also shown, together with the 
prevalence estimates and measures of heterogeneity. The dotted vertical line is centred on 
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The “Utilizing HIV/AIDS infrastructure as a gateway to chronic care for hypertension in 
Africa” is a research project conducted in three African countries including Rwanda, South 
Africa and Uganda. The project’s conception was guided by the principles that by utilizing 
the resources and lessons learned in HIV/AIDS, it would be possible to effectively reach out 
to a large population for hypertension and chronic diseases screening, prevention, 
treatment, control and retention in under-resourced African settings. The strategy of the 
project consisted of using the existing infrastructure of HIV/AIDS speciality clinics as a 
gateway to the larger population of at risk for hypertension. The project aimed to use a 
sequence of steps including screening campaigns; supply-chain management; task-shifting, 
adherence and retention; and business model to evaluate the epidemiology, create 
awareness, effectively treat and retain, and create a model whereby these steps can be 
scaled up at a country and regional level at a low cost . The present thesis uses data from 
the cross-sectional survey conducted as part of this broad programme in South Africa. 
Study design and setting 
This cross-sectional study was conducted among HIV-infected patients, who were treated at 
public healthcare facilities in the Western Cape Province, South Africa. The Western Cape 
Province, located in the southern west part of South Africa, is the fourth largest province, 
with a land area of approximately 130 km2 and 6.2 million inhabitants according to the 
Statistics South Africa 2015 [1]. Two-thirds of the Western Cape population live in the 
Metropole area (the City of Cape Town) and comprise 49% Coloureds, 33% black Africans, 
17% Whites, and 1% Indians or Asians. This Province has six municipal districts, which 
includes the City of Cape Town (Metropole) and five rural districts (non-Metropole) for 
government purposes. These districts are subdivided into 30 local municipalities (six in the 
Metropole and 24 in the non-Metropole areas) [2].  
The public healthcare facilities in the province comprise 428 clinics and community health 
centres, 32 district hospitals and six regional hospitals providing secondary healthcare 
services, and three central hospitals for tertiary care [2]. The healthcare facilities included in 
90 
this study were centres that provided HIV/AIDS treatment at primary and secondary levels 
such as clinics, community health centres, and district hospitals.  
Sampling procedure 
Healthcare facilities were selected using a stratified sampling technique. This was done by 
dividing the healthcare facilities into two strata, Metropole and non-Metropole, based on 
the municipal locations. Thereafter they were proportionally selected according to the size 
of the patient population. Those facilities providing HIV treatment for less than 325 patients 
per month were excluded from the survey. Sixty-two facilities, 42 in the Metropole and 20 in 
the non-Metropole areas met the selection criteria. Of these 62 potentially eligible facilities, 
17 (of which 13 were in the Metropole area) were included in the final sample of healthcare 
facilities (Table 5.1). 
Table 5.1. Details of the HIV/AIDS treatment facilities included in this study 













Khayelitsha 1. Khayelitsha (Site B) CHC 83209 57 
2. Nolungile CDC 55422 65 
Klipfontein 3. Guguletu CHC 54284 76 
Mitchells Plain 4. Crossroads CDC 47742 72 
5. Mitchells Plain CHC 32863 72 
Tygerberg 6. Karl Bremer Hospital 12863 42 
Cape Town Western 
Health sub-district 
7. Hout Bay clinic 16761 62 
8. Robbie Nurock CDC 22957 29 
Cape Town Northern 
Health sub-district 
9. Kraaifontein CHC 26234 66 
Cape Town Eastern 
Health sub-district 
10. Mzamomhle Clinic 22919 58 
11. Durbanville 8451 26 
Cape Town Southern 
Health sub-district 
12. Lady Michaelis CDC 12720 36 














 Overberg District 
Municipality 
14. Hermanus Hospital  16312 52 
 15. Grabouw CDC 14971 44 
West Coast District 
Municipality 
16. Vredendal Central Clinic  5841 25 
 17. Citrusdal Hospital  4355 30 
Total    831 
 
Participants from the 17 healthcare facilities were randomly selected. Table 5.1 depicts the 
number of adult patients randomly drawn at each of the participating facilities. The 
inclusion criteria were all HIV-positive adults attending primary and secondary healthcare 
facilities for ART who were willing to participate in the study by giving informed consent. 
Patients who were younger than 18 years old, pregnant, breastfeeding, bedridden, on 
cancer or chronic corticoid treatment and unwilling or unable to give informed consent 
were excluded from the study. 
Data collection 
The data were captured on personal digital assistants (PDA) using electronic case-report 
forms with built-in checks for quality control. At the collection point, data were encrypted 
and transmitted via secured mobile connection to a dedicated server where they were 
further checked, downloaded and stored for future use.  
Data were collected from March 2014 to February 2015 by a team of trained fieldworkers 
including nurses, dietitians, and a clinician using standardised structured questionnaires, 
and clinical and biochemical measurements. The questionnaire, previously translated into 
other two official languages in the Western Cape including Xhosa and Afrikaans and piloted, 
was administered by the trained fieldworkers. Participants were interviewed and examined 
clinically on the day of recruitment, while their blood specimens were drawn the following 
day after an overnight fast.  
Information on socio-demography, medical history and lifestyle habits were obtained using 
a structured questionnaire adapted from the WHO’s STEPwise approach to NCD risk factor 





the duration of diagnosed HIV infection and CD4 counts that were obtained from 
participants’ records (patient files) as well as their ARV medication which they brought to 
the clinic. 
Clinical examination including anthropometry and blood pressure (BP) measurements were 
obtained using standardised techniques. Anthropometric measurements of height, weight, 
and waist- and hip circumferences were taken with the participant wearing light clothes, 
standing in an upright position and barefoot. Height was measured to the nearest 
0.1 centimetre using a Leicester Height Scale (Seca, Liverpool, UK). Weight, to the nearest 
0.1 kilogram, was determined on an A&D Personal Scale (Model UC-321, Toshima-Ku Tokyo, 
Japan). Waist circumference was measured to the nearest 0.1 centimetre, and was taken as 
the smallest circumference between the xiphisternum and the umbilicus on exhalation using 
a non-stretched measuring tape. The tape was placed parallel to the floor and applied with 
tension but without pressure on the abdominal wall. Hip circumference, to the nearest 
0.1 centimetre, was measured around the widest portion of the buttocks [4]. All 
anthropometric measures were performed twice and the average value used for analyses. 
The BP was measured on the left arm, using a digital BP monitor (Omron, M6 Comfort, 
Netherland) after the participant was seated in a resting position with the feet on the floor 
for at least five minutes. The participant’s left arm was supported at the level of the heart. 
The measurement was repeated three times at three-minute intervals. 
Registered professional nurses performed a venepuncture on participants to collect fasting 
blood samples. These were kept on ice and transported to the laboratory on the collection 
day for processing. Serum from clotted blood and plasma from whole blood were separated 
through centrifugation at 2000 revolution per minute for 15 minutes. All participants who 
did not have a history of diagnosed diabetes underwent a standard 2-hour 75-gram OGTT 
following an overnight fast of at least eight hours as prescribed by the WHO [5]. Plasma 
glucose levels were determined at fasting and at 2-hour postprandial (2h-PG). Glycated 
haemoglobin (HbA1c) was determined using high-performance liquid chromatography 
(Variant Turbo, EDTA tubes) in accordance with the National Glycohaemoglobin 
Standardization Programme (NGSP). All glucose, lipid and aminotransferase concentrations 





glucose was measured by the hexokinase method. Serum cholesterol and triglycerides were 
analysed by enzymatic colorimetric methods. Serum creatinine was determined by kinetic 
colour tests using Beckman AU 500 spectrophotometer. Serum high-sensitivity C-reactive 
protein (hs-CRP) was read with Beckman AU1. All biochemical parameters were analysed at 
an ISO 15189 accredited pathology laboratory (PathCare, Reference Laboratory, Cape Town, 
South Africa) which had no access to participants’ clinical information.  
Sample size 
This study comprised 748 of the 831 recruited participants since 83 with missing data on MS 
variables were excluded from these analyses. With the primary aim to determine the 
prevalence of MS, the precision of 3% was projected using post-hoc power calculation for 
the sample size of the 748 participants based on 95% CI, and the MS prevalence of 25% as 
estimated in our earlier meta-analysis. This is an indication that our data analyses were well-
powered. 
Ethical considerations 
The South African Medical Research Council Ethics Committee provided ethical approval for 
this study (EC021-11/2013). Additional ethic approval was obtained from the University of 
Cape Town for this PhD Project (HREC 622/2014). 
The Department of Health provided permission to conduct this study as did the Western 
Cape Government in accordance with their Guidelines for Approval of Health Research in 
the Western Cape 2012/3. Authorisations for conducting the surveys were obtained from 
the relevant healthcare facilities.  
All participants provided written informed consent following a detailed explanation of the 
study procedure.  
Details of the statistical approaches used and the findings relating to the study’s specific 
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Objectives: We determined metabolic syndrome (MS) prevalence and assessed the 
agreement between different diagnostic criteria in HIV-infected South Africans. 
Method: A random sample included 748 HIV-infected adult patients (79% women) across 17 
HIV healthcare facilities in the Western Cape Province. MS was defined using the Joint 
Interim Statement (JIS-2009), the International Diabetes Federation (IDF-2005), and the 
Adult Treatment Panel III (ATPIII-2005) criteria.  
Results: Median values were 38 years (age), 5 years (diagnosed HIV duration), 392 
cells/mm3 (CD4 count), and 93% of participants were on antiretroviral therapy (ART). MS 
prevalence was 28.2% (95%CI: 25-31.4), 26.5% (23.3-29.6), and 24.1% (21-27.1) based on 
the JIS, IDF, and ATPIII-2005 criteria. Across the three criteria, the prevalence was always 
higher in women than in men (all p <0.001), in participants with longer HIV-infected 
duration (all p ≤0.003), and in ART users not receiving 1st line regimens (all p ≤0.039). The 
agreement among the three criteria was very good overall and in most subgroups (all 
kappa ≥0.81).  
Conclusions: The three most popular diagnostic criteria yielded similarly high MS prevalence 
in this relatively young population receiving care for HIV infection. Very good levels of 
agreement between criteria that unaffected by some HIV-specific features highlighting the 









The introduction of multiple components antiretroviral therapy (ART) has led to a global 
decline in AIDS-related mortality among HIV-infected people, with the disease now regarded 
as a chronic condition. It remains, however, a major contributor to the global burden of 
disease, with HIV-infected individuals now succumbing to non-AIDS-related co-morbidities. 
These are commonly associated with unhealthy lifestyle behaviours and ageing, similar to 
the general population, and are a testimony to the success of ART in extending lifespans. 
Cardiovascular diseases (CVDs) and their cardio-metabolic risk factors of hypertension, type 
2 diabetes mellitus (hereafter referred to as diabetes), dyslipidaemia and obesity are rising 
health priorities in the HIV-infected population [1, 2]. Notably, these cardio-metabolic 
conditions appear to be more prevalent and to occur at younger ages in the HIV-infected 
compared to non-infected populations [3].  
Cardio-metabolic diseases are known to frequently cluster with this constellation referred to 
as the metabolic syndrome (MS). A diagnosis of MS is important because it identifies 
individuals at increased risk for CVDs, diabetes and all-cause mortality [4]. The 
pathophysiology of MS in HIV-infected individuals is thought to be complex with HIV-
infection per se, prolonged use of ART drugs and traditional CVD risk factors contributing to 
the process [5]. Moreover, weight gain among HIV-infected individuals following the uptake 
of ART and improvements in their health status also contributes to the development of the 
MS [6].   
Considering the possible additional pathways, and thus the subsequent greater risk for the 
development of MS in HIV-infected individuals, it is essential to determine the MS 
prevalence in this population. According to a recent meta-analysis, the prevalence of MS in 
the HIV-infected was 17-31% worldwide, depending on the diagnostic criteria used [7]. 
Although South Africa has the greatest number of HIV-infected individuals, who account for 
17% of the global HIV/AIDS population [8], there is a dearth of literature on the MS in the 
local HIV-infected population. Such data is required to guide the appropriate allocation of 
resources and the development of cost-effective therapeutic strategies and programmes for 
MS care in the HIV-infected. Furthermore, it underscores the importance of a holistic 





determine the MS prevalence in HIV-infected patients receiving care at public healthcare 
facilities in the Western Cape Province of South Africa using various diagnostic criteria and 
to assess the agreement between these criteria.  
Methods 
Study population and sampling 
A cross-sectional study was conducted between March 2014 and February 2015 among HIV-
infected men and women aged 18 years and older, who received care at primary healthcare 
facilities in the Western Cape. Details of the study method have been described previously 
(Chapter 5). In brief, the participants were sampled from 17 healthcare facilities including 10 
facilities in Cape Town and seven in the surrounding rural municipalities using random 
sampling procedures. Patients who were pregnant or breastfeeding, bedridden, undergoing 
treatment for cancer, on corticosteroid treatment, unwilling or unable to give consent were 
excluded from the study. 
Data collection 
A team of trained clinicians, nurses and fieldworkers collected the data using 
questionnaires, clinical measurements and biochemical analyses. The data were captured on 
personal digital assistants, using the electronic case report forms with built-in checks for 
quality control. These were then encrypted at the point of collection and sent via mobile 
connections to a dedicated server where it was further checked, downloaded and stored for 
future use. While the interviews and physical examinations were done on the day of 
recruitment, blood samples were taken the following day after the participant had fasted 
overnight.  
Socio-demographic data and medical history were obtained using a structured interviewer-
administered questionnaire adapted from the World Health Organisation’s (WHO) STEPwise 
approach to Surveillance (STEPS) tool. Duration of diagnosed HIV infection, CD4 counts and 
ART regimens were obtained from participants’ records. 
Anthropometric measurements used standardised techniques. Heights and weights were 
taken with the participants in light clothing and bare-footed. Waist circumference (WC) to 
100 
the nearest centimetre was measured as the smallest circumference between the 
xiphisternum and the umbilicus on exhalation using a non-stretched measuring tape. Blood 
pressure (BP) was measured on the left arm, using a digital automatic BP monitor (Omron, 
M6 Comfort, Netherland) after the participant was seated in a resting position for at least 
five minutes; three measurements were taken three minutes apart whereas the average 
value of the 2nd and 3rd measurements was used as BP level in the analysis.  
Biochemical parameters were analyzed at an ISO 15189 accredited pathology laboratory 
(PathCare, Reference Laboratory, Cape Town, South Africa). Serum cholesterol and 
triglycerides were analyzed by enzymatic colorimetric methods; plasma glucose was 
measured by hexokinase method; all implemented using a Beckman Coulter AU 500 
spectrophotometer. Insulin concentrations were measured by the Chemiluminesecence 
Immunoassay method. The homeostatic model assessment of insulin resistance (HOMA-IR) 
was calculated as the product of insulin (mIU/L) and glucose (mmol/L) by 22.5 [9].  
Definitions of MS 
Several international organisations have proposed various definitions for MS [10]. Those 
considered in the current study were the European Group for the Study of Insulin Resistance 
criteria (EGIR 1999) [11], ATPIII 2005 [12], IDF 2005 [13], and JIS 2009 [10], described in 
Table 6.1. Both WHO and EGIR definitions have proposed insulin resistance as a prerequisite 
for diagnosing the MS. EGIR defines insulin resistance as plasma insulin levels above 75th 
percentile from non-diabetes populations [11] while WHO recommends the use of 
hyperinsulinaemic, euglycaemic clamp-glucose uptake values below 25th percentile [14]. 
Because the hyperinsulinaemic euglycaemic clamp and urinary albumin excretion 






Table 6.1. Criteria used for the diagnosis of the metabolic syndrome  
Criteria EGIR (1999) [11] ATPIII (2005) [12] IDF (2005) [13] JIS (2009) [10] 





None WC ≥94 cm (men) 
WC ≥80 cm 
(women) 
None 
Additional any 2 other criteria  any 3 criteria  any 2 other criteria any 3 criteria  
Obesity:  men 
            women 
WC ≥94 cm  
WC ≥80 cm  
WC ≥102 cm  
WC ≥88 cm 
- WC ≥94 cm  
WC ≥80 cm 
Triglycerides >2.0 mmol/L ≥1.7 mmol/L ≥1.7 mmol/L ≥1.7 mmol/L 
HDL-C:   men 
             women  
<1.0 mmol/L  
<1.0 mmol/L 
<1.03 mmol/L 
<1.3 mmol/L  
or on dyslipidaemia 
Rx 
<1.03 mmol/L, 
<1.3 mmol/L  
or on dyslipidaemia 
Rx 
<1.03 mmol/L 
<1.3 mmol/L  
or on dyslipidaemia 
Rx 
Blood pressure ≥140/90 mmHg ≥130/85 mmHg  
or on hypertension 
Rx 
 ≥130/85 mmHg  
or on hypertension 
Rx 
≥130/85 mmHg  
or on hypertension 
Rx 
Glucose ≥6.1 mmol/L ≥ 5.6 mmol/L  
or on diabetes Rx 
≥ 5.6 mmol/L  
or on diabetes Rx 
≥ 5.6 mmol/L  
or on diabetes Rx 
ATPIII, Adult Treatment Panel III; EGIR, European Group for the Study of Insulin Resistance; IDF, 
International Diabetes Federation; JIS, Joint Interim Statement; HDL-C, high-density lipoprotein 
cholesterol; IR, insulin resistance; Rx, treatment; WC, waist circumference 
 
Statistical analysis 
The R statistical software version 3.0.3 (2014-03-06) was used for statistical analysis. The 
numerical variables are expressed as medians (25th-75th percentiles) and categorical 
variables as counts and percentages. Groups’ comparison used Mann-whiney U test and chi-
square test as appropriate.  The agreement between the diagnostic criteria for the MS was 
assessed with the use of the kappa statistic. Kappa statistic values were interpreted as poor 
(kappa ≤0.2), fair (0.2< kappa ≤0.4), moderate (0.4 < kappa ≤0.6), substantial 
(0.6 < kappa ≤0.8), and very good (kappa >0.8) [15]. In the main analysis, we determined the 
prevalence of the MS by the ATPIII 2005, the IDF and the JIS criteria, and assessed the 
agreement between these three criteria. The criteria were then expanded to include the 
EGIR criteria in secondary analyses of a sub-sample of participants with data available on 
insulin resistance. A p-value of 0.05 is considered statistical significance. 
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Results 
Characteristics of the participants 
Of the 831 participants recruited, 748 had complete data on all components of the MS 
(response rate: 90%) and are included in the present analyses. As presented in Table 6.2, 
79% (591 participants) of the sample consisted of women. The median age of the 
participants was 38 years (25th-75th percentiles: 32-44), with men significantly older than 
women (41 years vs 37 years, p<0.001). The median duration of diagnosed HIV infection was 
5 years (25th-75th percentiles: 2-9) with women diagnosed longer than men (5 years vs. 4 
years, p <0.001). The median CD4 count was 392 cells/mm3 (25th-75th percentiles: 240-604) 
with counts higher in women (410 cells/mm3, 253-627) compared to men (272 cells/mm3, 
193-448), p=0.001. Most participants (93%) were on ART, with the majority being 1st line
ART users (61%), and the distribution of ART regimens differing in men and women 
(p=0.005). Compared with men, women were more likely to have greater BMI, waist 
circumference, total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density 
lipoprotein cholesterol (HDL-C) and HOMA-index (all p <0.012), but had a lower waist-to-hip 
ratio (WHR), systolic BP, triglycerides (TG) and fasting plasma glucose (FPG) levels (all 


















 percentiles):     
Age (years) 38 (32-44) 41 (35-47) 37 (31-43) <0.001 
Anthropometry     
Body mass index (kg/m
2
) 26.3 (22.1-32) 21.4 (19.8-22.4) 28.3 (23.8-28.9) <0.001 
Waist circumference (cm) 88 (78-98) 79 (74-88) 90 (80-101) <0.001 
Waist-to-hip ratio 0.86 (0.8-0.91) 0.87 (0.84-0.93) 0.85 (0.8-0.9) <0.001 
Blood pressure (mmHg)     
Systolic 117 (107-130) 123.5 (114.5-140) 115 (105.8-127) <0.001 
Diastolic 82 (75-91) 83 (76-94) 81.5 (74.8-89.8) 0.129 
Lipid variables (mmol/L)     
Total cholesterol 4.3 (3.7-5.1) 4.2 (3.5-3.8) 4.4 (3.8-5.1) 0.009 
LDL-C 2.5 (2.0-3.1) 2.3 (1.7-3.0) 2.5 (2.0-3.1) 0.012 
HDL-C 1.3 (1-1.5) 1.2 (1.0-1.5) 1.29 (1.08-1.52) 0.010 
Triglycerides 1 (0.7-1.3) 1.12 (0.75-1.27) 0.97 (0.74-1.28) 0.023 
Fasting glucose (mmol/L) 5 (4.6-5.4) 5.1 (4.8-5.5) 4.9 (4.6-5.4) 0.010 
HOMA-IR 1.36 (0.84-2.24) 0.94 (0.53-1.64) 1.49 (0.93-2.37) <0.001 
HIV-related factors     
HIV duration (years) 5 (2-9) 4 (2-7) 5 (2.5-9) <0.001 
CD4 count (cells/mm
3
) 392(240-604) 272 (193-448) 410 (253-627) 0.001 
Number (%): n=699 n=149 n=550  
Antiretroviral treatment    0.005 
None 46 (6.6) 7 (4.7) 39 (7.1)  
1
st
 line 426 (60.9) 78 (52.3) 348 (63.3)  
2
nd
 line 79 (11.3) 17 (11.4) 62 (11.3)  
Others 148 (21.2) 47 (31.5) 101 (18.3)  
     
LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; HIV, human 





Prevalence of the MS by the JIS, IDF, and ATPIII-2005 criteria 
The prevalence of MS (95%CI) by the JIS, IDF and ATPIII 2005 criteria was 28.2% (25-31.4), 
26.5% (23.3-29.6) and 24.1% (21-27.1), respectively (Table 6.3). The MS prevalence was 
significantly higher in women compared to men across the three criteria (all p <0.001): JIS 
(31.3% vs. 16.6%), IDF (30.5% vs. 11.5%) and ATPIII 2005 (26.9% vs. 13.4%).  
The prevalence of MS by the HIV-related characteristics is also presented in Table 6.3. MS 
prevalence was higher in participants with ≥5 years compared with <5 years’ duration of 
diagnosed HIV infection (all p <0.003): JIS (32.6% vs. 22.5%), IDF (30.5% vs. 21%), ATPIII 2005 
(28.8% vs. 17.9%). With regards to ART use, the prevalence of MS in the 46 participants who 
were not on ART was 34.8% (21-48.6) by the JIS, and 32.6% (19.1-46.2) by the IDF and ATPIII 
2005 criteria. This was not significantly different compared to those on ART (all p ≥0.175). 
Across the three criteria by ART regimens, participants on 1st line ART regimens had lower 
MS prevalence compared with 2nd line or other regimens, (all p <0.039). There was a trend 
towards higher MS prevalence with CD4 counts ≥392 cells/mm3 compared with 
<392 cells/mm3. However, these were not significantly different by any of the three criteria 
(all p >0.06): JIS (32.6% vs. 25.3%), IDF (32.1% vs. 24.7%) and ATPIII 2005 (29.4% vs. 21.0%).  
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Table 6.3. Prevalence (95% confidence intervals) of the metabolic syndrome by the 
JIS, IDF and ATPIII-2005 criteria and their variations presented by gender and HIV-








Overall 28.2 (25.0-31.4) <0.001 26.5 (23.3-29.6) <0.001 24.1 (21.0-27.1) <0.001 
Men 16.6 (10.8-22.4) 11.5 (6.5-16.5) 13.4 (8.1-18.7) 
Women 31.3 (27.6-35.0) 30.5 (26.8-34.2) 26.9 (23.3-30.5) 
HIV-duration 
(n=740) 
Overall 27.8 (24.6-31.1) 0.002 26.1 (22.9-29.2) 0.003 23.7 (20.6-26.7) 0.001 
HIV-duration<5yrs 22.5 (18.1-26.9) 21.0 (16.8-25.3) 17.9 (13.8-21.9) 
HIV-duration≥5yrs 32.6 (27.9-37.2) 30.5 (26.0-35.1) 28.8 (24.3-33.2) 
CD4 count (n=373) 
Overall 29 (24.4-33.6) 0.118 28.4 (23.8-33) 0.115 25.2 (20.8-29.6) 0.060 
CD4 count<392 25.3 (19.0-31.5) 24.7 (18.5-30.9) 21.0 (15.1-26.8) 
CD4 count≥392 32.6 (25.9-39.3) 32.1 (25.4-38.8) 29.4 (22.9-35.9) 
ART use (n=699) 
Overall 28.0 (24.7-31.4) 0.292 26.2 (22.9-29.4) 0.305 24.3 (21.1-27.5) 0.175 
No-ART 34.8 (21.0-48.6) 32.6 (19.1-46.2) 32.6 (19.1-46.2) 
On-ART 27.6 (24.1-31.0) 25.7 (22.4-29.1) 23.7 (20.5-27.0) 
ART regimens 0.017 0.031 0.039 
1
st
 line 23.9 (19.9-28.0) 22.5 (18.6-26.5) 20.7 (16.8-24.5) 
2
nd
 line 32.9 (22.5-43.3) 29.1 (19.1-39.1) 30.4 (20.2-40.5) 
Others 35.1 (27.4-42.8) 33.1 (25.5-40.7) 29.1 (21.7-36.4) 
Data are percentage; ATPIII, Adult Treatment Panel III; EGIR, European Group for the Study of Insulin 
Resistance; IDF, International Diabetes Federation; JIS, Joint Interim Statement; HIV, human 
immunodeficiency virus; ART, antiretroviral therapy. Data were missing for some characteristics. For 
each grouping variable for which data were missing for some participants, the number of participants 
with valid data is provided (attached to the name of the variable) as well as the overall prevalence of 
metabolic syndrome in that subsample 
Concordance between different MS criteria 
The concordance between the JIS, IDF and ATPIII 2005 MS criteria overall and by subgroups 
is shown in Table 6.4. The overall agreement was very good with a kappa of 0.96 (95%CI: 
0.93-0.98) between the JIS and IDF criteria, 0.89 (95%CI: 0.86-0.93) between the JIS and 
ATPIII 2005 criteria, and 0.84 (95%CI: 0.80-0.89) between the IDF and ATPIII 2005 criteria. 
Similarly, high levels of agreement were found in women, by subgroups of diagnosed HIV 
infection duration, CD4 counts and ART regimens. The level of concordance in men was very 





the JIS & IDF criteria [kappa=0.79 (0.65-0.93)] and the IDF & ATPIII 2005 criteria [0.62 (0.43-
0.81)]. 
Table 6.4. Kappa statistics and 95% confidence intervals for the concordance between 
the JIS, IDF and ATPIII 2005 metabolic syndrome criteria presented by gender and HIV-
related subgroups 
Group & Subgroup Criteria IDF JIS 
Overall (n=748)    
 IDF - 0.96 (0.93-0.98) 
 ATPIII 2005 0.84 (0.80-0.89) 0.89 (0.86-0.93) 
Men    
 IDF - 0.79 (0.65-0.93) 
 ATPIII 2005 0.62 (0.43-0.81) 0.88 (0.77-0.98) 
Women    
 IDF - 0.98 (0.96-1.00) 
 ATPIII 2005 0.87 (0.83-0.92) 0.89 (0.85-0.93) 
HIV duration-overall (n=740)    
 IDF - 0.96 (0.93-0.98) 
 ATPIII 2005 0.84 (0.80-0.89) 0.89 (0.85-0.93) 
    
HIV-duration<5yrs    
 IDF - 0.96 (0.92-0.99) 
 ATPIII 2005 0.81 (0.73-0.89) 0.86 (0.79-0.92) 
HIV-duration≥5yrs    
 IDF - 0.95 (0.92-0.99) 
 ATPIII 2005 0.86 (0.80-0.92) 0.91 (0.87-0.95) 
CD4 count-overall (n=373)    
 IDF - 0.99 (0.97-1.00) 
 ATPIII 2005 0.89 (0.84-0.94) 0.91 (0.86-0.95) 
CD4 count<392cells/mm
3 
   
 IDF - 0.99 (0.96-1.00) 
 ATPIII 2005 0.86 (0.78-0.95) 0.88 (0.80-0.96) 
CD4 count≥392cells/mm
3 
   
 IDF - 0.99 (0.96-1.00) 
 ATPIII 2005 0.91 (0.85-0.98) 0.93 (0.87-0.98) 
Antiretroviral therapy use-overall (n=699)    
 IDF - 0.95 (0.93-0.98) 
 ATPIII 2005 0.85 (0.81-0.90) 0.90 (0.87-0.94) 
No-antiretroviral treatment    
 IDF - 0.95 (0.86-1.00) 
 ATPIII 2005 0.9 (0.77-1.00) 0.95 (0.86-1.00) 
On antiretroviral treatment    
 IDF - 0.95 (0.93-0.98) 
 ATPIII 2005 0.85 (0.80-0.90) 0.90 (0.86-0.94) 
1
st
 line antiretroviral therapy regimen    
 IDF - 0.96 (0.93-0.99) 
 ATPIII 2005 0.86 (0.80-0.92) 0.91 (0.86-0.95) 
2
nd
 line antiretroviral therapy regimen    
 IDF - 0.91 (0.81-1.00) 
 ATPIII 2005 0.85 (0.72-0.98) 0.94 (0.86-1.00) 
Other antiretroviral therapy regimens    
 IDF - 0.95 (0.90-1.00) 





ATPIII, Adult Treatment Panel III; EGIR, European Group for the Study of Insulin Resistance; IDF, 
International Diabetes Federation; JIS, Joint Interim Statement; HIV, human immunodeficiency virus. 
Data were missing for some characteristics. For each grouping variable for which data were missing 
for some participants, the overall agreement between criteria in that subsample is provided 
 
Secondary analyses in participants with insulin resistance data 
In the subgroup of participants with data available on insulin resistance (N=711), the 
prevalence of MS and the agreement between the JIS, IDF and ATPIII 2005 criteria, overall 
and within subgroups, were mostly similar to those observed in the main analysis. In this 
sub-sample, the prevalence of MS according to the EGIR criteria was as follows: overall: 
12.4%; men vs. women: 6.7% vs. 13.9%, p=0.018; shorter vs. longer duration of diagnosed 
HIV infection: 9.5% vs. 15.2%, p=0.022; CD4 count <392 cells/mm3 vs. ≥392 cells/mm3: 7.9% 
vs. 17.2, p=0.007; and ART regimens: 10.1 % (1st line), 19.4% (2nd line) and 14.4% (other 
regimens) (p=0.051); Table 6.5. The agreement between EGIR and the other criteria was at 
most fair: EGIR vs. JIS 0.33 (0.25-0.40), EGIR vs. IDF 0.32 (0.24-0.40); and EGIR vs. ATPIII 2005 





Table 6.5. Prevalence (95% confidence intervals) of the metabolic syndrome across different definitions and their variations 
presented by gender and HIV-related subgroups in a subsample of participants 
Subgroups JIS P-value IDF P-value ATPIII-2005 P-value EGIR P-value 
Gender (n=711)         
Overall 28.1 (24.8-31.4) <0.001 26.3 (23.1-29.5) <0.001 23.8 (20.6-26.9) <0.001 12.4 (10-14.8) 0.018 
Men 16.1 (10.2-22)  10.7 (5.8-15.7)  12.8 (7.4-18.1)  6.7 (2.7-10.7)  
Women 31.3 (27.5-35.2)  30.4 (26.6-34.2)  26.7 (23-30.4)  13.9 (11-16.7)  
HIV-duration (n=703)         
Overall 27.7 (24.4-31.1) 0.002 25.9 (26.7-29.1) 0.003 23.3 (20.2-26.5) 0.001 12.5 (10.1-15) 0.022 
HIV-duration<5yrs 22.3 (17.8-26.8)  20.7 (16.3-25.1)  17.4 (13.3-21.5)  9.5 (6.3-12.6)  
HIV-duration≥5yrs 32.5 (27.8-37.3)  30.4 (25.7-35.1)  28.5 (24.0-33.1)  15.2 (11.6-18.8)  
CD4 count (n=358)         
Overall 29.6 (24.9-34.3) 0.187 29.1 (24.4-33.8) 0.184 25.7 (21.2-30.2) 0.103 12.6 (9.1-16.0) 0.007 
CD4 count<392cells/mm
3 
26.4 (19.9-32.9)  25.8 (19.4-32.3)  21.9 (15.8-28)  7.9 (3.9-11.8)  
CD4 count≥392cells/mm
3 
32.8 (25.9-39.6)  32.2 (25.4-39.1)  29.4 (22.8-36.1)  17.2 (11.7-22.7)  
Antiretroviral therapy use (n=663)         
Overall 28.1 (24.6-31.5) 0.565 26.1 (22.8-29.4) 0.589 24.1 (20.9-27.4) 0.385 12.7 (10.1-15.2) 0.108 
No antiretroviral therapy 31.8 (18.1-45.6)  29.6 (16.1-43.0)  29.6 (16.1-43.0)  20.5 (9.1-31.8)  
On antiretroviral therapy 27.8 (24.3-31.3)  25.9 (22.4-29.3)  23.8 (20.4-27.1)  12.1 (9.6-14.7)  
Antiretroviral therapy regimens  0.015  0.031  0.032  0.051 
1
st
 line 24 (19.9-28.2)  22.6 (18.5-26.6)  20.6 (16.7-24.5)  10.1 (7.1-13)  
2
nd
 line 34.7 (23.7-45.7)  30.6 (19.9-41.2)  31.9 (21.2-42.7)  19.4 (10.3-28.6)  
Others 35.3 (27.3-43.2)  33.1 (25.3-40.9)  28.8 (21.3-36.3)  14.4 (8.6-20.2)  
         
ATPIII, Adult Treatment Panel III; EGIR, European Group for the Study of Insulin Resistance; IDF, International Diabetes Federation; JIS, Joint Interim 
Statement; HIV, human immunodeficiency virus. Data were missing for some characteristics. For each grouping variable for which data were missing 
for some participants, the number of participants with valid data is provided (attached to the name of the variable), as well as the overall prevalence 
of Metabolic syndrome in that subsample. 
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Table 6.6. Kappa statistics and 95% confidence intervals for the concordance 
between the JIS, IDF, ATPIII 2005 and EGIR metabolic syndrome criteria presented by 
gender and HIV-related subgroups in a subsample of participants 
Group & Subgroup Criteria ATPIII-2005 IDF JIS 
Overall (n=711) IDF 0.95 (0.93-0.98) 
ATPIII 2005 0.84 (0.79-0.88) 0.89 (0.85-0.93) 
EGIR 0.38 (0.30-0.46) 0.32 (0.24-0.40) 0.33 (0.25-0.40) 
Men IDF 0.77 (0.62-0.92) 
ATPIII 2005 0.58 (0.37-0.78) 0.86 (0.75-0.98) 
EGIR 0.51 (0.28-0.74) 0.25 (0.01-0.49) 0.42 (0.20-0.63) 
Women IDF 0.98 (0.96-1.00) 
ATPIII 2005 0.87 (0.82-0.91) 0.89 (0.85-0.93) 
EGIR 0.36 (0.27-0.44) 0.32 (0.24-0.40) 0.31 (0.23-0.39) 
HIV duration-overall (n=703) IDF 0.95 (0.93-0.98) 
ATPIII 2005 0.83 (0.78-0.88) 0.88 (0.84-0.9) 
EGIR 0.39 (0.31-0.48) 0.33 (0.25-0.41) 0.34 (0.26-0.41) 
HIV-duration <5 yrs IDF 0.95 (0.92-0.99) 
ATPIII 2005 0.79 (0.71-0.88) 0.85 (0.77-0.92) 
EGIR 0.43 (0.29-0.57) 0.36 (0.23-0.49) 0.36 (0.23-0.48) 
HIV-duration ≥5 yrs IDF 0.95 (0.92-0.98) 
ATPIII 2005 0.85 (0.79-0.91) 0.91 (0.86-0.95) 
EGIR 0.36 (0.26-0.47) 0.30 (0.2-0.41) 0.32 (0.22-0.41) 
CD4 count-overall (n=358) IDF 0.99 (0.97-1.00) 
ATPIII 2005 0.89 (0.83-0.94) 0.90 (0.85-0.95) 
EGIR 0.32 (0.21-0.44) 0.28 (0.17-0.38) 0.28 (0.18-0.39) 
CD4 count <392 IDF 0.99 (0.96-1.00) 
ATPIII 2005 0.86 (0.77-0.95) 0.88 (0.80-0.96) 
EGIR 0.30 (0.13-0.46) 0.24 (0.09-0.39) 0.24 (0.09-0.38) 
CD4 count ≥392 IDF 0.99 (0.96-1.00) 
ATPIII 2005 0.91 (0.84-0.97) 0.92 (0.86-0.98) 
EGIR 0.33 (0.18-0.48) 0.29 (0.14-0.44) 0.31 (0.17-0.45) 
Antiretroviral therapy use-
overall (n=663) 
IDF 0.95 (0.92-0.98) 
ATPIII 2005 0.84 (0.80-0.89) 0.90 (0.86-0.94) 
EGIR 0.40 (0.32-0.48) 0.35 (0.27-0.43) 0.35 (0.28-0.43) 
No antiretroviral therapy IDF 0.95 (0.84-1.00) 
ATPIII 2005 0.89 (0.74-1.00) 0.95 (0.84-1.00) 
EGIR 0.52 (0.24-0.80) 0.40 (0.10-0.70) 0.48 (0.20-0.76) 
1
st
 line antiretroviral therapy 
regimen 
IDF 0.96 (0.93-0.99) 
ATPIII 2005 0.86 (0.79-0.92) 0.90 (0.85-0.95) 
EGIR 0.40 (0.28-0.51) 0.36 (0.25-0.47) 0.37 (0.26-0.48) 
2
nd
 line antiretroviral therapy 
regimen 
IDF 0.91 (0.80-1.00) 
ATPIII 2005 0.84 (0.70-0.97) 0.94 (0.85-1.00) 
EGIR 0.32 (0.09-0.56) 0.34 (0.11-0.58) 0.28 (0.06-0.51) 
Other antiretroviral therapy 
regimens 
IDF 0.95 (0.90-1.00) 
ATPIII 2005 0.80 (0.69-0.91) 0.85 (0.76-0.94) 
EGIR 0.38 (0.21-0.55) 0.28 (0.12-0.44) 0.29 (0.14-0.44) 
ATPIII, Adult Treatment Panel III; EGIR, European Group for the Study of Insulin Resistance; IDF, 
International Diabetes Federation; JIS, Joint Interim Statement; HIV, human immunodeficiency virus. 
Data were missing data for some characteristics. For each grouping variable for which data were 






In the present study among HIV-infected participants who were mostly on ART, we found 
that: 1) the prevalence of MS was high based on the JIS, IDF, and ATPIII-2005 criteria, but 
much lower by the EGIR criteria; 2) Across the MS definitions, the prevalence appeared to 
be higher among women, participants with longer duration of diagnosed HIV infection, and 
ART users not receiving 1st line regimens, but was mostly unaffected by CD4 count levels; 3) 
The agreement between the JIS, IDF, and ATPIII-2005 was very good overall and in most 
subgroups, while the agreement of the three criteria with EGIR was generally fair.  
MS prevalence by different criteria in the HIV-infected population 
The prevalence of the MS in this study by the different criteria was in line with the findings 
of a recent meta-analysis which revealed that nearly one-third of global HIV-infected 
populations have the MS [7]. Compared with other criteria, the JIS identified the most 
participants with MS, which was not surprising. The higher thresholds for WC in the ATPIII 
2005 and the mandatory use of WC in the IDF criteria, likely ruled out the participants 
diagnosed with MS by the JIS criteria, but who did not qualify for central obesity based on 
the IDF or ATPIII criteria. Similarly, the presence of insulin resistance, the higher thresholds 
for TG and FPG), as well as lower thresholds for HDL-C in women in the EGIR criteria, would 
explain the differences in the magnitude of MS prevalence between EGIR and the three 
other sets of criteria.  
Comparison of MS prevalence in the HIV-infected and general populations 
The MS prevalence in this study was within the range of 17-46% published in the general 
population internationally [16-18] and locally [19, 20]. Studies on the epidemiology of MS in 
South Africa have provided the prevalent rates of 30.7% in urban black residents of Cape 
Town [20], and 26.5% in black adults in rural KwaZulu-Natal with the JIS criteria [19]. Using 
the JIS, IDF and ATPIII-2001 criteria, and in a much older (mean age of 51 years) and highly 
obese urban coloured population in Cape Town, Erasmus and co-workers found MS 
prevalence of 62%, 60.6% and 55.4% respectively [21].  
The higher prevalence of MS among women compared to men in this study is consistent 





prevalence reports of MS in the general population [19-21]. Notably, the similarities in 
prevalent MS between young HIV-infected people and a much older general population 
suggests the likely comparable risk of developing MS related conditions such as CVDs and 
diabetes in people with HIV infection, but at a much younger age.  
MS prevalence and HIV-related characteristics 
Higher prevalence of MS was found among participants with longer duration of diagnosed 
HIV infection, and ART users who were not on 1st line regimens. These associations may in 
part be explained by older age and drug-related toxicity secondary to prolonged use of ART 
[22] or the 2nd line regimens that contain protease inhibitors (PIs). Results of clinical trials 
suggest that PI-based regimens accelerate the progression of MS, likely via chronic 
inflammation and incomplete restoration of the immune system after commencing ART [23, 
24]. The lack of effect of CD4 count or ART use, mainly with 1st line regimens, on the 
presence of MS reported in this study, mirror the results of a recent meta-analysis [7]. It is 
of note however that the effect of the CD4 count was explored in a relatively small sample, 
with a possibility of low statistical power. 
Agreement between sets of criteria 
In the present study, the agreement between JIS, IDF, and ATPIII-2005 criteria was generally 
good, implying that with the exception of some subgroups, these sets of criteria generally 
classify the same individuals as having MS, or ruled out the diagnosis in the same people. 
This is not surprising since all three criteria are based on the same components although not 
always with the same threshold for waist circumference. Generally, the agreement between 
EGIR and other three criteria was at most fair. The key feature explaining the low agreement 
was the use of insulin resistance as a criterion in the EGIR definition.  
Only two studies have previously assessed the agreement between MS criteria in HIV-
infected people, and these have provided findings mostly in line with ours. Ayodele and 
colleagues reported a very good agreement between JIS and IDF criteria (kappa =0.88) [25], 
whereas the agreement between IDF and EGIR was fair (kappa=0.30) in the report by 
Cubero and co-workers [26].  
112 
The degree of agreement between the JIS, IDF, and ATPIII-2005 criteria in this study is 
consistent with data from studies conducted in general populations in Africa [19, 21, 27, 28] 
and other parts of the world [29-31] with the agreement being better in women than in men 
[27, 28, 31]. Furthermore, the agreement in our sample was unaffected by HIV-specific 
characteristics, supporting the comparable diagnostic performance of the commonest sets 
of diagnostic criteria for MS in a broader population of people with HIV infection, and across 
the continuum of HIV care.  
Strengths and limitations 
The present study has some limitations. The relatively fewer men and ART-naïve 
participants may lead to unstable estimates of MS prevalence in these subgroups. The 
absence of an HIV-negative subgroup limits the direct comparison of our findings with those 
in the general population. In addition, missing data on HIV-related variables did not allow us 
to perform a regression analysis, which limited the identification of HIV-specific associations 
with MS in our study.  
Considering that most HIV-related studies in Africa are single-clinic-based, a major strength 
of this study is the inclusion of multiple healthcare facilities. Moreover, the included 
healthcare facilities, selected using random sampling methods, were based in both urban 
and rural areas that being known for influencing on MS prevalence. This allows for the 
generalizability of the results to other South African HIV-infected populations. Furthermore, 
this study has provided the most comprehensive analysis of the agreement between MS 
diagnostic criteria in people with HIV infection.  
Conclusions 
This study has reported a high prevalence of MS according to three recent criteria in young 
adult South Africans with HIV infection, and the likely influence of some, but not all HIV-
related characteristics on the estimates. The very good agreement between these sets of 
criteria suggests that their sequential application is unlikely to explain differences in MS 
prevalence in HIV-infected people across settings and time periods, nor would result in a 
substantial mismatch of individuals’ MS status if these criteria were applied interchangeably 





against the uncritical application to the general population in Africa, of internationally 
advocated diagnostic thresholds for some common parameters to these criteria such as WC, 
as this could lead to unacceptable MS risk stratification. Extending these investigations to 
people with HIV infection should be part of future efforts to promote MS screening in HIV-
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The distribution of body size phenotypes in people with human immunodeficiency virus 
(HIV) infection has yet to be characterized. We assessed the distribution of body size 
phenotypes overall, and according to antiretroviral therapy (ART), diagnosed duration of 
the infection and CD4 count in a sample of HIV-infected people recruited across primary 
care facilities in the Western Cape Province, South Africa. Adults aged ≥ 18 years were 
consecutively recruited using random sampling procedures, and their cardio-metabolic 
profile was assessed during March 2014 and February 2015. They were classified across 
body mass index (BMI) categories as normal-weight (BMI < 25 kg/m2), overweight (25 ≤ 
BMI < 30 kg/m2), and obese (BMI ≥ 30 kg/m2), and further classified according to their 
metabolic status as “metabolically healthy” vs. “metabolically abnormal” if they had less 
than two vs. two or more of the following abnormalities: high blood glucose, raised blood 
pressure, raised triglycerides, and low HDL-cholesterol. Their cross-classification gave the 
following six phenotypes: normal-weight metabolically healthy (NWMH), normal-weight 
metabolically abnormal (NWMA), overweight metabolically healthy (OvMH), overweight 
metabolically abnormal (OvMA), obese metabolically healthy (OMH), and obese 
metabolically abnormal (OMA). Among the 748 participants included (median age 38 years 
(25th–75th percentiles: 32–44)), 79% were women. The median diagnosed duration of HIV 
was five years; the median CD4 count was 392 cells/mm3 and most participants were on 
ART. The overall distribution of body size phenotypes was the following: 31.7% (NWMH), 
11.7% (NWMA), 13.4% (OvMH), 9.5% (OvMA), 18.6% (OMH), and 15.1% (OMA). The 
distribution of metabolic phenotypes across BMI levels did not differ significantly in men 
vs. women (p = 0.062), in participants below vs. those at or above median diagnosed 
duration of HIV infection (p = 0.897), in participants below vs. those at or above median 
CD4 count (p=0.447), and by ART regimens (p=0.205). In this relatively young sample of 
HIV-infected individuals, metabolically abnormal phenotypes are frequent across BMI 
categories. This highlights the importance of general measures targeting an overall 
improvement in cardiometabolic risk profile across the spectrum of BMI distribution in all 





People living with HIV infection constitute a sizable proportion of the world population 
and the number is increasing [1]. The advent and uptake of antiretroviral therapy (ART) 
have turned HIV infection from a highly fatal infectious disease into a chronic manageable 
condition [2]. Consequently, the lifespan of HIV-infected patients receiving ART is now 
close to that of the general population [3]. This has led to a rise in chronic and age-related 
conditions such as cardio-metabolic disorders in HIV-infected people [4, 5], that is 
contributing substantially to the overall morbidity and mortality in this population [6, 7]. 
A major contributor to cardio-metabolic diseases is the global obesity epidemic with 52% 
(1.9 million) of the worldwide adult population being either overweight or obese in 2014 
[8]. Obesity contributes to cardio-metabolic abnormalities by impairing metabolic 
functions that promote dyslipidemia, insulin resistance, as well as chronic inflammation 
[9]. Consequently, concepts such as “metabolically healthy” and “metabolically abnormal” 
have been used to characterize individuals across the distribution of body mass index 
(BMI) as a function of the underlying burden of metabolic abnormalities [10]. However, 
evidence on the associations of different obesity phenotypes and cardio-metabolic risk are 
inconclusive, and standard criteria to define obesity phenotypes are still lacking. Studies 
on the prevalence of obesity phenotypes are thus of importance as these may help 
understand the disease risk relating to obesity and importantly develop more effective 
prevention and control strategies. 
The changes in body fat distribution associated with HIV infection are well-described [11]. 
The advanced stage of untreated HIV infection is associated with changes in body fat content 
and distribution, which are partially and perhaps non-optimally restored following 
treatment with ART [12]. ART extends the lifespan of HIV-infected people by reducing the 
viral load with a subsequent strengthening of the immune system; notably, it does not 
eliminate the HIV infection. Hence, chronic inflammation persists and there is an 
incomplete restoration of the immune system [13]. Additionally, various metabolic 





include dyslipidemia, insulin resistance, and abnormal blood pressure levels, [13], which 
contribute to cardiovascular diseases (CVD) and type 2 diabetes mellitus (T2DM) [13, 16]. 
While obesity and HIV infection have been extensively researched separately and there is 
a dearth of data on the distribution of obesity phenotypes in HIV-infected people [17]. 
Therefore, in the current study, we assessed the distribution of obesity phenotypes, and 
the effects if any, of ART and other major distinctive characteristics of HIV infection, in a 
representative sample of people with HIV recruited across primary healthcare facilities in 
the Western Cape Province, South Africa. 
Methods 
Study Design and Sampling Procedure 
A cross-sectional survey was conducted from March 2014 to February 2015 in a random 
sample of HIV-infected adults aged 18 years and older being treated at public healthcare 
facilities across the Western Cape Province in South Africa. Permission to conduct the 
survey was obtained from Health Research Office of the Western Cape Department of 
Health, and the relevant healthcare facilities. 
The healthcare facilities considered for this study needed to provide ART to at least 325 
HIV-infected patients per month to ensure adequate recruitment within a reasonable 
period. Thus, the sample frame comprised a total of 62 healthcare facilities with 42 across 
Cape Town and 20 in the surrounding rural municipalities. Of these, 17 facilities, including 
four rural, were randomly selected for inclusion in this study. At each participating 
healthcare facility, 15–60 patients were randomly sampled. 
Data Collection 
A team of trained clinician, nurses, and field workers collected data by administering 
questionnaires, clinical measurements, and biochemical analyses. Data were captured on 
electronic case report forms, which were available on personal digital assistants (PDAs), 
with built-in checks for quality control. Data were encrypted at the point of collection and 





downloaded, and stored for future use. The interviews and the physical assessments were 
conducted on the day of recruitment while the blood specimens were drawn the following 
day after the participant had fasted overnight. 
Interviews 
Socio-demographic data and medical history were obtained using a structured 
interviewer-administered questionnaire adapted from the World Health Organization‘s 
STEPwise approach to Surveillance (STEPS) tool. Self-reported data included the duration 
of being diagnosed HIV infection and CD4 counts, whereas information on HIV treatment 
was obtained by capturing medications brought to by the participants. 
Physical Examination 
Anthropometric parameters including height, weight, and waist circumference (WC) were 
measured using standardized techniques. Height was measured to the nearest millimeter 
using a Leicester Height Scale (Seca, Liverpool, UK) with the participant barefoot and in the 
upright position. Weight was measured to the nearest gram using A&D Personal Scale 
(Model UC-321, Toshima-Ku Tokyo, Japan) with the participant in light clothes, and 
without shoes. WC, recorded to the nearest millimeter, was taken as the smallest 
circumference between the xiphisternum and the umbilicus on exhalation using a non-
stretched measuring tape. After the participant was seated in a resting position for at least 
five minutes, blood pressure (BP) was measured in mmHg on the left arm, using a digital 
automatic BP monitor (Omron, M6 Comfort, Hoofddorp, Netherland); three 
measurements were taken three minutes apart. 
Laboratory Measurements 
Biochemical parameters were analyzed at an ISO 15189 accredited pathology laboratory 
(PathCare, Reference Laboratory, Cape Town, South Africa) which had no access to 
participants’ clinical information. All analyses were performed on venous blood samples 
collected after an overnight fast of at least eight hours. Serum cholesterol and triglycerides 
were measured by enzymatic colorimetric methods; ultrasensitive C-reactive protein was 
read; plasma glucose was measured by hexokinase method; all implemented using a 
123 
Beckman Coulter AU 500 spectrophotometer. Insulin concentrations were measured by the 
Chemiluminesecence Immunoassay method while the HbA1c level was determined using 
high-performance liquid chromatography technique. The homeostatic model assessment 
of insulin resistance (HOMA-IR) was calculated as the product of insulin (mIU/L) and 
glucose (mmol/L) by 22.5 [18]. 
Definitions 
Socio-Demographic Characteristics 
Education level was distinguished into primary education and secondary education or 
above. Smoking status was categorized as never-smoker, past-smoker (stopped smoking 
during the past 12 months), and current-smoker. Alcohol intake behavior was classified as 
non-heavy drinker (consumed <5 standard alcoholic drinks for men and <4 standard 
alcoholic drinks for women in a row during the past 30 days), and heavy-drinker 
(consumed ≥5 standard alcoholic drinks for men and ≥4 standard alcoholic drinks for 
women in a row during the past 30 days). A standard alcoholic drink was corresponding to 
one can (340 mL) of beer, one glass (125 mL) wine, or one shot (25 mL) of spirits. Duration 
of diagnosed HIV infection was the time since being diagnosed with HIV. ARTs were 
categorized as first-line ART, second-line ART, and other regimens [19]. 
Body Size Phenotype 
Body mass index (BMI) was calculated as weight (kg)/height × height (m2). BMI was used 
to classify participants into three categories: normal weight (BMI <25 kg/m2), overweight 
(BMI ≥25 kg/m2 and BMI <30 kg/m2) and obese (BMI ≥30 kg/m2). There is no consensus on 
the definition and number of cardio-metabolic abnormalities to use when characterizing 
obesity phenotypes [20]. In the current study, we considered the following four 
abnormalities: (1) elevated BP determined using the average of the second and third BP 
measurements (systolic BP ≥130 mmHg or diastolic BP ≥85 mmHg or known hypertension 
on treatment); (2) high triglycerides (≥1.69 mmol/L); (3) low high-density lipoprotein 
cholesterol (HDL-C ≤1.0 mmol/L in men; ≤1.3 mmol/L in women); (4) high blood glucose 





analysis, in a subset of participants with data available on insulin levels, we included 
insulin resistance as a fifth metabolic abnormality, by classifying as insulin resistant all 
participants with HOMA-IR above the data specific 90th percentile. Considering the lack of 
consensus on waist circumference (or waist-to-hip ratio) threshold to define abdominal 
obesity in African populations, the criteria of abdominal obesity which has been included 
in about 30% of studies on obesity phenotype [20] was not included in our panel of 
metabolic abnormalities. 
Participants were then classified for metabolic status as “metabolically healthy” if they 
had none or one metabolic abnormality, and as “metabolically abnormal” if they had two 
or more metabolic abnormalities. Cross-classification of participants by BMI and metabolic 
status led to the following six phenotypes: (1) normal weight and metabolically healthy 
(NWMH); (2) normal weight and metabolically abnormal (NWMA); (3) overweight and 
metabolically healthy (OvMH); (4) overweight and metabolically abnormal (OvMA); (5) 
obese and metabolically healthy (OMH), and (6) obese and metabolically abnormal (OMA). 
Statistical Analysis 
Participants’ characteristics are summarized as means (standard deviation, SD) and 
medians (25th to 75th percentiles) for continuous variables, and as count (percentages) 
for categorical variables. Comparison of baseline characteristics across BMI categories, by 
metabolic status, and by HIV-related characteristics were done using chi-square tests, 
fisher-exact test, t-tests or Kruskal-Wallis tests for non-parametric data or Analysis of 
Variance test (ANOVA) where appropriate. The linear trends across BMI categories overall 
and by metabolic status were examined using the Cochrane-Armitage trend tests and 
Brown-Forsythe Levene procedures. The two-way interactions between BMI categories 
and metabolic status (BxM), and metabolic status and gender (MxG) were tested using 
linear and logistic regression models, by incorporating in the same model the main effects 
of the variables of interest as well as their interaction term. 
To assess the association between each continuous metabolic trait and BMI categories, 
multinomial logistic regressions models (age and sex adjusted) were used to derive the 





in relation to overweight and obesity risk, always using normal weight are reference 
category. The McFadden’s R2 [21] was then used as a measure of the overall performance 
of models containing age, gender, and each metabolic trait of interest. A two-sided p-
value < 0.05 indicates a statistical significance. All analyses were performed using the R 
statistical software (version 3.0.3, online by http://cran.r-project.org). For a z-value of 1.96 
(corresponding to a 95% confidence interval), and an effective sample size of 748 
participants, our study had a margin of error of 0.05% to detect a prevalence of normal 
weight metabolically abnormal phenotype of 1% in the total sample. The acceptable 




Of the 831 participants who were interviewed and clinically assessed, 754 (91%) returned 
for biochemical measurements. Blood samples from six participants were inadequate for 
analyses resulting in 748 (99%) participants being included in the study. This comprised 
591 women and 157 men who had complete data on the variables of interest. 
The median age (25th–75th percentiles) was 38 (32–44) years overall, 41 (35–47) years in 
men, and 37 (31–43) years in women (p <0.001). As shown in Table 7.1, most participants 
(84.9%) had secondary education or higher with a lower prevalence in men (75.8%) than in 
women (87.3%) (p <0.001). About half of the participants (54.6%) were employed at 
similar rates for men and women (49.7% vs. 55.9%, p=0.162). Current smoking was more 
prevalent in men than in women (58.8% vs. 16.1%, p <0.001) but heavy alcohol 
consumption was similar (34.1% vs. 34.1%, p=0.975). 
Profile of HIV Infection 
The median duration of diagnosed HIV infection was five years (25th–75th percentiles: 2–
9) with no difference by gender (p=0.223). The median CD4 count was 392 cells/mm3 





vs. 272 cells/mm3, p=0.002). Most participants were receiving ART (93.4%) with the 
majority on first line ART (63.9%), while 11.8% received second-line ART and 17.4% were 
on other ART regimens. Interestingly, there were significant differences in the distribution 
by gender (p=0.005). 
Profile of Cardio-Metabolic Abnormalities 
The mean BMI was 26.3 kg/m2 overall with significantly lower levels in men compared 
with women (21.4 kg/m2 vs. 28.3 kg/m2, p <0.001). Overall, 43.4% of participants had 
normal BMI levels while 22.9% were overweight and 33.7% obese with significant 
differences by gender (p <0.001). Women compared to men had larger WCs (90 cm vs. 
79 cm, p <0.001), higher HOMA-IR indices (1.49 vs. 0.94, p <0.001), and total cholesterol 
levels (4.4 vs. 4.2 mmol/L, p=0.009). However, they had lower levels of triglycerides (0.97 
vs. 1.12 mmol/L, p=0.023), fasting glucose (4.9 vs. 5.1 mmol/L, p=0.010) and systolic BP 
(115 vs. 124 mmHg, p <0.001). Furthermore, HDL-cholesterol levels (1.29 vs. 1.2 mmol/L, 
p=0.010) and prevalent treated hypertension (16.8% vs. 7.0%, p=0.002) were higher in 
women than men. Diastolic BP, hs-CRP, as well as prevalent treated diabetes, were similar 








(n = 748) 
Men  
(n = 157) 
Women  
(n = 591) 
p-value 
Age, year 38 (32–44) 41 (35–47) 37 (31–43) <0.001 
Education level, n (%)    <0.001 
Primary 113/746 (15.1) 38/157 (24.2) 75/589 (12.7)  
Secondary and above 633/746 (84.9) 119/157 (75.8) 514/589 (87.3)  
Employed, n (%) 408/747 (54.6) 78/157 (49.7) 330/590 (55.9) 0.162 
Smoking habit, n (%)    <0.001 
Never smoke 461/718 (64.7) 34/156 (22.2) 427/562 (76.4)  
Current smoker 187/718 (25.3) 93/156 (58.8) 90/562 (16.1)  
Past smoker 70/718 (13.3) 29/156 (45.3) 42/562 (9.0)  
Heavy drinker, n (%) 64/187 (34.2) 22/64 (34.4) 42/123 (34.1) 0.975 
HIV duration, years 5 (2–9) 4 (2–7) 5 (2.5–9) <0.001 
CD4, cells/mm
3
 392(240–604) 272(193–448) 410(253–627) 0.001 
ART treatment, n (%) n=699 n=149 n=550 0.005 
Non-ART 46 (6.6) 7 (4.7) 39 (7.1)  
first line 426 (60.9) 78 (52.3) 348 (63.3)  
second line 79 (11.3) 17 (11.4) 62 (11.3)  
Others 148 (21.2) 47 (31.5) 101 (18.3)  
Body mass index (kg/m
2
)     
Median (P25–P75) 26.3 (22.1–32) 21.4 (19.8–22.4) 28.3 (23.8–28.9) <0.001 
<25, n (%) 325 (43.4) 126 (80.3) 199 (33.7)  
25.0–29.9, n (%) 171 (22.9) 21 (13.4) 150 (25.4)  
≥30, n (%) 252 (33.7) 10 (6.4) 242 (40.9)  
Waist circumference, cm 88 (77.5–98) 78.9 (73.9–88.3) 90 (79.5–100.8) <0.001 
Systolic BP, mmHg 117 (107–129.5) 123.5 (114.5–140) 115 (105.8–127) <0.001 
Diastolic BP, mmHg 82 (75–90.5) 83 (76–94) 81.5 (74.8–89.8) 0.129 
Total cholesterol, mmol/L 4.3 (3.7–5.1) 4.2 (3.5–5.0) 4.4 (3.8–5.1) 0.009 
HDL-cholesterol, mmol/L 1.27 (1.03–1.5) 1.2 (1.0–1.5) 1.29 (1.08–1.52) 0.010 
LDL-cholesterol, mmol/L 2.5 (2.0–3.1) 2.3 (1.7–3.0) 2.5 (2.0–3.1) 0.012 
Triglycerides, mmol/L 1.0 (0.74–1.34) 1.12 (0.75–1.27) 0.97 (0.74–1.28) 0.023 
Fasting glucose, mmol/L 5.0 (4.6–5.4) 5.1 (4.8–5.5) 4.9 (4.6–5.4) 0.010 
HOMA-IR 1.36 (0.84–2.24) 0.94 (0.53–1.64) 1.49 (0.93–2.37) <0.001 
C-reactive protein, mg/L 5.6 (2.4–12) 5.0 (2.1–16.2) 5.6 (2.4–14.2) 0.728 
Treated hypertension, n (%) 110 (14.7) 11 (7) 99 (16.8) 0.002 
Treated diabetes, n (%) 28 (3.7) 8 (5.1) 20 (3.4) 0.432 
ART, antiretroviral; BP, blood pressure; HDL, high-density lipoprotein; HIV, human immunodeficiency 
virus; AIDS, acquired immunodeficiency syndrome; HOMA-IR, homeostatic model assessment of 






Distribution of Body Size Phenotypes 
The proportion of ≥2 metabolic abnormalities across normal-weight (27.1%), overweight 
(41.5%), and obese (44.8%) categories increased significantly in a linear trend (p-
trend=0.001). The distribution of body size phenotypes in the overall sample was 31.7% 
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Figure 7.1. Distribution of metabolic phenotypes across body mass index 
categories  
Each vertical bar represents the proportion of participants in the total sample with the 
corresponding combination of body size (normal-weight, overweight, or obese) and metabolic 




In men, the majority (54.1%) were NWMH, just over a quarter (26.1%) were NWMA, while 
few fell into the other categories: 6.4% (OvMH), 7% (OvMA), 0.7% (OMH), and 5.7% 
(OMA). In contrast, the distribution in women was as follows: 25.7% (NWMH), 8% 
(NWMA), 15.2% (OvMH), 10.1% (OvMA), 23.4% (OMH), and 17.6% (OMA) (Figure 7.2). 
There was no statistically significant interaction by gender in the distribution of body size 
phenotypes (p-interaction=0.062). 
Figure 7.2. Distribution of metabolic phenotypes across body mass index 
categories in men and women  
Each vertical bar represents the proportion of participants in the total gender-specific sub-sample 
with the corresponding combination of body size (normal-weight, overweight, or obese) and 
metabolic phenotype (healthy or abnormal). The accompanying gender-specific proportions are 
shown at the tip of each bar. The p-values for the interaction by gender in the distribution are 
shown, together with the p-value for le linear trend (p-trend) in the distribution of metabolic 
phenotypes across body mass index categories, separately in men and women. 
The distribution of metabolic phenotypes across BMI categories was not significantly 
different by longer or shorter duration of diagnosed HIV infection (median five years, 
p-interaction=0.897) (Figure 7.3a), higher or lower CD4 count (median 392 cells/mm3,
p-interaction=0.447) (Figure 7.3b) or across the three ART regimens (p-interaction=0.205)
(Figure 7.3c). The proportion of ≥2 metabolic abnormalities tended to increase 
significantly and linearly across BMI categories within most of the latter subgroups except 
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Figures 7.3a–7.3c. Distribution of body size phenotypes by major HIV-predictive characteristics  
(a) Distribution of metabolic phenotype across body mass index categories in participants below, and 
those at or above the median of diagnosed duration of HIV infection; (b) Distribution of metabolic 
phenotype across body mass index categories in participants below, and those at or above the 
median CD4 count; (c) Distribution of metabolic phenotype across body mass index categories in 
participants on different antiretroviral treatment regimens. For each figure panel, the p-values for the 
interaction (interaction p) in the distribution across complementary subgroups are, together with the 
p-value for linear trend in the distribution of metabolic phenotype across body mass index categories 
within each subgroup (p-value attached to the name of the subgroup). Each vertical bar represents 
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body size (normal-weight, overweight, or obese) and metabolic phenotype (healthy or abnormal). The 
accompanying proportions are shown at the tip of each bar. 
Distribution of Metabolic Phenotypes within and Across BMI Categories 
Within BMI categories, in addition to the expected differences in the levels of cardio-
metabolic risk factors, participants with metabolically abnormal phenotypes tended to be 
older (all p ≤0.001) and unemployed, although differences were significant only among 
normal weight and overweight (all p ≤0.002), but not among obese participants (both 
p ≥0.215). Furthermore, metabolically abnormal obese participants were likely to be men 
(8.0% vs. 0.7%, p=0.006) and included fewer participants on first line ART (p=0.009). 
Age and level of education across BMI categories increased linearly overall (both 
p ≤0.012), driven by a significant linear trend in metabolically healthy participants (both 
p ≤0.005) but not in the metabolically abnormal (both p ≥0.396), with however no 
evidence of statistical interaction (both p-interaction ≥0.065). The proportion of men who 
were current smokers decreased linearly overall across increasing BMI categories 
(p <0.001 for linear trend), and within both metabolic phenotype groups (p-trend=0.001), 
with no evidence of statistical interaction (both interactions p >0.759), Table 7.2. 
Median WC, HOMA-IR, and HDL-C levels across BMI categories increased significantly 
overall (p-trend ≤0.001) and within the metabolic phenotype groups (all p-trend ≤0.024), 
without evidence of statistical interaction (all p-interaction ≥0.560). Fasting glucose, 
triglycerides, and prevalence of hypertension also increase across increasing BMI 
categories but only on the total cohort (p-trend ≤0.038). Interaction analyses found BMI 
categories and metabolic status interacted to affect the distribution of fasting glucose  
(p-interaction=0.044) whereas metabolic status interacted with gender to influence 
triglycerides distributions across BMI categories (p-interaction=0.002). 
Moreover, when further analyses in the subgroup of participants with data on insulin level 
(n=711) that included insulin resistance (HOMA-IR in 90th) as a fifth metabolic 
abnormality. The prevalence ≥2 risk factors was found to increase slightly across BMI 
categories: NWMA (12.8%), OvMA (9.3%), and OMA (16.6%), but the patterns within and 






Figure 7.4. Distribution of metabolic phenotypes across body mass index by major 
characteristics  
(a) Overall and in men and women; (b) In participants below, and those at or above the median of 
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count; (d) In participants on different antiretroviral treatment regimens. Metabolically abnormal 
phenotype is based on the presence of any two of the following five abnormalities: Elevated blood 
pressure or known hypertension; high triglycerides; low HDL-cholesterol, high blood glucose, or known 
diabetes; insulin resistance. For each figure panel, the p-values for the interaction (interaction p) in the 
distribution across complementary subgroups are, together with the p-value for linear trend in the 
distribution of metabolic phenotype across body mass index categories within each subgroup (p-value 
attached to the name of the subgroup). Each vertical bar represents the proportion of participants in 
the subgroup-specific sample with the corresponding combination of body size (normal-weight, 
overweight, or obese) and metabolic phenotype (healthy or abnormal). The accompanying proportions are 
shown at the tip of each bar.  
  
 
Table 7.2. Characteristics of participants across body mass index (BMI) categories and metabolic status [n (%), or median (25th-75th percentiles)] 
BMI categories Normal weight (N=325)  Overweight (N=171)  Obese (N=252) P-trend P-interaction 
Metabolic status Healthy Abnormal P Healthy Abnormal P Healthy Abnormal P Overall Healthy Abnormal B*M M*G 
Prevalence, n (%)  237 (31.7) 88 (11.7)  100 (13.4) 71 (9.5)  139 (18.6) 113 (15.1)  <0.001 - - - - 
Men, n (%) 85 (35.9)  41(46.6)  0.078 10 (10.0) 11 (15.5) 0.281 1 (0.7) 9 (8.0) 0.006 <0.001 <0.001 <0.001 0.759 - 
Age, years 36 (30-44) 42 (34-49) <0.001 36 (31-42) 43 (36-47.5) <0.001 37 (31.5-41) 39 (34-47) 0.001 0.002 <0.001 0.396 0.065 0.340 
≥ 7school-years, n (%) 190/236 (80.5) 71/88 (80.7) 0.972 89/100 (89.0) 58/70 (82.9) 0.249 128/139 (92.1) 97/113 (85.8) 0.111 0.012 0.005 0.617 0.532 0.067 
Unemployed, n (%) 84/236 (35.6) 48/88 (54.5) 0.002 38/100 (38.0) 47/71 (66.2) <0.001 64/139 (46.0) 58/113 (51.3) 0.404 0.081 0.131 0.132 0.056 0.061 
Smoking habit, n (%)   0.523   0.327   0.144 <0.001 <0.001 <0.001 0.925 0.238 
Never  105/230 (45.7) 33/85 (38.8)  78/96 (81.3) 49/68 (72.0)  111/132 (84.1) 85/107 (79.4)       
Current smoker 99/230 (43.0) 40/85 (47.1)  12/96 (12.5) 11/68 (16.2)  15/132 (11.4) 10/107 (9.3)       
Past smokers 26/230 (11.3) 12/85 (14.1)  6/96 (6.2) 8/68 (11.8)  6/132 (4.5) 12/107 (11.2)       
Heavy drinkers, n (%) 26/74 (35.1) 8/27 (29.6) 0.643 7/25 (28.0) 8/19 (42.1) 0.356 7/22 (31.8) 8/20 (40.0) 0.748 0.973 0.801 0.638 0.518 0.766 
HIV diagnosed duration, years 4 (2-7.8) 5 (2-8) 0.577 4.3 (2-8) 6 (2-9) 0.149 5 (3-10) 6 (4-10) 0.334 0.413 0.435 0.436 0.820 >0.999 
Median CD4 count, /mm3  311 (172-473) 350 (232-544) 0.288 433 (187-630) 395 (252-626) 0.494 452 (297-677) 434 (267-699) 0.627 0.335 0.213 0.627 0.77 0.430 
Antiretroviral regimens, n (%)  0.448   0.201   0.009 0.947 0.386 0.963 0.363 0.179 
1st line 140/208 (67.3) 45/76 (59.2)  60/88 (68.3) 34/60 (56.6)  93/125 (74.4) 54/96 (56.2)       
2nd line 24/208 (11.5) 11/76 (14.5)  7/88 (8.0) 10/60 (16.7)  14/125 (11.2) 13/96 (13.5)       
Others 44/208 (21.2) 20/76 (26.3)  21/88 (23.7) 16/60 (26.7)  18/125 (14.4) 29/96 (30.2)       
Waist circumference, cm 77 (72-80) 78 (72-86) 0.016 89 (85-92) 93 (86-95) 0.005 101(95-108) 104 (99-111) 0.005 <0.001 <0.001 0.016 0.560 0.780 
135 
Systolic blood pressure, mmHg 114 (105-125) 128 (116-145) <0.001 112 (104-124) 125 (117-140) <0.001 113 (106-119) 124 (114-138) <0.001 0.230 0.136 0.560 0.620 0.610 
Diastolic blood pressure, mmHg 78 (72-85) 88 (81-92) <0.001 81 (73-85) 88 (82-97) <0.001 81 (75-85) 88 (80-96) <0.001 0.954 0.771 0.819 0.230 0.510 
Fasting glucose, mmol/l  4.9 (4.6-5.2) 5.3 (4.8-6.3) <0.001 4.9 (4.6-5.2) 5.2 (4.7-5.7) 0.001 4.9 (4.6-5.2) 5.6 (5.0-6.4) <0.001 0.010 0.583 0.049 0.044 0.510 
Median HOMA-IR,  0.85 (0.57-1.27) 1.16 (0.82-1.79) <0.001 1.31(0.931.81) 1.76(1.05-2.49) 0.003 1.9(1.33-2.44) 2.52(1.54-4.67) <0.001 <0.001 0.001 0.006 0.630 0.290 
Diabetesa, n (%) 2/227 (0.9)  21/87 (24.1)  <0.001 1/96 (1.0) 10/68 (14.7) 0.001 2/128 (1.6) 27/110 (24.6) <0.001 0.077 0.839 0.252 0.148 0.752 
Hypertensionb, n (%) 52 (21.9)  50 (56.8) <0.001 20 (20.0) 43 (60.6) <0.001 35 (25.2) 70 (62.0) <0.001 0.038 0.615 0.757 0.841 0.107 
Triglycerides, mmol/l  0.9 (0.7-1.2) 1.2 (1.0-1.9) <0.001 0.9 (0.7-1.2) 1.2 (1.0-1.9) <0.001 0.9 (0.7-1.2) 1.4 (1.0-1.9) <0.001 0.033 0.647 0.472 0.720 0.002 
HDL-cholesterol, mmol/l  1.4 (1.1-1.7) 1.2 (0.9-1.3) <0.001 1.4 (1.2-1.7) 1.1 (1.0-1.2) <0.001 1.4 (1.2-1.6) 1.1 (1.0-1.2) <0.001 0.001 0.021 0.024 0.790 0.640 
LDL-cholesterol, mmol/l 2.2 (1.8-2.9) 2.5 (1.9-3.1) 0.181 2.4 (2.0-3.0) 2.5 (2.0-3.3) 0.423 2.6 (2.2-3.1) 2.8 (2.3-3.4) 0.019 0.867 0.769 0.713 0.910 0.330 
Total cholesterol, mmol/l 4.2 (3.6-5.0) 4.2 (3.5-4.9) 0.483 4.3 (3.7-5.1) 4.2 (3.6-4.9) 0.665 4.5 (3.9-5.1) 4.5 (4.0-5.2) 0.208 0.126 0.350 0.438 >0.999 0.710 
C-reactive protein, mg/l 4.2 (1.5-12.1) 5.2 (2.5-16.1) 0.102 4.4 (2.3-10.4) 4.4 (2.0-8.5) 0.959 7.8 (3.5-15.8) 8.0 (3.8-16.6) 0.590 0.803 0.523 0.236 0.770 0.130 
a
Diabetes as FPG ≥7.0 mmol/l or on treatment; 
b
Hypertension as blood pressure (BP) ≥140/90 mmHg or on treatment 
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Prediction of Body Mass Index Categories by the Continuous Metabolic Traits 
In multinomial logistic regression models, mutually adjusted for each other and using 
normal weight as a reference, male sex was associated with 81% (95% confidence interval: 
68%–89%) lower odds of overweight and 94% (89%–97%) lower odds of obesity; while each 
year of older age was associated with 2% (0%–4%) higher odds of overweight and a non-
significant 1% (−1% to 4%) higher odds of obesity. The McFadden R2 for the overall 
performance of this basic model was 0.081. In the presence of age and sex, all metabolic 
trait with the exception of systolic blood pressure (for both overweight and obesity) and 
fasting plasma glucose (for overweight only) were significantly associated with odds of 
overweight and obesity (Table 7.3). The direction of the effect with increasing metabolic 
traits levels was always positive, except for HDL-cholesterol where increasing levels were 
associated with decreasing odds of overweight and obesity. The highest R2 for the overall 
performance of resulting models was recorded for the model containing HOMA-IR 
(R2=0.183); and ranged from 0.083 (for the model containing systolic blood pressure) to 0.103 
(for the model containing either triglycerides or HDL-cholesterol), Table 7.3. 
Table 7.3. Odds ratios (OR) and 95% confidence intervals (95% CI) from multinomial age- 
and sex-adjusted multinomial logistic regression models showing the association of 




Overweight Obese R2 
Reference OR (95% CI) p-Value OR (95% CI) p-Value
Age, per year 1.00 1.02 (1.00–1.04) 0.093 1.01 (0.99-1.04) 0.195 
0.081 
Sex, men 1.00 0.19 (0.11–0.32) <0.001 0.06 (0.03-0.11) <0.001 
Systolic blood pressure, per mmHg 1.00 1.01 (1.00–1.02) 0.204 1.01 (1.00-1.02) 0.167 0.083 
Diastolic blood pressure, per mmHg 1.00 1.02 (1.00–1.04) 0.012 1.02 (1.01-1.04) 0.005 0.087 
Triglycerides, per mmol/L  1.00 2.06 (1.41–3.02) <0.001 2.70 (1.86-3.92) <0.001 0.102 
HDL-Cholesterol, per mmol/L 1.00 0.40 (0.24–0.66) <0.001 0.27 (0.16-0.44) <0.001 0.102 
LDL-cholesterol, per mmol/L 1.00 1.15 (0.92–1.45) <0.001 1.56 (1.26-1.93) <0.001 0.092 
Fasting plasma glucose, per mmol/L 1.00 0.93 (0.79–1.10) 0.417 1.18 (1.04-1.32) 0.007 0.090 
HOMA-IR 1.00 1.42 (1.19–1.70) <0.001 1.77 (1.49-2.10) <0.001 0.183 
R
2
 is the McFadden pseudo-R
2
 for the overall performance of the model containing age, sex, and the 






Although there have been rigorous reports on fat distribution and obesity in individuals with 
HIV infection, to our knowledge, this is one of the first studies to document the distribution 
of cardio-metabolic abnormalities in relation with body size in an HIV-infected population. 
Metabolically abnormal phenotypes, defined as the presence of ≥2 cardio-metabolic risk 
factors, were high across all BMI categories. Even in normal weight participants, over a 
quarter (27.1%) had metabolically abnormal phenotypes with this rising to 41.5% and 44.8% 
in the overweight and the obese, respectively. This suggests the likely influence of multiple 
factors in the development of cardio-metabolic abnormalities in this population. The high 
prevalence in normal weight HIV-infected individuals suggests the possible contribution of 
HIV-related factors and underscores the need to examine for cardio-metabolic 
abnormalities even in the absence of overweight and obesity. 
In contrast, the much higher prevalence demonstrated with increasing adiposity may be 
attributable to the greater role of this conventional risk factor in the development of cardio-
metabolic abnormalities in the HIV-infected population. This highlights the fine balance that 
needs to be maintained between ensuring adequate nutrition and optimal weight in the 
HIV-infected while simultaneously monitoring and guarding against excess weight gain. 
Thus, there is a need for holistic management of these co-morbidities that may indirectly be 
associated with HIV infection. 
The prevalence of overweight and obesity, at 13.4% and 6.4% in men and 25.4% and 40.9% 
in women in this study approximated the adiposity distribution reported in South African 
National Health and Nutrition Survey (SANHANES-1) [22]. The overweight and obesity rates 
in the SANHANES-1 were 20.1% (95% CI: 13.7–26.4) and 11.6% (95% CI: 7.5–15.7) in men 
and 26.4% (95% CI: 21.7–31.0) and 44.8% (95% CI: 38.8–50.8) in women, respectively. 
Similar findings have been reported in the United States where obesity levels in HIV-infected 
men (19%) and women (42%) were comparable to the general population (men: 24.7%, 
women: 37%) [17]. It is thus important to assess adiposity in HIV-infected individuals and to 
implement appropriate management strategies for weight reduction, similar to general 
populations. Notably, that the distribution of overweight and obesity in this study mirrors 
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that of the general population in the country is testimony of the successful implementation 
of ART strategies in this community. 
Although the prevalence of the metabolically abnormal phenotypes by the BMI categories 
described in this study was significant at 11.7% (NWMA), 9.5% (OvMA), and 15.1% (OMA), a 
substantial proportion of participants were obese but metabolically healthy (18.6%). This 
agrees with the 6%–75% estimate of OMH in general populations globally and is likely 
because BMI is a proxy marker of cardiovascular risk. BMI measures the general fat 
distribution and not visceral adipose tissue specifically, which is linked closely to insulin 
resistance and cardio-metabolic abnormalities. A better proxy for visceral adipose tissue is 
WC and, unsurprisingly, within BMI categories, participants with compared to without 
metabolic abnormalities had greater WC and elevated HOMA-IR index, a proxy measure of 
insulin resistance. Similar findings have also been reported in other studies [20, 23-25]. 
Recent studies in Caucasians that have included insulin resistance among abnormal 
metabolic traits have reported a high prevalence of metabolically abnormal phenotypes 
both in obese and non-obese people [26, 27]. 
The distribution of body size phenotypes in our study is comparable with results of local 
studies conducted in the general population in South Africa [24, 28]. Our previous 
community-based study in mixed-ancestry adults in Cape Town applying the same definition 
criteria found OMH and NWMA to be present respectively 16.5% and 5% of the sample [24]. 
Furthermore, among normal-weight participants (17.1% of the sample), 29.1% were 
classified as metabolically abnormal, while among obese participants (53.7% of the sample), 
30.8% were classified as metabolically healthy [24]. In another study in 103 normal-weight 
and 122 obese premenopausal urban black South African women, Jennings and co-workers 
found that 22% of the normal-weight participants were metabolically abnormal (defined by 
the presence of insulin resistance), while 38% of obese women were metabolically healthy 
(i.e., did not have insulin resistance) [28]. There are no recent reports available from Africa 
for comparison of the metabolically abnormal phenotypes that include insulin resistance. 
Nevertheless, data from a study conducted almost two decades ago in Cameroon revealed a 
much lower prevalence of metabolic abnormalities with 1.4% (NWMA), 1.6% (OvMA), and 





Africa with most of this study’s participants having normal weight (61%) in the year 1994, 
unlike more recent reports, and the expected lower prevalence of cardio-metabolic risk 
factors compared with the present study [23]. Interestingly, there was no significant 
difference in the distribution of metabolic abnormalities across BMI groups by the duration 
of diagnosed HIV infection, CD4 count levels or ART regimens. There have been diverse 
reports on the effects of HIV-specific factors on body fat de-arrangement, dyslipidemia, 
hyperglycemia, and metabolic syndrome. However, results from a recent systematic review 
and meta-analysis indicated that HIV-related characteristics had minor, if any, influence on 
the presence of metabolic syndrome [29]. Nevertheless, longitudinal studies are ideally 
required to pronounce on the absence or presence, if any, of a relationship between specific 
HIV-related factors and the development of cardio-metabolic abnormalities by body size 
phenotype. 
The relationship of gender, smoking status, and alcohol consumption on the distribution of 
body size phenotypes remains inconclusive in studies conducted in general populations [10, 
30, 31]. The findings of this study accorded with reports that showed little or no effect of 
smoking status and alcohol use on the distribution of body size phenotypes [26]. However, a 
few studies showed a higher prevalence of OMH in women than in men [26, 32]. 
Limitations and Strengths 
The cross-sectional design of this study precludes inferences of causal associations between 
the variables of interest and the development of cardio-metabolic abnormalities. The 
inclusion of an HIV-uninfected and HIV-infected ART-naïve comparative groups would have 
strengthened our analyses. Seeing that this was a clinic-based study limits its generalizability 
since it did not include HIV-infected individuals not attending healthcare facilities. However, 
these limitations are inevitable because the present project is part of a broad intervention 
study, which aims to explore the utilization of HIV-care infrastructure as a gateway to 
detect, manage, and control non-communicable diseases in HIV-infected populations in 
Africa. The relatively fewer men compared to women in the study, characteristic of 
epidemiological studies in the country, might overestimate the prevalence of obesity 
phenotypes. In the absence of detailed information on dietary habits/food consumption and 
data on ethnicity, we could not explore possible effects of lifestyle factors and ethnicity on 
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the distribution of body size phenotypes among the participants. Nevertheless, differences 
in MHO prevalence according to ethnicity have been reported, although this recent meta-
analysis did not include any studies based on African cohorts [33]. There are reports 
indicating that overall dietary intake was not associated with healthy obesity in both 
Europeans and African Americans [27, 34]. In addition to lifestyle and ethnicity, data was 
not available on the pharmacological compounds included in the ART regimens of the 
participants as well as the duration of treatment with those compounds, precluding detailed 
analyses by the potency of pharmacological compounds and duration of treatments. 
Nonetheless, the inclusion of participants from 17 healthcare facilities, including both urban 
and rural sites strengthens the representativeness in terms of the characteristics assessed. 
Furthermore, this study is among the first to describe the high prevalence of metabolically 
abnormal phenotypes across BMI categories in a relatively young HIV-infected population. 
The study findings underscore the need for further research, particularly longitudinal 
studies, to understand the development of cardio-metabolic abnormalities in the local HIV-
infected population and the differential role played by conventional risk factors as opposed 
to HIV-related influences. 
Conclusions 
The high prevalence of metabolically abnormal phenotypes across all BMI categories, 
notably in a relatively young HIV-infected population, highlights the importance of holistic 
management in HIV-infected individuals. Ideally, cardio-metabolic assessments/screenings 
should be done at baseline and at regular intervals thereafter, particularly in high-risk 
groups. Furthermore, considering the high prevalence of overweight and obesity in the HIV-
infected, lifestyle measures for weight reduction need to be encouraged. This is a captive 
audience who present regularly to healthcare facilities and the opportunity should be used to 
raise greater awareness on cardiovascular disease prevention. Such a strategy, targeting all 
HIV-infected patients, may contribute to a general improvement in cardiovascular health 
across the spectrum of BMI distribution. If proven successful, it may possibly have wider 
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Background: The applicability of the internationally advocated cut-off points of waist 
circumference (WC) derived from Caucasians to diagnose metabolic syndrome (MS) in HIV-
infected Africans is unknown. This study aimed to determine the optimal WC cut-offs for MS 
diagnosis in HIV-infected people receiving care at public healthcare facilities in the Western 
Cape Province in South Africa. 
Methods: Data from 748 randomly selected participants (591 women), with a median age of 
38 years, were analysed. The Youden’s index and the top-left-point approaches were used 
to determine the optimal cut-offs of WC for predicting ≥2 non-adipose MS components.  
Results: The two approaches generated the same WC cut-off point in women, 92 cm 
(sensitivity 64%, specificity 64%) but different cut-off points in men: 87 cm (sensitivity 48%, 
specificity 85%) based on the Youden’s index and 83 cm (sensitivity 59%, specificity 74%) by 
the top-left-point method. The advocated thresholds of 94 cm in men had low sensitivity 
(30%) but high specificity (92%) whereas 80 cm in women showed low specificity (32%) but 
high sensitivity (85%) for diagnosing MS in this sample. Most African-specific cut-off points 
performed well, with 90 cm providing acceptable performance in both men (sensitivity 43%, 
specificity 88%) and women (sensitivity 66%, specificity 59%).  
Conclusions: This study underlines the sub-optimal performance of internationally 
recommended WC thresholds for MS diagnosis in HIV-infected Africans, and supports the 
need to revisit the guidelines on WC criterion in African population across the board. A 





Metabolic syndrome (MS) represents the constellation of cardio-metabolic risk factors that 
includes abnormal fat distribution, dyslipidaemia, hyperglycaemia, and hypertension. Since 
it was first described by Reaven in 1988, several international organisations, and expert 
groups have proposed diagnostic criteria for the MS based on variable combinations of 
cardio-metabolic risk factors and at times, at variable thresholds [1]. Popular diagnostic 
criteria include those of the World Health Organization (WHO) in 1998, the European Group 
for the Study of Insulin Resistance (EGIR) in 1999, the Adult Treatment Panel III (ATPIII) 
(2001, 2004, 2005), the International Diabetes Federation (IDF) in 2005, and most recently 
in 2009 the harmonized Joint Interim Statement (JIS) [1]. 
Body fat distribution is an important criterion in the MS definition, but variably captured 
across diagnostic criteria. Body mass index (BMI) and waist-to-hip ratio (WHR) were 
indicators of body fat used in the WHO criteria [2], while waist circumference (WC) has been 
recommended as a surrogate for abnormal fat distribution in more recent MS criteria [1]. 
Using WC over BMI and other markers of adiposity emphasised the important role of central 
obesity in the development of cardiovascular diseases (CVD) and diabetes mellitus, which 
are major consequences of the MS. Furthermore, WC is the simplest clinical measure of fat 
distribution [3]. However, selecting the most appropriate WC thresholds to diagnose MS has 
appeared to be complex because of its likely dependence on gender and ethnicity [4]. 
Although the IDF and JIS criteria have attempted to incorporate ethnic-specific cut-off points 
for WC in the MS definition, these criteria advocate using Europid thresholds (men ≥94cm, 
women ≥80 cm) in African people in the absence of specific thresholds for African 
populations [3]. However, emerging evidence from few cross-sectional studies across Africa 
are not in support of uncritical application of Europid WC thresholds in African populations 
[5-9]. These studies have been consistent in suggesting that their application will likely 
results in over-diagnosis of women and under-diagnosis of men with abdominal obesity and 
accordingly, the MS.  
In the era of highly active antiretroviral therapy (HAART), people with HIV infection, most 
whom are found in Africa, are increasingly living longer, with cardio-metabolic diseases 
becoming a new threat to their healthy survival. As many as 46% of HIV-infected people 
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have hypertension [10], and nearly one third of them have MS regardless of the diagnostic 
criteria [11]. Considering that HIV infection and related treatments are associated with 
modifications of the distribution of body fat and metabolic factors, it is essential to confirm 
the applicability of recommended WC thresholds for MS diagnosis in people with HIV 
infection, or derived news ones with improved diagnostic accuracy for MS, particularly in 
African people, in view of informing appropriate screening and management of the 
condition. Therefore, this study aimed to determine the optimal WC cut-off points for MS 
diagnosis in patients receiving HIV-care at public healthcare facilities in the Western Cape 
Province in South Africa. 
Methods 
Study population and sampling 
The data for the present analysis are from a cross-sectional study conducted among HIV-
infected men and women aged 18 years and older, receiving care at primary healthcare 
facilities in the Western Cape Province, South Africa. The study methods have been 
described in detail elsewhere [12]. In brief, the patients were selected from 17 public 
healthcare facilities including ten in Cape Town and seven in the surrounding rural 
municipalities, applying random sampling procedures. Patients were included in the study if 
they were not pregnant or breastfeeding, bedridden, undergoing treatment for cancer, nor 
on corticosteroid treatment, and were willing and able to give consent. The study was 
approved by the South African Medical Research Council Ethics Committee and conducted 
in accordance with the principles of the Declaration of Helsinki. The Health Research Office 
of the Western Cape Department of Health, and the selected healthcare facilities granted 
permission to conduct the survey. 
Data collection 
The data were collected between March 2014 and February 2015 by a team of trained 
clinicians, nurses and fieldworkers, and captured on personal digital assistants (PDAs), using 
electronic case report forms with built-in checks for quality control. These were then 
encrypted at the point of collection and sent via mobile connections to a dedicated server 




interviewer-administered questionnaire adapted from the World Health Organization’s 
(WHO) STEPwise approach to Surveillance (STEPS) tool was used to obtain socio-
demographic and medical history. Duration of diagnosed HIV infection, CD4 counts and ART 
regimens were obtained from participants’ records. 
Anthropometric and blood pressure measurements 
Anthropometric measurements were taken using standardised techniques. Heights and 
weights were measured with the participants in light clothing and bare-footed. Waist and 
hip circumferences (HC) were measured to the nearest millimetre as the smallest 
circumference between the xiphisternum and the umbilicus on exhalation and around the 
largest circumference of the buttocks, respectively. Blood pressure (BP) was measured on 
the left arm, using a digital BP monitor (Omron, M6 Comfort, The Netherlands) after the 
participant was seated in a resting position for at least five minutes; three measurements 
were taken three minutes apart, and the average of the 2nd and 3rd readings used in the 
analysis.  
Biochemical analysis 
Fasting blood samples were drawn via venepuncture. All lipid and glucose concentrations 
were measured with an autoanalyzer, Beckman Coulter AU 500 spectrophotometer. Serum 
lipid triglycerides and high-density lipoprotein cholesterol (HDL-C) were analysed by 
enzymatic colorimetric method; plasma glucose was measured by hexokinase method. 
Definitions 
The individual components of the MS and their cut-off points were defined according to the 
JIS criteria [13]: elevated WC: men≥94 cm, women≥80 cm; elevated triglycerides: 
≥1.7 mmol/L; low HDL-C: men <1.03 mmol/L, women <1.3 mmol/L; elevated BP: 
≥130/85 mmHg or on hypertensive medication; hyperglycaemia: fasting glucose≥5.6mmol/L 
or on glucose control agents. WHR was calculated as WC (cm) divided by HC (cm) and waist-
to-height ratio (WHtR) as WC (cm) divided by height (cm).  
Statistical analysis  
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Data analyses, using R statistical software, version 3.0.3 (2014-03-06) (The R Foundation for 
Statistical Computing Platform, Vienna, Austria), were stratified by gender to account for 
gender related differences in body fat distribution. [1] Continuous variables are presented 
as means (± standard deviation, SD) or medians (25th-75th percentiles), and categorical 
variables as frequencies and percentages. Mann-Whitney U test and chi square test were 
used for men vs. women comparisons. The “pROC” package was used for receiver operating 
characteristic curves (ROC) analyses. The area under the curve (AUC) was used to assess and 
compare the ability of WC and other adiposity variables to detect the presence of two or 
more non-adipose components of the MS. The AUC values range between 0 and 1; an AUC 
value closer to 1 infers a better ability of the predictor/test to discriminate individuals with 
and without the defined condition or disease, whereas an AUC value of 0.5 indicates no 
discriminative power of the predictor/test of interest [14]. In the ROC curve, pairs of the 
false positive rate (1-specificity) and the true positive rate (sensitivity) for every individual 
cut-off point are plotted. The shape of the ROC curve indicates how high the discriminatory 
power of the test is; perfect discrimination has an ROC curve that passes through the upper 
left-hand corner (100% sensitivity, 100% specificity). Thus, the closer the ROC curve is 
located to the upper left-hand corner and the larger the AUC, the higher the overall 
accuracy of the test. The optimal WC was determined by applying both the Youden’s index 
approach and the closest-top-left-hand point approach [15]. The Youden’s index is 
calculated by sensitivity + specificity – 1, and ranges from 0 to 1, with values approaching 1 
indicating a better performant test and vice versa. Maximizing this index (J-point) allows 
finding an optimal level independently from the outcome prevalence. 
The diagnostic performance of the cut-off points derived in this study were assessed 
alongside the internationally advocated thresholds and those from other South African and 
African studies at large, by computing a number of diagnostic performance measures 
including the sensitivity (se) which is the probability of a positive test result in a person with 
the disease/target condition; the specificity (sp), the probability of a negative test result in a 
person without the disease/target condition; the positive predictive value (PPV), the 
probability of having the disease in a person with a positive test; the negative predictive 
value (NPV), the probability of no disease in a person with negative test; the likelihood ratio 




occur in persons with the disease/condition compared to those without the disease  and 
likelihood ratio for negative test results (LR-), how less likely the negative test result is to 
occur in persons with the disease than in those without the disease. [16] Additionally, global 
measures such as the Youden’s index, diagnostic odds ratio (DOR, the ratio LR+/LR-); 
diagnostic accuracy, expressing percentage of correctly classified subjects among all 
subjects; and number needed to diagnose (NND, = 1/Youden’s index) were also computed. 
Performance measures’ calculation used the “epiR” package of R.  
Results 
Characteristics of the participants 
The Standard of Reporting for Diagnostic Accuracy Studies (STARD) diagram for the flow of 
participants in the study is shown in Figure 8.1. Data for 748 participants, comprising 157 
men (21%) and 591 women (79%) were analysed.  
Table 8.1 shows the basic characteristics of the study participants. Men, with a median age 
of 41 years, were significantly older than women whose median age was 37 years (p<0.001). 
However, women compared with men had a longer duration of diagnosed HIV infection (5 
years vs. 4 years, p<0.001) and higher CD4 count levels (410 cells/mm3 vs. 272 cells/mm3, 
p=0.002). Most (93%) of the study participants were on ART with no difference by gender 
(p=0.296). Compared to men, women had higher BMI, larger WC, HC and WHtR but lower 
WHR, Table 8.1.  
The prevalence of the non-adipose components of the MS according to JIS criteria is 
presented in Table 8.1. Raised BP and low HDL-C levels were the most prevalent (46.3%), 
followed by hyperglycaemia (20.7%) and elevated triglycerides (13.6%). Raised BP and 
hyperglycaemia were similar in men and women (both p ≥0.443) while low HDL-C was more 
common in the latter (women: 50.1% vs. men: 31.9%, p <0.001) and elevated triglycerides 
more frequent in the former (men: 22.9% vs. women: 11.2%, p<0.001). Notably, while the 
prevalence of raised WC was significantly different in women and men according to the JIS 
criteria (74% vs. 16.6%, p <0.001), the prevalence of ≥2 non-adipose components of the MS 




Figure 8.1. Standard of Reporting for Diagnostic Accuracy Studies (STARD) diagram to report the flow of participants through the study 
WC, waist circumference; MA, metabolic abnormalities, ≥2 non-adipose components: BP ≥130/85 mmHg, triglycerides ≥1.7 mmol/L, high density 
lipoprotein cholesterol <1.03 mmol/l in men and <1.3 mmol/l in women, fasting glucose ≥5.6 mmol/l; a WC cut-offs recommended by the JIS 
criteria; bWC cut offs derived in the present study. 
Included in the final analysis; (N=748) 





 No return for blood sample (n=71)
 No anthropometric profile (n=7)
 No lipid profile (n=3)
 No glucose profile (n=2)
Women (n=591) 
MA+ (n=211 ) 










































































Table 8.1. HIV-related characteristics and median anthropometric and biochemical 









Age (years) 38 (32-44) 41 (35-47) 37 (31-43) <0.001 
Anthropometry     
WC (cm) 88 (78-98) 78.9 (74-88) 90 (80-101) <0.001 
Hip (cm) 102 (93-112) 92 (88-97) 105 (97-115) <0.001 
WHR 0.86 (0.80-0.91) 0.87 (0.84-0.93) 0.85 (0.80-0.90) <0.001 
WHtR 0.55 (0.48-0.61) 0.47 (0.44-0.52) 0.57 (0.50-0.63) <0.001 
BMI (kg/m
2
) 26.3 (22.1-32) 21.4 (19.8-22.4) 28.3 (23.8-28.9) <0.001 
Blood pressure     
Systolic (mmHg) 117 (107-130) 123.5 (114.5-140) 115 (105.8-127) <0.001 
Diastolic (mmHg) 82 (75-91) 83 (76-94) 81.5 (74.8-89.8) 0.129 
Glucose     
FPG (mmol/L) 5 (4.6-5.4) 5.1 (4.8-5.5) 4.9 (4.6-5.4) 0.010 
Lipids     
Triglycerides (mmol/L) 1 (0.7-1.3) 1.12 (0.75-1.27) 0.97 (0.74-1.28) 0.023 
HDL-C (mmol/L) 1.3 (1-1.5) 1.2 (1.0-1.5) 1.29 (1.08-1.52) 0.010 
Prevalence of MS components, % (95%CI), JIS criteria 
Raised WC 
a 
62.0 (58.6-65.5) 16.6 (10.8-22.4) 74.1 (70.6-77.6) <0.001 
Hypertension
b
 46.3 (42.7-49.8) 46.5 (38.7-54.3) 46.2 (42.2-50.2) 0.946 
Decreased HDL-C
c
 46.3 (42.7-49.8) 31.9 (24.6-39.1) 50.1 (46.1-54.1) <0.001 
Elevated Triglycerides
d
 13.6 (11.2-16.1) 22.9 (16.4-29.5) 11.2 (8.6-13.7) <0.001 
Hyperglycemia
e
 20.7 (17.8-23.6) 22.9 (16.4-29.5) 20.1 (16.9-23.4) 0.443 
≥2 MS components 36.4 (32.9-39.8) 38.9 (31.2-46.5) 35.7 (31.8-39.6) 0.466 
HIV-related factors 
HIV duration (years) 5 (2-9) 4 (2-7) 5 (2.5-9) <0.001 
CD4 count (cells/mm
3
) 392(240-604) 272 (193-448) 410 (253-627) 0.001 
ART-related factors, n (%) N=699 N=149 N=550 0.296 
ART-naive 46/699 (6.6) 7/149 (4.7) 39/550 (7.1)  
ART-treated 653/699 (93.4) 142/149 (95.3) 511/550 (92.9)  
     
ART, antiretroviral therapy; BMI, body mass index; FPG, fasting plasma glucose; HDL-C, high-density 
lipoprotein cholesterol; HIV, human immunodeficiency virus; LDL-C, low-density lipoprotein 
cholesterol; MS, metabolic syndrome, WHtR, waist-to-height ratio; WHR, waist-to-hip ratio. 
a
WC, 
waist circumference ≥94 cm in men & ≥80 cm in women, 
b
Blood pressure ≥130/85 mmHg or on 
hypertensive medication; 
c
HDL-C, high density lipoprotein-cholesterol <1.03 mmol/L in men & 
<1.3 mmol/L in women; 
d
triglycerides ≥1.7 mmol/L; 
e
FPG ≥5.6 mmol/L or on antidiabetic medication 
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Discriminatory power of adiposity markers to detect two or more non-adipose MS 
components  
Table 8.2 shows the discriminatory powers of different obesity indices in detecting ≥2non-
adipose components of the MS. The highest point estimates of the AUC among the indices 
was recorded for WHR in men [0.723 (95%CI: 0.640-0.807)] and WHtR in women [0.657 
(0.612-0.703)]. However, in both cases, the difference compared with WC was not 
significant (both p >0.087). The AUC for WC was 0.659 (0.565-0.754) in men and 0.649 
(0.603-0.695) in women. This was greater than the AUC for BMI found in women. HC 
showed the lowest predictive ability with AUCs of 0.590 (0.494-0.686) in men and 0.583 
(0.535-0.631) in women with significant differences when compared with the other markers 
(all p <0.016), except with WHR in women (p=0.107). 
Table 8.2. Comparative abilities of adiposity markers to predict two or more metabolic 
syndrome components  
AUC (95% CI) vs. WC vs. HC vs. WHR vs. WHtR vs. BMI 
Overall 
Waist circumference 0.646 (0.605-0.688) - <0.001 0.772 0.874 <0.001 
Hip circumference  0.569 (0.526-0.612) <0.001 - 0.006 <0.001 <0.001 
Waist-to-hip ratio  0.652 (0.611-0.693) 0.772 0.006 - 0.816 0.106 
Waist-to-height ratio 0.647 (0.606-0.688) 0.874 <0.001 0.816 - <0.001
Body mass index  0.609 (0.567-0.651) <0.001 <0.001 0.106 <0.001 -
Men 
Waist circumference  0.659 (0.565-0.754) - 0.011 0.087 0.071 0.663 
Hip circumference  0.590 (0.494-0.686) 0.011 - 0.016 0.008 
Waist-to-hip ratio 0.723 (0.640-0.807) 0.087 0.016 - 0.398 0.230 
Waist-to-height ratio 0.694 (0.604-0.783) 0.071 0.003 0.398 - 0.457
Body mass index  0.672 (0.583-0.762) 0.663 0.008 0.230 0.457 -
Women 
Waist circumference  0.649 (0.603-0.695) - <0.001 0.577 0.208 0.007 
Hip circumference  0.583 (0.535-0.631) <0.001 - 0.107 <0.001 0.001 
Waist-to-hip ratio 0.637 (0.590-0.684) 0.577 0.107 - 0.355 0.513 
Waist-to-height ratio 0.657 (0.612-0.703) 0.208 <0.001 0.355 - 0.001




AUC, area under the Receiver Operating Characteristic curve; BMI, body mass index; HC, hip 
circumference; WC, waist circumference; WHtR, waist-to-height ratio; WHR, waist-to-hip ratio, P-value 
for differences in the AUC. 
 
Optimal WC cut-off points to detect two or more non-adipose MS components  
Figure 8.2 presents the results of the ROC analyses for WC in predicting the presence of 
≥2 non-adipose MS components. The optimal cut-off points were 91.8 cm in the overall 
sample, 92 cm in women, and 83 cm in men using the closest-top-left point approach. The 
Youden’s index approach identified the same cut-off point in women, but a different cut-off 







Figure 8.2. Receiver operating characteristic (ROC) curve of the waist circumference in 
detecting the presence of two or more metabolic syndrome components in HIV-infected 
African men (A) and women (B) 
The ROC curves show the 82.9-cm optimal cut-off in men (sensitivity: 59%, specificity: 74%) 
corresponding to a c-statistic of 0.659 (A), and the 92.0-cm optimal cut-off in women (sensitivity: 
63.5%, specificity: 64.2%) corresponding to a c-statistic of 0.649 (B). 
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As shown in Table 8.3, the WC cut-off in women of 92 cm had the following performance: se 
64%, sp 64%, Youden’s index 0.28, PPV 50%, NPV 76%, LR+ 1.77, LR- 0.57, DOR 3.12. In men, 
the 83-cm WC cut-off had the following performance: se 59%, sp 74%, Youden’s index 0.33, 
PPV 59%, NPV 74%, LR+ 2.27, LR- 0.55, DOR 4.09; while equivalents for the cut-off point of 
87 cm were: se 48%, sp 85%, Youden’s index 0.33, PPV 67%, NPV 72%, LR+ 3.26, LR- 0.61, 
DOR 5.31.  
The performances of various cut-off points including the internationally advocated and 
those recommended by African studies for diagnosing MS are presented in Table 8.3. 
Compared with the derived cut-off points, the internationally advocated cut-off point of 94 
cm in men showed higher specificity (92%) but lower sensitivity (30%), whereas the WC cut-
off in women of 80 cm produced a lower specificity (32%), though a higher sensitivity (85%) 
in the current study sample. The Youden’s indices were 0.21 and 0.17 for the cut-off points 
in men and women of 94 cm and 80 cm, respectively. 
The African-specific thresholds generated diagnostic performances close to those of our 
derived cut-off points, particularly for the cut-off values of 84 cm (Youden’s index 0.29, se 
52%, sp 76%), 86 cm (Youden’s index 0.31, se 49%, sp 82%), and 90 cm (Youden’s index 
0.30, se 43%, sp 88%) in men; and the cut-off points of 90 cm (Youden’s index 0.25, se 66%, 
sp 59%), 91.5 cm (Youden’s 0.27, se 65%, sp 62%), and 94 cm (Youden’s index 0.23, se 55%, 
sp 68%) in women; Table 8.3.  
Based on the JIS criteria, the MS prevalence was 16.6% in men and 31.3% in women in our 
sample, Table 8.4. When applying the derived WC thresholds, the MS prevalence would 
increase to 24.2% (95% CI: 17.5-30.9) in men but decrease to 25.6% (22-29.1) in women. 





Table 8.3. Performance measures of different waist circumference cut-offs to predict two or more metabolic syndrome components in men and women  























Men            
Mabchour [9] 80 0.62 (0.49-0.74) 0.64 (0.53-0.73) 0.52 (0.40-0.64) 0.73 (0.62-0.82) 1.71 (1.23-2.37) 0.59 (0.42-0.85) 0.63 (0.55-0.71) 2.88 (1.48-5.59) 0.26 (0.02-0.48) 3.87 (2.10-48.62) 
Current study 82.9 0.59 (0.46-0.71) 0.74 (0.64-0.82) 0.59 (0.46-0.71) 0.74 (0.64-0.82) 2.27 (1.52-3.37) 0.55 (0.40-0.77) 0.68 (0.60-0.75) 4.09 (2.06-8.10) 0.33 (0.10-0.54) 3.03 (1.86-10.33) 
Peer [8] 83.9  0.52 (0.39- 0.65) 0.76 (0.66-0.84) 0.58 (0.44-0.71) 0.72 (0.62-0.80) 2.19 (1.43, 3.36) 0.63 (0.47-0.83) 0.67 (0.59-0.74) 3.50 (1.76-6.96) 0.29 (0.06-0.49) 3.51 (2.02-18.12) 
Motala [6] 86  0.49 (0.36-0.62) 0.82 (0.73-0.89) 0.64 (0.49-0.77) 0.72 (0.62-0.80) 2.78 (1.68-4.58) 0.62 (0.47-0.80) 0.69 (0.62-0.77) 4.50 (2.18-9.29) 0.31 (0.09-0.52) 3.18 (1.94-10.74) 
Current study 87  0.48 (0.35-0.61) 0.85 (0.77-0.92) 0.67 (0.51-0.81) 0.72 (0.63-0.80) 3.26 (1.88-5.66) 0.61 (0.48-0.79) 0.71 (0.63-0.78) 5.31 (2.49-11.32) 0.33 (0.11-0.53) 3.03 (1.90-8.82) 
Prinsloo [17]; Kalk 
[18]; Matsha [7] 
90  0.43 (0.30-0.56) 0.88 (0.79-0.93) 0.68 (0.51-0.82) 0.71 (0.62-0.79) 3.41 (1.86-6.24) 0.66 (0.52-0.82) 0.70 (0.62-0.77) 5.20 (2.36-11.45) 0.30 (0.09-0.49) 3.32 (2.03-10.84) 
JIS 2009 [1] 94  0.30 (0.19-0.43) 0.92 (0.84-0.96) 0.69 (0.48-0.86) 0.67 (0.58-0.75) 3.54 (1.64-7.64) 0.77 (0.65-0.91) 0.68 (0.60-0.75) 4.60 (1.86-11.43) 0.21 (0.03-0.39) 4.72 (2.57-36.29) 
Women            
JIS 2009 [1] 80 0.85 (0.80-0.90) 0.32 (0.27-0.37) 0.41 (0.36-0.46) 0.80 (0.72-0.86) 1.26 (1.15-1.37) 0.46 (0.32-0.65) 0.51 (0.47-0.55) 2.75 (1.77-4.25) 0.17 (0.07-0.27) 5.74 (3.72-13.82) 
Matsha [7] 90 0.66 (0.59-0.72) 0.59 (0.54-0.64) 0.47 (0.41-0.53) 0.76 (0.70-0.80) 1.60 (1.37-1.87) 0.58 (0.47-0.71) 0.61 (0.57-0.65) 2.77 (1.95-3.94) 0.25 (0.13-0.36) 4.03 (2.76-7.77) 
Crowther [5] 91.5 0.65 (0.58-0.71) 0.62 (0.57-0.67) 0.49 (0.43-0.55) 0.76 (0.71-0.81) 1.71 (1.46-2.02) 0.56 (0.46-0.69) 0.63 (0.59-0.67) 3.03 (2.14-4.31) 0.27 (0.15-0.38) 3.70 (2.61-6.62) 
Current study; 
Motala [6] 
92.05 0.64 (0.57-0.70) 0.64 (0.59-0.69) 0.50 (0.44-0.56) 0.76 (0.71-0.81) 1.77 (1.50-2.10) 0.57 (0.47-0.69) 0.64 (0.60-0.68) 3.12 (2.20-4.43) 0.28 (0.16-0.39) 3.61 (2.56-6.34) 
Peer [8] 94 0.55 (0.48-0.62) 0.68 (0.63-0.73) 0.49 (0.42-0.55) 0.73 (0.68-0.78) 1.73 (1.43-2.09) 0.66 (0.56-0.78) 0.63 (0.59-0.67) 2.61 (1.85-3.70) 0.23 (0.11-0.35) 4.32 (2.89-8.92) 
Prinsloo [17] 98 0.41 (0.34-0.48) 0.78 (0.73-0.82) 0.51 (0.43-0.58) 0.70 (0.66-0.75) 1.84 (1.44-2.37) 0.76 (0.67-0.86) 0.65 (0.61-0.68) 2.42 (1.68-3.49) 0.19 (0.07-0.30) 5.36 (3.37-13.43) 
            
Sensitivity=TP/(TP+FN); Specificity=TN/(TN+FP); PPV, positive predictive value=TP/(TP+FP); NPV, negative predictive value=TN/(TN+FN); LR+, likelihood ratio positive=sensitivity/1-
specificity; LR-, likelihood ratio negative=1-sensitivity/specificity; Diagnostic accuracy = (TP+TN)/(TP+TN+FP+FN); DOR, diagnostic odds ratio=LR+/LR-; Youden’s index = (sensitivity 
+ specificity) – 1; NND, number needed to diagnose=1/Youden’s index, where TP, true positive; FP, false positive; TN, true negative; FN, false negative. 
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Table 8.4. Comparison of the MS prevalence using the JIS waist circumference 
thresholds and the derived cut-offs in this and other African populations  





WC cutoff prevalence WC cutoff prevalence 
JIS 2009
*
94 cm 16.6 (10.8-22.4) 80 cm 31.3 (27.6-35.0) <0.001 28.2 (25.0-31.4) 
Modified JIS: 
Current study 83 cm 24.2 (17.5-30.9) 92 cm 25.6 (22-29.1) 0.730 25.3 (22.2-28.4) 
Current study 87 cm 19.8 (13.5-26.0) 92 cm 25.6 (22-29.1) 0.132 24.3 (21.3-27.4) 
Motala [6] 86 cm 20.4 (14.1-26.7) 92 cm 25.6 (22-29.1) 0.181 24.5 (21.4-27.6) 
Matsha [15] 90 cm 18.5 (12.4-24.5) 90 cm 26.1 (22.5-29.6) 0.049 24.5 (21.4-27.6) 
Peer [8] 84 cm 21.7 (15.2-28.1) 94 cm 22.8 (19.5-26.2) 0.752 22.6 (19.6-25.6) 
Prinsloo [17] 90 cm 18.5 (12.4-24.5) 98 cm 19.0 (15.8-22.1) 0.891 18.9 (16.1-21.7) 
El Mabchour [9] 80 cm 25.5 (18.7-32.3) 94 cm 22.8 (19.5-26.2) 0.488 23.4 (20.4-26.4) 
*metabolic syndrome (MS) based on JIS criteria: ≥3 of waist circumference (WC) ≥94 cm in men & ≥80 cm in 
women, blood pressure ≥130/85mmHg or on hypertensive medication, HDL-C, high-density lipoprotein-
cholesterol <1.03 mmol/L in men & <1.3 mmol/L in women, triglycerides ≥1.7 mmol/L, FPG, fasting plasma
glucose ≥5.6 mmol/L or on anti-diabetic medication. Modified JIS criteria using the waist circumference cut-offs
recommended from African studies to replace the JIS WC cut-offs.
Discussion 
This study is among the first to determine the optimal WC thresholds for diagnosing the MS 
in an HIV-infected African population. The findings demonstrate that the optimal WC cut-off 
points in both men and women do not accord with the internationally recommended 
criteria for African populations. Notably, the optimal WC thresholds described in this study 
approximate those reported in other African studies conducted in the general population. In 
women, the optimal WC cut-off points in this and other local studies of 92 cm and 90-98 cm, 
respectively [5, 6, 8, 15, 17], were higher than the 80 cm advocated by the JIS criteria.  
In contrast to the women in this study whose optimal WC threshold was higher than the JIS 
values, the optimal WC cut-off points in men of 83-87 cm were lower than the JIS 
recommended criteria of 94 cm. These findings were nevertheless in keeping with the 80-




optimal WC thresholds of 80 cm and 94 cm in men and women, respectively, in Benin and 
Haiti also approximated this and other regional studies [9].   
In this study, the Youden’s index and the closest-top-left point criteria identified the same 
cut-off point for WC in women but two different cut-off points in men. This discrepancy may 
be related to the small sample of 157 men in this study. The inconsistency of optimal cut-off 
points using the two ROC based approaches has been reported previously [19]. Perkins and 
Schisterman examined the situations when the closest-top-left point and the Youden’s index 
(J point) criteria agreed and disagreed with each other using the data of the placenta growth 
levels to classify women with preeclampsia [19]. They showed that when equal weight is 
given to sensitivity and specificity, the “closest-top-left point” and the Youden’s index 
methods identify the same cut-off point as “optimal” in certain situations and different cut-
off points in others. They further demonstrated that when the two approaches give 
different values, the cut-point resulting in J-point was the only “optimal cut-point” with 
respect to minimising the overall misclassification rates. The authors therefore suggested 
that the Youden’s index approach should be used to find the optimal cut-off point [19]. 
The small variations among the African-specific thresholds could be attributed at least in 
part to differences in methodological approaches. For example, while Matsha et al., [7] Peer 
et al. [8] and Motala et al. [6] determined the optimal WC cut-off points for the presence of 
≥2 MS components,  Crowther and Norris [5] determined the optimal WC cut-off points for 
≥3 out of 4 MS components, Prinsloo et al. [17] used raised BP, Kalk et al. [18] used insulin 
resistance (IR) and triglycerides-to-HDL-C ratio, Mabchour et al. [9] used elevated BP, total 
cholesterol-to-HDL-C ratio and IR as the outcome. 
The measures of diagnostic accuracy indicate that the JIS-advocated thresholds for WC did 
not perform well in these study participants. The advocated WC threshold of 80 cm for 
women yielded considerably low specificity, resulting in an overestimation of the MS 
prevalence by about 22%. The cut-off in men of 94 cm generated very low sensitivity, 
confirming that cut-off would underestimate the prevalence of MS among HIV-infected 
African men. Indeed, the prevalence of MS in men increased by nearly 20% when our 
Youden index-based cut-off was applied, instead of the JIS one. The combination of the 
under-diagnosis in men and over-diagnosis in women using the internationally advocated 
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thresholds, led to 16% overestimation of MS prevalence at the overall sample level, relative 
to estimates using the derived optimal cut-off points. Therefore, in addition to improving 
the gender specific allocation of interventions to mitigate diseases risk associated with the 
MS, applying the African specific cut-off points will likely be cost-saving as fewer people will 
require such interventions. 
Results of our validation studies demonstrate that thresholds of 86-90 cm in men and 90-94 
cm in women, derived from other African studies, performed well in this HIV-infected 
sample. The overall accuracies were close to that of the derived cut-off points shown in this 
study and better than those internationally advocated. Other investigators have suggested 
the unique WC threshold of 90 cm in men and women as a practical recommendation for 
MS screening in the general population in Africa [15]. Our validation studies would tend to 
support the application of those recommendations in people with HIV infection. 
With regards to the use of specific measures of adiposity, the ROC curves showed that WC, 
WHR, WHtR and BMI were equally effective in men; while in women WC, along with WHR 
and WHtR, had a better ability to discriminate individuals with and without the MS 
compared to BMI. This is unsurprising since BMI measures total fat mass while WC assessed 
subcutaneous and intra-abdominal fat mass or visceral obesity, a key player in the 
aetiological pathways of the MS [3, 4]. Therefore, the findings suggest that WC is not only a 
simpler but also an accurate index to identify MS in HIV-infected individuals. Our findings 
are supported by those of Beraldo et al. who found that WC was a good tool for identifying 
individual cardio-metabolic risk factors as well as the MS in both genders in 280 Brazilians 
on ART [20].  
Strength and limitations 
This is the first study attempting to investigate the relevance of WC and the applications of 
the recommended cut-off points including those internationally advocated and African-
specific to predict the presence of MS in Africans living with HIV infection. Including 
participants from many primary health care facilities in both urban and rural areas is a major 
strength and will likely enhance the external validity of our findings. The small sample size, 
particularly in men, and the lack of external validation on another sample of people with HIV 




population in Africa, follow-up studies are needed to determine the effect of baseline MS 
status on the incidence of major health outcomes reported elsewhere to be associated with 
MS, and to what extent those effects can be mitigated by lifestyle and pharmacological 
interventions. 
Conclusions 
This study underlines the sub-optimal applicability of the currently advocated WC thresholds 
for MS diagnosis in HIV-infected African men and women, supporting the need to revisit the 
WC thresholds in use in African people including those living with HIV infection. Our study 
findings extend to African people with HIV infection, and together with reports from 
previous studies conducted in the general population across Africa, suggest that the 
uncritical application of the internationally advocated WC thresholds will lead to MS over-
diagnosis in women and under-diagnosis in men. This will result in an overall over-diagnosis 
at the population level, and accordingly an overuse of health resources. Our study also 
provides additional support for the unique WC threshold of 90 cm in both men and women, 
as a practical and more accurate approach to MS diagnosis in African populations, including 
those living with the HIV infection.  
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Abstract 
Objectives: To assess the diagnostic accuracy of glycated haemoglobin (HbA1c) for 
dysglycaemia including fasting plasma glucose (FPG)-defined and oral glucose tolerance test 
(OGTT)-defined dysglycaemia, and OGTT-defined diabetes in African population with HIV 
infection, and assess the effect of HbA1c-predicted dysglycaemia on Joint Interim Statement 
(JIS)-based prevalent metabolic syndrome (MS). 
Research Design and Methods: A cross-sectional, multi-clinic-based study included 748 
randomly selected participants (157 men) with a median age 38 years. The recommended 
HbA1c cut-points were tested alongside the optimal cut-points obtained from receiver 
operating characteristic curve analyses. 
Results: The optimal HbA1c cut-points of 5.75% (39.3 mmol/mol) showed 54% sensitivity, 
84% specificity for FPG-defined dysglycaemia, and 52% sensitivity, 85% specificity for OGTT-
defined dysglycaemia. The HbA1c value of 5.85% (40.4 mmol/mol) (63% sensitivity, 99% 
specificity) was optimal for diabetes. The internationally advocated cut-point of 6.5% 
(48 mmol/mol) had 99% specificity and 37% sensitivity for diabetes, while HbA1c ≥5.7% 
(≥39 mmol/mol) yielded similar performance with the study-specific cut-point for any 
dysglycaemia. MS prevalence by the JIS criteria (28.2%) increased to 29.7% when using 
HbA1c ≥5.75% (≥39.3 mmol/mol) and to 32.9% with HbA1c ≥5.7% (≥39 mmol/mol); 
agreement between the original and modified criteria was generally good.  
Conclusions: This study agrees with the internationally recommended HbA1c cut-point for 
detecting dysglycaemia, but not for diabetes. In line with previous studies in general African 
populations, our findings suggest that similar factors interfere with HbA1c values regardless 
of HIV infection status. Replacing FPG-based with HbA1c-predicted dysglycaemia in the JIS 





Measuring fasting plasma glucose (FPG) levels or performing an oral glucose tolerance test 
(OGTT), are the currently recommended tools for diagnosing diabetes and other categories 
of dysglycaemia [1, 2]. However, these tests are inconvenient requiring an overnight fast 
and the OGTT is cumbersome as it necessitates a 2-hour waiting period. Given these 
inconveniences and the day-to-day variability in glucose, there is a need for a reliable, high 
performance, convenient and low-cost alternative. Glycated haemoglobin (HbA1c), which 
reflects the average plasma glucose concentration over the previous 8–12 weeks, has been 
used in diabetes care to monitor glucose control [3]. Notably, it has also been suggested for 
use as an alternate diagnostic tool [1]. Previously, the test was expensive and there were 
concerns about the accuracy of measurements. However, since 2009, with advances in 
technology, assay standardisation and costs have improved. HbA1c affords the convenience 
of not requiring an overnight fast nor a waiting period. It can be performed at any time of 
the day and overcomes the day-to-day variability in glucose levels [3]. Consequently, HbA1c 
is now increasingly considered for use as a diagnostic tool for diabetes and high-risk of 
diabetes, and has also been endorsed by the World Health Organization (WHO) for 
diagnostic purposes under the appropriate conditions, e.g. low prevalence of 
haemoglobinopathies in a particular population in addition to the use of standardised assays 
[1, 2] . 
The use of a convenient test that does not require pre-planning nor a waiting period would 
be particularly advantageous in Sub-Saharan Africa where there are numerous barriers to 
healthcare service access. These include travelling long distances and high out-of-pocket 
expenses which prevent revisits, particularly at short intervals, and consequently, a large 
proportion of individuals with diabetes remain undiagnosed in the region [4]. However, the 
ability of HbA1c to diagnose dysglycaemia in African populations has been variable [5]. 
Haemoglobinopathies, anaemia and haemolysis influencing the accuracy of HbA1c results 
are frequent in Africa. Furthermore, the burden of HIV infection is high in Africa, and 
anaemia and haemolysis are more common in HIV-infected individuals compared with the 
general population [6, 7]. However, the ability of HbA1c to accurately diagnose diabetes and 
other dysglycaemia in HIV-infected individuals has not yet been established. 
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Therefore, in the current study, we assessed the accuracy of HbA1c for diagnosing any 
dysglycaemia (impaired fasting glycaemia and/or impaired glucose tolerance) and screen-
detected diabetes in a population of South Africans living with HIV infection. Additionally, 
we assessed the prevalence of metabolic syndrome (MS), defined by the Joint Interim 
Statement (JIS) criteria, when HbA1c was used to diagnose hyperglycaemia instead of 
fasting glucose.  
Methods 
Design and population 
The current study is based on cross-sectional data collected between March 2014 and 
February 2015; the methodological approach has been described in detail elsewhere [8]. In 
brief, the participants were recruited from public healthcare facilities in Cape Town (10) and 
the surrounding rural municipalities (seven), using random sampling procedures. Consenting 
HIV-positive men and women, aged 18 years or older, and were not pregnant, 
breastfeeding, bedridden, undergoing treatment neither for cancer nor on corticosteroid 
treatment were included.  
Data collection 
The data were collected by a team of trained clinicians, nurses and fieldworkers, and 
captured on personal digital assistants, using electronic case report forms with built-in 
checks for quality control. Data on socio-demographic and medical history were obtained 
from a structured interviewer-administered questionnaire adapted from the WHO STEPwise 
approach to Surveillance (STEPS) tool. Duration of diagnosed HIV infection, CD4 counts and 
antiretroviral therapy (ART) regimens were obtained from the participants’ records. 
Measurements 
Anthropometric measurements were taken using standardised techniques. Heights and 
weights were measured with the participants in light clothing and without shoes. Blood 
pressure (BP) was measured on the left arm, using a digital BP monitor (Omron, M6 
Comfort, The Netherlands) after the participant was seated in a resting position for at least 
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five minutes; three measurements were taken three minutes apart, and the average of the 
2nd and 3rd readings used in the analysis.  
All participants who did not have a history of diabetes underwent a standard 2-hour 75 
gram OGTT after an overnight fast. Plasma glucose levels were determined at fasting (FPG) 
and at 2-hour post-OGTT (2h-PG). Blood samples were drawn and processed for laboratory 
analyses. Glucose and lipid concentrations were measured with an autoanalyzer, Beckman 
Coulter AU 500 spectrophotometer. Plasma glucose was measured by hexokinase method, 
and serum lipids triglycerides and high-density lipoprotein cholesterol (HDL-C) were 
analysed by the enzymatic colorimetric method. HbA1c was measured using high-
performance liquid chromatography (Variant Turbo, EDTA tubes) in accordance with the 
National Glycohaemoglobin Standardisation Programme (NGSP).  
Definitions 
The following dysglycaemia categories were defined: Raised FPG: FPG ≥5.6 mmol/L, raised 
2h-PG: 2h-PG ≥7.8 mmol/L, and diabetes as FPG ≥7.0 mmol/L and/or 2h-PG ≥11.1 mmol/L 
[9]. The individual components of MS and their cut-offs were defined according to the JIS 
criteria: elevated waist circumference (WC): men ≥94 cm, women ≥80 cm; elevated 
triglycerides: ≥1.7 mmol/L; low HDL-C: men<1.03 mmol/L, women<1.3 mmol/L; elevated BP: 
≥130/85 mmHg or on hypertensive medication; hyperglycaemia: FPG ≥5.6 mmol/L or on 
glucose control agents [10].  
Statistical analysis 
The R statistical software version 3.3.1 (2016-06-21), (The R Foundation for Statistical 
Computing Platform, Vienna, Austria) was used for data analyses. Continuous variables are 
presented as means (± standard deviation, SD) or medians (25th-75th percentiles), and 
categorical variable as frequencies and percentages. Mann-Whitney U test and chi-square 
test were used for men vs. women comparisons. Kappa statistic was computed to assess the 
concordance between the diagnostic criteria of MS: the JIS and those modified using HbA1c 
instead of FPG. The kappa values are interpreted as poor (kappa ≤0.2), fair (kappa ≤0.4), 




The “pROC” package was used for receiver operating characteristic curves (ROC) analyses. 
The optimal cut-point level of HbA1c was determined using two methods: 1) the closest top-
left point and 2) the Youden’s index (J-point). 1) In the ROC analysis, pairs of the false 
positive rate (1-specificity) and the true positive rate (sensitivity) for every individual cut-
point are plotted. The shape of the ROC curve indicates how high the discriminative power 
of the test is where the perfect discrimination has a ROC curve that passes through the 
upper-left corner (100% sensitivity, 100% specificity). Thus, the closer the ROC curve locates 
to the upper-left corner and the larger area under the curve (AUC), the higher the overall 
accuracy of the test and the cut-point nearest to the upper-left corner is defined as the 
optimal one. The Youden’s index is calculated as sensitivity + specificity – 1 and ranges from 
0 to 1. Maximising this index (J-point) allows finding an optimal level independently from 
the outcome prevalence. The 95% confidence interval of the derived optimal cut-point was 
computed using bootstrap sampling based on 2000 replicates. 
The diagnostic accuracy of the derived cut-off level was assessed alongside American 
Diabetes Association (ADA)/International Diabetes Federation (IDF) recommended 
thresholds by computing a number of diagnostic performance measures including the 
sensitivity which is the probability of a positive test result in a person with the 
disease/target condition; the specificity, the probability of a negative test result in a person 
without the disease/target condition; the positive predictive value (PPV), the probability of 
having the disease in a person with a positive test; the negative predictive value (NPV), the 
probability of no disease in a person with negative test, and the Youden’s index. These 
calculations were done with the “epiR” package of R. 
Results 
General characteristics of the participants 
Figure 9.1, which is the Standard of Reporting for Diagnostic Accuracy Studies (STARD) 
diagram, demonstrates the flow of participants in the present study. The starting sample 
comprised 831 participants of which 83 had missing data on at least one component of the 
JIS-defined MS, and were excluded. Therefore, the main analytic sample comprised 748 
participants including 157 men and 591 women. Of these, 48 with missing 2h-PG data were 
excluded from the OGTT-related analyses.  
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Initial participants; (N=831)
Included in the final analysis; (N=748)
Excluded (n=83)
• No return for blood 
sample (n=71)
• No anthropometric 
profile (n=7)
• No lipid profile (n=3)



















































































Index test (HbA1c) and reference standard (FPG) (n=720)
b
Index test (HbA1c) and reference standard (OGTT) (n=672)
• Excluded known diabetes (n=28)
• 2h-plasma glucose data missing (n=48)
Figure 9.1. STARD diagram describes the flow of the participants throughout the study 
analyses  
a
DGL, dysglycaemia is based on fasting plasma glucose (FPG) ≥5.6 mmol/L; 
b
DGL is based on FPG ≥5.6 
mmol/L and/or 2h-plasma glucose ≥7.8 mmol/L; Diabetes is defined as WHO criteria (FPG ≥7.0 mmol/L 
and/or 2h-plasma glucose ≥11.1 mmol/L)
The clinical and biochemical characteristics of the participants are summarised in Table 9.1. 
Their median age was 38 years (25th-75th percentiles: 35-42), and 93% were ART users. The 
median CD4 count was 392 cells/mm3 (240-604) and the median duration of diagnosed HIV 
infection was 5 years (2-9). Women had higher CD4 counts and longer duration of diagnosed 
HIV infection than men (both p ≤0.001).  
The median HbA1c was 5.5% (5.2-5.8) [37 mmol/mol (33-40)] with no difference between 
men and women (p=0.344). Compared with men, women had greater WC, BMI, systolic BP, 
higher levels of HDL-C, high-sensitivity C-reactive protein (hs-CRP), but lower values of 
triglycerides, gamma-glutamyl transferase (gamma-GT) as well as serum creatinine (all 
p≤0.023). The overall prevalence of dysglycaemia was 17.6% based on FPG alone, and 19.6% 
based on OGTT. Nineteen participants (2.8%) were newly diagnosed with diabetes; while 28 
171 
(3.7%) participants had known diabetes. The prevalence of dysglycaemia, newly diagnosed 
diabetes and previously diagnosed diabetes did not vary significantly among men and 
women (all p ≥0.305).  
Table 9.1. Cardio-metabolic risk and HIV-related characteristics in men and women 






Age (years) 38 (32-44) 41 (35-47) 37 (31-43) <0.001 
Known diabetes, n (%) 28 (3.7) 8 (5.1) 20 (3.4) 0.315 
Waist circumference (cm) 88 (78-98) 78.9 (74-88) 90 (80-101) <0.001 
Body mass index (kg/m
2
) 26.3 (22.1-32) 21.4 (19.8-22.4) 28.3 (23.8-28.9) <0.001 
Systolic blood pressure (mmHg) 117 (107-130) 123.5 (114.5-140) 115 (105.8-127) <0.001 
Diastolic blood pressure (mmHg) 82 (75-91) 83 (76-94) 81.5 (74.8-89.8) 0.129 
HbA1c (%) 








Fasting plasma glucose (mmol/L) 5 (4.6-5.4) 5.1 (4.8-5.5) 4.9 (4.6-5.4) 0.010 
2h-plasma glucose (mmol/L) 5.3 (4.6-6.2) 5.15 (4.4-6.3) 5.4 (4.6-6.2) 0.262 
FPG-based dysglycemia
1
, n (%) 127/720 (17.6) 28/149 (18.8) 99/571 (17.3) 0.678 
OGTT based dysglycemia
2
, n (%) 132/672 (19.6) 32/141 (22.7) 100/531 (18.8) 0.305 
Diabetes
3
, n (%) 19 (2.8) 2 (1.4) 17 (3.2) 0.392 
Triglycerides (mmol/L) 1 (0.7-1.3) 1.12 (0.75-1.27) 0.97 (0.74-1.28) 0.023 
HDL-C (mmol/L) 1.3 (1-1.5) 1.2 (1.0-1.5) 1.29 (1.08-1.52) 0.010 
hs-CRP (mg/L) 5.6 (2.4-14.5) 4.9 (2.1-16.2) 5.6 (2.4-14.2) 0.728 
gamma-GT (IU/L) 39 (26-66) 53 (30-96) 38 (25-58) <0.001 
Creatinine (𝜇mol/L) 58 (51-67) 70 (61-79) 56 (49-62) <0.001 
HIV duration (years) 5 (2-9) 4 (2-7) 5 (2.5-9) <0.001 
CD4 count (cells/mm
3
) 392(240-604) 272 (193-448) 410 (253-627) 0.001 
ART-usage, n (%) 0.296 
ART-naive 46/699 (6.6) 7/149 (4.7) 39/550 (7.1) 
ART-treated 653/699 (93.4) 142/149 (95.3) 511/550 (92.9) 
ART, antiretroviral therapy; BMI, body mass index; FPG, fasting plasma glucose; HDL-C, high-density 
lipoprotein cholesterol; HIV, human immunodeficiency virus; hs-CRP, high sensitivity C-reactive 
protein; gamma-GT, gamma-glutamyl transferase; 
1
FPG ≥5.6 mmol/L; 
2
FPG ≥5.6 mmol/L and/or 2h-
plasma glucose ≥7.0 mmol/L; 
3
FPG ≥7.0 mmol/L and/or 2h-plasma glucose ≥11.1 mmol/L. 
Optimal cut-point of HbA1c for dysglycaemia and diabetes 
The AUCs for HbA1c to identify participants with dysglycaemia was 0.733 (95% confidence 
interval [CI]: 0.682-0.784) for FPG-diagnosed dysglycaemia and 0.722 (0.670-0.774) for 
OGTT-diagnosed dysglycaemia (Figure 9.2). The optimal HbA1c cut-point for either FPG or 
OGTT-diagnosed dysglycaemia was 5.75% (95%CI: 5.35-5.75) [39 mmol/mol (35-39)]. Table 




diabetes among participants. For FPG-defined dysglycaemia, the derived cut-point was 
5.75% (39 mmol/mol) with the following performance measures: sensitivity 54% (95%CI: 44-
62), specificity 84% (80-87), Youden’s index 0.37 (0.25-0.49), PPV 41% (34-49), and NPV 89% 
(87-92). The cut-point 5.7% (39 mmol/mol), which is recommended by the ADA and the IDF, 
showed a sensitivity of 58% (49-67), specificity 77% (73-80), Youden’s index 0.35 (0.22-0.47), 
PPV 35% (29-42), and NPV 0.90 (0.87-0.92). For OGTT-defined dysglycaemia, the derived 
HbA1c cut-point of 5.75% (39 mmol/mol) yielded a sensitivity of 52% (43-60), specificity 85% 
(81-88), Youden’s index 0.37 (0.23-0.45), PPV 48% (40-56), and NPV 85% (82-88) while the 
cut-point of 5.7% (39 mmol/mol) gave a sensitivity of 56% (47-65), specificity 78% (74-81), 
Youden’s index 0.34 (0.21-0.46), PPV 38% (31-45), and NPV 88% (85-91).  
The AUC of HbA1c to diagnose participants with diabetes was 0.797 (0.686-0.907) (Figure 
9.2). The optimal cut-point was 5.85% (5.25-6.65) [40 mmol/mol (34-49)], and the resultant 
performance measures were: sensitivity 63% (38-84), specificity 86% (83-88), Youden’s 
index 0.49 (0.22-0.73), PPV 11% (6-19), and NPV 99% (97-100), (Table 9.2). The HbA1c cut-
point of 6.5% (48 mmol/mol), recommended by the ADA and IDF had a sensitivity of 37% 
(16-62), specificity 99% (98-100), Youden’s index 0.36 (0.22-0.80), PPV 55% (30-80), and NPV 
98% (97-99), Table 9.2. 
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Figure 9.2. ROC curve characteristics of HbA1c corresponding with fasting plasma glucose (FPG) ≥5.6 mmol/L  
(A), FPG ≥5.6 mmol/L or 2-hour oral glucose tolerance test (OGTT) ≥7.8 mmolL (B), and FPG ≥7.0 mmol/L and 2-hour OGTT ≥11.1 mmol/L (C) in HIV-
infected participants without known diabetes: The ROC curves show the same optimal cut-point of HbA1c of 5.75% (39.3 mmol/mol) for diagnosing 
dysglycaemia based on FPG (A) (AUC: 0.659, sensitivity: 54%, specificity: 84%) or based on OGTT (B) (AUC: 0.722, sensitivity: 52%, specificity: 85%), 
and the optimal HbA1c of 5.85% (40.4 mmol/mol) for diabetes (C) (AUC: 0.797, sensitivity: 63%, specificity: 86%) 
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Table 9.2. Performances of HbA1c corresponding with dysglycaemia and diabetes among the participants without history of diabetes from 














mmol/L % mmol/mol 
FPG ≥5.6 
5.7 39 0.58 (0.49-0.67) 0.77 (0.73-0.80) 0.35 (0.22-0.47) 0.35 (0.29-0.42) 0.90 (0.87-0.92) 
5.75 (5.35 -5.75) 39 (35-39) 0.54 (0.44-0.62) 0.84 (0.80-0.87) 0.37 (0.25-0.49) 0.41 (0.34- 0.49) 0.89 (0.87-0.92) 
FPG ≥5.6 and/or 2h-glucose ≥7.8 
5.7 39 0.56 (0.47-0.65) 0.78 (0.74-0.81) 0.34 (0.21-0.46) 0.38 (0.31-0.45) 0.88 (0.85-0.91) 
5.75 (5.35-5.75) 39 (35-39) 0.52 (0.42-0.58) 0.85 (0.81-0.88) 0.37 (0.23-0.45) 0.48 (0.40-0.56) 0.85 (0.82-0.88) 
FPG ≥7.0 and/or 2h-glucose 
≥11.1 
5.85 (5.25-6.65) 40 (34-49) 0.63 (0.38-0.84) 0.86 (0.83-0.88) 0.49 (0.22-0.73) 0.11 (0.06-0.19) 0.99 (0.97-1.00) 
6.5 48 0.37 (0.16-0.62) 0.99 (0.98-1.00) 0.36 (0.22-0.80) 0.55 (0.30-0.80) 0.98 (0.97-0.99) 
FPG, fasting plasma glucose; Sensitivity=TP/(TP+FN); Specificity=TN/(TN+FP); Youden’s index = (sensitivity + specificity) – 1; PPV, positive predictive 




Prevalence of MS using FPG or HbA1c as the hyperglycaemia criterion  
Figure 9.3 depicts the prevalence of MS according to the original and modified JIS using 
HbA1c cut-points. Based on the original JIS criteria which use FPG ≥5.6 mmol/L, the 
prevalence of MS was 28.2% (211/748) overall, 16.6% (26/157) in men, and 31.3% (185/591) 
in women (p <0.001). Replacing FPG with HbA1c ≥5.75% (≥39 mmol/mol) yielded the 
prevalence of 29.7% (222/748) overall, 15.3% (24/157) in men, and 33.5% (198/591) in 
women (p <0.001). Out of 246 participants who were diagnosed with the MS based on 
either FPG or HbA1c ≥5.75% (≥39 mmol/mol)], 187 (76%) were identified by both criteria, 35 
participants (14.2%) met the HbA1c criteria only while 24 (9.7%) participants met the FPG 
criteria only, [kappa=0.81 (95%CI: 0.76-0.86)].  





Figure 9.3. Metabolic syndrome by the Joint Interim Statement criteria comparing the 
prevalence using dysglycaemia criteria of fasting plasma glucose with HbA1c in participants 
without knowing diabetes 
The first row shows prevalence of MS based on JIS-HbA1c >=5.75% and JIS criteria, overall (A1), men 
(B1), women (C1); the second row shows the prevalence of MS based on JIS-HbA1c >=5.7% and JIS 




If HbA1c ≥5.7% (≥39 mmol/mol) was used, the MS prevalence would be 32.9% (246/748) 
overall, 18.5% (29/157) in men, and 36.7% (217/591) in women (p<0.001). Among 266 
participants with MS according to either FPG or HbA1c [cut-point 5.7% (39 mmol/mol)], 72% 
were diagnosed by both criteria, 20.7% by only HbA1c and 7.5% by FPG, [kappa=0.76 (0.71-
0.81)].  
Discussion 
The present study is among the first to examine the performance of HbA1c as a diagnostic 
test for dysglycaemia or diabetes in a sub-Saharan African population living with HIV 
infection. Our key findings are the following: 1) HbA1c had an acceptable-to-good 
discriminatory ability to detect prevalent dysglycaemia (impaired fasting glycaemia, and/or 
impaired glucose tolerance) and screen-detected diabetes; 2) The study-specific optimal 
HbA1c cut-point to detect the presence of dysglycaemia was not appreciably different from 
the advocated cut-point by the ADA and IDF, while the optimal cut-point to detect screen-
detected diabetes was lower than that recommended by the two organisations, but in line 
with previous studies in the general population in Africa; 3) Replacing FPG-based with 
HbA1c-predicted dysglycaemia in the JIS MS criteria led to marginally higher prevalence 
estimates, with generally good agreement between the original JIS and the modified 
criteria.  
Using HbA1c as a diagnostic test for diabetes and dysglycaemia 
Although HbA1c has been recommended by the ADA and IDF as an alternative test for 
diagnosing diabetes and individuals at high risk for diabetes, its applicability and suitable 
thresholds in various populations remain unresolved. In the present study, the optimal cut-
point of HbA1c for detecting diabetes was lower than the one recommended by the 
ADA/IDF but within the range of the cut-point found in a mixed-ancestry South African 
population [5]. The data in that study were from 819 participants with a median age of 52 
and residing in the local community [5]. We found no similar data from HIV-infected 
Africans for direct comparison. Nonetheless, our findings agreed with a  study from the 
United State which showed that the HbA1c threshold of 6.5% (48 mmol/mol) was 
insensitive but highly specific, while the HbA1c level of 5.8% (40 mmol/mol)  was ideal for 
diagnosing diabetes in HIV-infected patients [11].  
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For the detection of dysglycaemia, the derived HbA1c cut-point of 5.75% (39 mmol/mol) is 
similar to that found in mixed-ancestry South Africans [12] and not appreciably different 
from the 5.7% (39 mmol/mol) recommended by the ADA/IDF. The present and previous 
studies in South Africa tend to agree more on HbA1c-based diagnosis for dysglycaemia than 
diabetes. However, it has been reported that HbA1c may not accurately reflect glycaemia in 
individuals with abnormal haemoglobin [13]. Iron and vitamin B12 deficiency with and 
without anaemia have been reported to reduce erythropoiesis, and thus reduce erythrocyte 
turnover which leads to increase in HbA1c values independently of glucose levels [13]. Some 
studies have suggested that low-grade haemolysis might contribute to lower HbA1c value at 
a given glucose level in HIV-infected patients than HIV-uninfected individuals [6, 14]. Despite 
the above, the derived cut-points in our study appear consistent with those obtained in the 
local general population [5, 12]. This suggests that the factors that influence HbA1c values in 
African populations are unlikely to differ by HIV status.  
Using HbA1c as the hyperglycaemia criterion for the MS 
Replacing FPG with HbA1c showed the change in MS prevalence to be marginal, with HbA1c 
diagnosing slightly more people than FPG while missing only a tiny proportion diagnosed by 
FPG in the present study. This suggests that HbA1c could be used as the hyperglycaemia 
criterion for MS in HIV-infected individuals. This finding is essential in African populations, 
especially people infected with HIV. Although MS definitions have used FPG as the 
diagnostic criterion for hyperglycaemia, African studies have found FPG alone to be an 
inadequate screening test for dysglycaemia or diabetes in general populations since it 
misses a significant proportion of individuals who tend to only have 2-hour abnormalities 
[15]. Replacing FPG with HbA1c to identify hyperglycaemia or diabetes in the diagnosis of 
MS in African populations has relevance as HbA1c could possibly identify individuals who 
may also have dysglycaemia on the 2-hour OGTT while overcoming the challenges of 
performing the OGTT in these specific populations. This is particularly relevant for Africans 
living with HIV infection who regularly require routine screening for cardiovascular health. 
Indeed, the requirement for an overnight fasting and the long waiting periods for the 
completion of the OGTT would be problematic for both HIV-care providers and the patients.  
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Strengths and limitations 
Our study had some limitations with the wide confidence interval of the optimal HbA1c cut-
point for diagnosing diabetes indicating a lack of statistical power due to the small sample 
size. The absence of an HIV-uninfected group and of external validation limited the 
recommendation of our results for application in a routine setting. Another limitation was 
that data on erythrocyte abnormalities were not collected in the present study. 
Nonetheless, our study has numerous strengths. Apart from a multiple-clinic study, this is 
the first to examine the performance of HbA1c as a diagnostic test for glycaemic disorders 
and the MS in a sub-Sahara African population living with HIV infection. Another strength 
was the availability of not only FPG but also 2h-PG levels for the analyses of HbA1c cut-
points corresponding to both FPG and 2h-OGTT. 
Conclusions 
In conclusion, in this HIV-infected African population, the optimal HbA1c cut-point to detect 
the presence of dysglycaemia was not appreciably different from the advocated cut-point by 
the ADA and IDF, while the optimal cut-point to detect screen-detected diabetes was lower 
than that recommended by the two organisations. Importantly, these findings are in line 
with previous studies in the general population in Africa, suggesting that factors influencing 
HbA1c values are likely to be similar in African HIV-infected and uninfected populations. Our 
study findings further support replacing the FPG criterion in the JIS MS definition with 
HbA1c as this will have marginal effects on the MS prevalence while facilitating the 
screening of the condition. However, these findings need to be confirmed by other studies 
in HIV-infected African populations. Ideally, such studies should be nested with 
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Chapter 10 




Summary of novel insights from this study 
The following section reflects the novel contributions made by the various Chapters in 
addressing the aims and objectives of this thesis. Also discussed are the public health 
implications and the recommendations for future research.  
This thesis comprises a systematic review on the MS prevalence in HIV-infected populations 
worldwide and four original research publications from a cross-sectional study conducted in 
≥18-year-old PLWHIV attending healthcare clinics in the Western Cape, South Africa. The 
original papers focus on the prevalence and optimal diagnosis of MS. 
Using the meta-analytic methods, Chapter 4 was the first to quantify the prevalence of MS 
in the global HIV-infected population. The estimated prevalence appears to be similar to 
that found in general populations with a third of HIV-infected individuals having MS 
worldwide [1]. With very few studies that simultaneously applied multiple diagnostic 
criteria, there was a wide range of MS prevalence with substantial heterogeneities that 
were not fully explained by major study characteristics. These included sample size, study 
location, year of publication, gender and age of participants, and HIV-related factors such as 
exposure to ART, duration of diagnosis and HIV treatment, severity of HIV infection, and ART 
regimens. This systematic review provided significant justifications for comparing different 
MS diagnostic criteria in a single HIV-infected population.  
The primary study, investigating the characteristics of MS in a random sample of HIV-
infected patients, was the first multi-clinic-based study in South Africa to determine the 
prevalence of MS and assess the concordance of different MS criteria in HIV-infected South 
Africans living in the Western Cape Province (Chapter 6). There was a high prevalence of MS 
using different diagnostic criteria with very good concordance between sets of recent MS 
criteria. HIV-related characteristics such as duration of HIV diagnosis, CD4 level, and ART use 
and regimens in the study setting did not affect the MS prevalence. 
Additionally, this study investigated the distribution of cardio-metabolic abnormalities 
across BMI categories using a cross-classification of BMI and metabolic status (Chapter 7). 
Among the study participants, two or more cardio-metabolic abnormalities (hypertension, 
elevated triglycerides, low HDL-C or hyperglycaemia) were prevalent across BMI levels; even 
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one in ten normal-weight participants had cardio-metabolic abnormalities. The distribution 
was comparable to that in general African populations [2, 3], which suggests the possible 
influence of similar factors in the development of CVD risk in this population. 
This study also adds to the existing evidence in general populations on the optimal African-
specific thresholds for WC (Chapter 8). In line with other African studies conducted in 
general populations, this study confirmed that WC thresholds were lower in African HIV-
infected men but greater in the women compared to MS advocated criteria (WC >94 cm in 
men, >80 cm in women) [4]. The thresholds of 86-90 cm in men and 90-94 cm in women 
derived from studies in South Africa and other African countries showed better 
performances in this study setting.  
Finally, as depicted in Chapter 9, this study examined the utility of glycated haemoglobin 
(HbA1c) to screen for dysglycaemia and as an alternative to FPG as the dysglycaemia criteria 
for diagnosing MS in HIV-infected Africans. The optimal HbA1c cut-point of 5.75% 
(39.3 mmol/mol) for dysglycaemia defined by FPG and OGTT was similar to the cut-point of 
5.7% (39 mmol/mol) advocated by the ADA and the IDF for the general populations. The 
replacement of FPG with HbA1c when determining MS as per the JIS criteria was found to 
be acceptable with a slight increase in MS prevalence from 28.2% using FPG-defined 
dysglycaemia to 32.9% using HbA1c-defined dysglycaemia; a very small percentage of 
individuals diagnosed according to the FPG were missed.  
Public health implications 
High burden of cardio-metabolic risk factors in South Africa 
The frequent clustering of cardio-metabolic risk factors in HIV-infected patients attending 
public healthcare facilities highlights a significant burden of cardio-metabolic diseases in this 
population. This is a public health challenge because of the high burden of HIV infection in 
the country. South African has the largest ART programme in the world, with about 2.6 
million HIV-infected individuals on ART in 2015 [5, 6]. Additionally, together with the 
continued expansion of the ART programme and ageing of HIV patients, the CVD burden is 
likely to increase further in the near future. Therefore, ensuring detection and treatment of 
PLWHIV who are at high risk for developing CVD, is critical.  
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Optimal diagnosis of MS in African people with HIV in clinical practice 
Since various criteria are available for MS screening, there have been concerns about the 
variable MS prevalence among studies [7]. The high-level of agreement among the three 
most popular MS criteria, i.e. ATPIII-2005, IDF-2005 and JIS-2009, found in this study 
(Chapter 6), suggests that any of these criteria may be used interchangeably to screen and 
monitor MS in the local HIV-infected population. The misclassification of individuals with MS 
will be modest with possibly no sizable impact on health resources allocation at population 
level.  
Optimal WC thresholds in MS criteria 
The optimal WC thresholds for abdominal obesity determined in this study and African 
studies in general populations differed from those recommended in the JIS-based MS 
criteria. These suggest that the application of current MS criteria in African PLWHIV could 
over-diagnose women and underdiagnose men with MS resulting in missed opportunities 
for CVD prevention and misuse of resources. Notably, the single African-specific threshold of 
90 cm for both genders was proven more accurate and thus may be convenient for public 
health and clinical utility in Africa.  
HbA1c as dysglycaemia index in MS criteria 
With the finding that HbA1c could be used to adequately screen for the dysglycaemia 
component of the MS in HIV-infected Africans, this study sheds light on the potential use of 
HbA1c as the dysglycaemia index in the diagnosis of MS in HIV-infected Africans. The use of 
HbA1c could increase dysglycaemia detection, as it could possibly identify individuals with 
raised 2-hour OGTT glucose levels. This would overcome the challenges of performing the 
OGTT and may increase detection compared to FPG alone. The HbA1c application is a 
convenient approach to managing CVD risk in African PLWHIV in whom screening for CVD 
health is routinely required. However, the test is currently more expensive than FPG and 
these cost-effective considerations need to be addressed, particularly in Africa, before 
HbA1c can be used as a practical tool to improve the detection and treatment of CVD risk in 




Implications for the management of cardiovascular health in HIV-infected people 
The clustering of cardio-metabolic risk factors frequently present in PLWHIV at a younger 
age and, regardless of their weight status, highlights the need for their ongoing cardio-
metabolic assessments. This includes regular screening for MS components together with 
appropriate management taking into account its predictive ability, cost-effectiveness of 
interventions, as well as the consequences of deferred actions. 
Management of CVD risk in PLWHIV will require addressing traditional and HIV-related risk 
factors. These include traditional lifestyle modification which should be introduced early 
and sustained, along with pharmacological interventions such as lipid-lowering, anti-
hypertensive and anti-diabetes treatments [9, 10]. The selection of pharmacological 
therapies must consider the potential interactions between cardio-preventive therapies and 
ART [9, 10]. The use of ART with minimal cardiovascular effects and fewer drug interactions 
is recommended [9, 11]. Although existing data indicate that newer drugs, such as entry 
inhibitors, fusion inhibitors and integrase inhibitors are not associated with adverse side 
effects, these new ART have not been studied thoroughly [9, 11]. Besides, diagnosed HIV-
infected people are already in regular contact with the healthcare system, and as such, 
opportunities for cardiovascular screening and optimal management including health 
promotion should not be missed.  
Integration of care for HIV-infection and cardio-metabolic diseases 
Considering the high burden of cardio-metabolic disease in the HIV-infected population, a 
comprehensive management approach is required. The concurrent problems of CVD risk 
and HIV-related infections among PLWHIV require integrated management strategies to 
simultaneously address cardio-metabolic diseases and provide treatment for HIV and 
opportunistic infections. Nevertheless, the integration of these services presents several 
challenges. These include overloaded clinics without the capacity to take on a greater 
workload, and healthcare staff unskilled in CVD care and reluctant to perform the additional 
tasks of CVD/NCD management [12]. To ensure the successful integration of services 
requires a shift from vertical programmes to multidisciplinary collaboration, capacity 
building and adequate staff training, and additional investment for the provision of 
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combined services. Close monitoring and continuous feedback and training will be necessary 
to ensure that quality of care remains uncompromised. 
These recommendations are in line with global declarations and strategies for “the 
prevention and control of NCDs” which favour integration of HIV and NCD management 
[13]. In South Africa, the National Department of Health introduced the Integrated Chronic 
Disease Management Model (ICDM) for both NCD and chronic communicable diseases such 
as HIV and tuberculosis as part of the South African Strategic Plan for the Prevention and 
Control of Non-Communicable Diseases 2013-17 [14]. This study provides greater impetus 
for the implementation of the ICDM to ensure adequate CVD care in PLWHIV.   
Future research 
Given the high prevalence of cardiovascular risk factors in PLWHIV globally and that the data 
were mostly from clinic-based studies, there is a need for population-based studies in 
PLWHIV who do not seek care at health facilities to accurately screen and monitor their 
burden of CVD risk. These population-based studies are particularly necessary for South 
Africa with the high prevalence of HIV infection and its associated stigma where such results 
can be used to develop and improve the CVD risk management strategies. However, there 
are ongoing national active screening and treatment programmes for HIV in South Africa 
which suggests that most, if not all, PLWHIV could be tested and treated. Therefore, 
research in clinical facilities with a representative sample will be relevant.  
Considering the high prevalence of cardiovascular risk factors in PLWHIV in South Africa, 
implementation studies to promote the uptake of lifestyle modifications and 
pharmacological therapies especially in the study population, are required. Data on the 
barriers and enablers of such interventions are needed to inform the healthcare providers 
on strategies to improve the management of cardio-metabolic risk in PLWHIV in South 
Africa. 
Studies with large sample sizes and adequate numbers of male participants are needed to 
further examine the optimal thresholds of WC to predict central obesity and HbA1c for 




group samples by HIV characteristics are required to adequately assess the impact of HIV-
related factors on the development of cardio-metabolic abnormalities and CVD in PLWHIV. 
There is a lack of robust evidence to confirm that the integration of care for infectious and 
NCD improves service delivery and health outcomes in PLWHIV in low-resource settings [15, 
16]. Therefore, there is a need for impact analysis studies to determine the effect of 
introducing CVD prevention and control strategies in HIV care, on the behaviour of 
healthcare providers and the future cardiovascular health of the patients. Research such as 
optimal implementation techniques and monitoring of integrated services to assess levels of 
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Appendix 4: Participant information sheet and consent form 
 
PARTICIPANT INFORMATION SHEET 
 
 
TITLE OF THE RESEARCH PROJECT:  Investigating the prevalence, awareness, treatment and control 
of chronic non-communicable disease risk factors, particularly hypertension, in patients attending 
HIV-treatment centres in the Western Cape Province of South Africa 
Dear Sir/Madam 
We are scientists from the Non-communicable Disease Research Unit at the Medical Research 
Council (MRC). We want to find out how testing and treatment for conditions like high blood 
pressure, diabetes and high cholesterol is carried out within the HIV/AIDS treatment programme 
because people with HIV can also suffer from these disorders.  
What is the “Investigating the prevalence, awareness, treatment and control of chronic non-
communicable disease risk factors, particularly hypertension, in patients attending HIV-treatment 
centres in the Western Cape Province of South Africa” Study?  
South Africa is burdened with the highest level of HIV in the world. Anti-retroviral medications are 
now widely available and have made a huge difference in the lives of those living with HIV. HIV-
positive people can now expect to live almost as long as those who are HIV-negative.  
This means that HIV-positive people may suffer from other conditions/diseases that occur as people 
grow older, like high blood pressure, high cholesterol, diabetes and certain cancers. The aim of this 
study is to find out whether HIV treatment is combined with treatment for other chronic medical 
problems, and whether integrating HIV treatment with that of other conditions will be practical and 
appropriate in South Africa today. 
Very little information is available about how common high blood pressure, diabetes or high 
cholesterol is in people who suffer from HIV, and it is hoped that this study will provide valuable and 
interesting information for future healthcare planning. 
Who can take part in the study? 
In order to participate, you must: 
 Be older than 18 years  
 Be HIV-positive  
 Have been attending your HIV-treatment facility regularly for some time  
You may however be excluded for a number of reasons including: medical problems, pregnancy or 
breastfeeding, medication use or diet history. 
Do I have to take part in the study? 
You have no obligation to participate in the study and you may withdraw from the study at any time. 
There will be no penalty if you decide not to participate in the study, or if you want to withdraw 
from the study later on. Remember: Your participation in this study is completely voluntary. 
If you decide to withdraw from the study, you may be asked why you have decided to withdraw for 




What will be expected of me if I decide to take part in the study? 
1. You will be one of approximately 1 000 participants selected from healthcare facilities across the 
Western Cape. You will need to attend your clinic on two separate days to participate in the 
study. 
2. On the first day:  
a. You will be asked to undergo a physical assessment that includes a medical history 
questionnaire (along with a list of the medications you are taking), 3 blood pressure 
readings and body measurements – conducted by a doctor, nurse or trained fieldworker. 
Your height, waist and hip diameters will be measured using a standard measuring tape. 
For measurements to be taken, you will be asked to remove your shoes and outer layer 
of clothing.  
b. You will be asked to complete a questionnaire/interview that includes information about 
your life and lifestyle habits like your work, education level, home circumstances, eating 
pattern, exercise routine and some opinions on your health and healthcare. This will 
take approximately 30 to 45 minutes and will be conducted in a private room so that no-
one except you and the interviewer will hear your answers.  
3. On the second day, you will be asked to have blood tests done for cholesterol/blood fat levels 
and your blood sugar level after an overnight fast. Approximately 30 ml (2 tablespoons) of blood 
will be taken twice over a 2-hour period on the same morning. At the beginning of the 2-hour 
period, you will be given a glass of sugar water containing 75 g of glucose to drink. The needle 
prick may cause some discomfort at the point where the needle enters the skin, but this will last 
for a few seconds only. The procedure will be performed by qualified and experienced personnel 
and all equipment will be sterile (free from germs) to minimise the risk of infection. Disposable 
equipment will be used once only, so there is no chance of transfer of infection between 
participants.  
4. We would like to store your blood for the duration of the study and an additional 25 years for 
future analysis relating to cardiovascular and metabolic disease (including genetic analysis 
specifically relating to these diseases). Any additional analysis to be done on your blood will first 
have to be approved by the MRC’s ethical committee. If you refuse the storing of your blood you 
could still participate in the study and we will not store any of your blood samples. You could 
request at any time for your stored blood samples to be destroyed. 
5. We also request access to your health records. Specifically, we would need to see what tests and 
measurements have been done by the clinic you attend, and also to find out whether there is a 
record of your latest CD4 count. A member of the research team (doctor or nurse) will request 
your medical file from the facility manager or records department at the clinic/health facility you 
attend. Your file will not be removed from the health facility. The research team member will 
look through your file for specific details: The date of HIV diagnosis, the date and results of 
certain blood tests like kidney functions and cholesterol or liver functions, and your medication 
list. This information will be recorded as part of the data record identified only by your 
participant number, not your name. This information will be helpful to see how long you have 
had HIV, how long you have been on treatment and what type of treatment you are receiving. 
6. We would like to ask your permission to contact you in the future to participate in a follow-up 
study. We plan to conduct another study in future that may involve a combination treatment for 
HIV and blood pressure or other chronic illnesses, depending on the needs identified through 





What about issues of confidentiality relating to HIV status? 
We know that HIV status is a sensitive issue and that HIV-positive people are sometimes victimised 
because of their status. For this reason, we will endeavour to protect your privacy at all times. No 
person outside the study will know that you have participated. All interviews will be conducted in 
private and other participants will be fellow patients from your own health facility, who share your 
concerns about HIV status and confidentiality. Your information will be stored in locked files and 
protected computer files ensuring your confidentiality.  
What can I expect to gain from participating in this study? 
1. You will have access to trained staff who will perform a health and a lifestyle assessment on you.  
2. You will receive copies of your blood tests and measurements for your records.  
3. You will be referred for appropriate treatment if any abnormalities are found. 
4. You will contribute to medical research that may provide very useful insights into how to plan 
HIV and chronic disease treatment programmes in the future 
5. You will receive R100-00 (One-hundred Rand) as reimbursement for your time and transport 
costs. This will be given as a R30 voucher on the first day and a R70 voucher when you come 
back for the tests. 
You will receive at no cost to yourself, a medical and laboratory assessment of your current medical 
condition. Specifically, your body measurements will be taken, blood pressure will be assessed and 
blood tests will be done to assess whether you have undetected or uncontrolled diabetes or high 
cholesterol/blood fat levels. 
What will be the costs of my participation in this study? 
1. You will need to provide your own transport to and from the research facility/clinic, but you will 
receive a money voucher of R100 towards the cost of the transport. 
2. You will be required to sacrifice your time for completing questionnaires, a group discussion 
session and medical assessments/testing. 
3. Participation in this study will not affect the care you receive at your clinic/healthcare facility. 
What will happen to the data collected during the study? 
The data collected will be sent to researchers at the MRC and used solely for the purpose of this 
study. 
Who will know that I participated in this study? 
Only the clinical staff and other participants in the study will know that you participated in the study. 
Your name will not be recorded or revealed to the researchers, nor will your name or other details 
be published in any documents. 
Will I be informed about the results of the study? 
You will be sent a copy of the study results after publication. 
How will I find out about my results? 
In the event of the discovery of any adverse laboratory result of your blood samples, a member of 
the research team will contact you directly by telephone and advise you or refer you for further 
medical assistance. Your blood results will be sent to an assigned and dedicated member of the 
clinical staff at your health facility who will then add these results to those in your medical records. 
At your next clinic visit you can discuss these results with your doctor or nurse practitioner. If you 
need to attend the clinic earlier than your next clinic date to discuss your results, you will be advised 
to do so either by a member of the research team or the staff member at your health facility. Please 




What are my rights while taking part in the study? 
Your taking part in this study is your choice and you are free to not take part. All information will be 
confidential and anonymous. You may also refuse to answer any questions you do not feel 
comfortable answering and you may stop during the interview and not continue. Your name will not 
be linked to the information collected at any time and will not appear in any report or publication. 
The only people with access linking your name to information collected will be the clinician, nursing 
staff and interviewer, who will respect the confidentiality of the information. What you tell us will be 
used for the purpose of research only and we will keep it confidential.  
What are the risks to my health in this study? 
Your participation in this study will involve answering questions, a medical examination and 
collection of blood for laboratory analysis. Blood will be collected by an experienced professional 
nurse, doctor or appropriately trained staff member. Having your blood drawn can cause bleeding, 
bruising and in rare cases an infection may occur at the site of the needle stick and may also be 
uncomfortable. Rarely, light-headedness or fainting may occur.  
This study has been approved by the Research Ethics Committee of the MRC, Cape Town and will be 
carried out according to the ethical guidelines and principles of the International Declaration of 
Helsinki, 2000. If you have questions about your rights as someone who took part in the study, you 
are welcome to contact the Chairperson of the Research Ethics Committee, Prof Danie du Toit, at the 
Medical Research Council, P.O. Box 19070, Tygerberg. 7505. Contact telephone number: 
0219380341; email: adri.labuschagne@mrc.ac.za. You will receive a copy of this information sheet 
and consent form for your own records. If you have any questions or concerns about the research, 





































Thank you for reading through the information sheet and your interest in participating in our study 
that aims to investigate the prevalence and treatment of chronic non-communicable disease risk 
factors (particularly hypertension) in patients attending HIV-treatment centres in the Western Cape 
Province, South Africa. 
Declaration by the participant 
By signing this form, I ……………………………………………………………………………………..  
  Tick those to which you agree  
1. Agree to take part in a research study entitled: 
Investigating the prevalence, awareness, treatment 
and control of chronic non-communicable disease risk 
factors, particularly hypertension, in patients 
attending HIV-treatment centres in the Western Cape 
Province of South Africa 
 
 
2. Agree to having my medical records studied   
3. Agree to have my blood samples stored (if you decide 
at any time to withdraw this consent you can contact 




4. Agree that the research team may contact me in the 
future for a follow-up study 
 
 
I declare that: 
 I have read (or had read to me) this information and consent form and it is written in a 
language with which I am fluent and comfortable.  
 I am older than 18 years old.  
 I have had a chance to ask questions and all my questions have been adequately answered. 
 I know that taking part in this study is voluntary and l have not been forced to take part. I 
may choose to leave the study at any time without any problems. 
Signed at (place):   on (date):  
Name of participant: 
  Signature of 
participant: 
 
Name of witness:   Signature of witness:  
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